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Summary 
Human cytomegalovirus (HCMV) is a ubiquitous pathogen that infects the 
majority of the adult population. Similarly to other herpesvirus, it is able to enter a state 
of latency, persisting within the host for life. Infection of healthy individuals is normally 
asymptomatic, however it is among the most common causes of allograft rejection, and 
can lead to several life-threatening diseases in the immunocompromised. Moreover, it is 
the leading viral infectious cause for congenital disease.  
HCMV encodes 171 canonical genes, and a substantial number of non-canonical 
ORFs have been identified by ribosome profiling and proteomics. The functions of many 
canonical HCMV proteins remain poorly understood, and it is not yet clear how many 
non-canonical ORFs encode functional polypeptides.  
Recent studies have provided an extensive overview on the modulation of gene 
expression as well as the spatio-temporal dynamics of viral and host proteins during 
HCMV infection.  However, characterisation of specific protein-protein interactions and 
the exact molecular mechanisms underpinning the biological changes observed during 
viral infection are beyond the scope of these approaches.  
Affinity-purification mass spectrometry was performed to identify binding 
partners for 169 canonical, and 2 non-canonical HCMV proteins in infected cells. 
CompPass filtering determined an extensive network of high-confidence interacting 
proteins, with >3,400 virus-host and >150 virus-virus protein interactions.  
II 
 
Domain association analysis identified protein domains co-occurring with 
unusual frequency, while functional enrichment analysis provided an insight into novel 
functions of multiple viral genes as well as how HCMV systematically modulates host 
environment, for example interacting with transcriptional repressive complexes or 
families of ubiquitin E3 ligases. Furthermore, combining interaction data with a recently 
published systematic analysis of HCMV-induced protein degradation identified viral 
interactors for 31/133 degraded host targets.  
Finally, the uncharacterised, non-canonical ORFL147C protein was found to interact 
with elements of the mRNA splicing machinery, and a mutational study suggested its 
importance in viral replication. The interactome data will be important for future 
studies of herpesvirus infection. 
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1 | Introduction 
1.1 Herpesviridae 
The Herpesviridae family is comprised of viruses that can infect amniotes 
(mammals, birds and reptiles) [1]. This family is part of the order Herpesvirales, along 
with two other families of herpesvirus which infect mollusks (Malacoherpesviridae) and 
anamniotes (fishes and amphibians, Alloherpesviridae) [1]. Inclusion of viruses into the 
Herpesviridae family is based on a characteristic virion morphology, which consists of an 
envelope, tegument, capsid, and core containing a linear, double-stranded DNA genome 
[2]. Known herpesviruses share four properties: (a) their genome encodes enzymes and 
other factors involved in nucleic acid synthesis and metabolism, as well as proteases and 
protein kinases; (b) synthesis of viral DNA and capsid assembly occurs in the nucleus; (c) 
generation of infectious progeny is commonly followed by death of the infected cell; (d) 
an ability to enter a state of latency, persisting within the host for life [2, 3]. Similarities 
in the phylogenetic relationships among viruses and their hosts suggest that 
herpesviruses have co-evolved with their hosts over long periods of time and are well 
adapted to them [4, 5]. Thus, herpesvirus species are generally named after a taxon of the 
host which harbours the virus [2]. 
Herpesviruses have been divided into three subfamilies, the Alpha-, Beta-, and 
Gamma-herpesvirinae (see Table 1.1.1). This classification was based on biological (range 
of hosts, duration of the life cycle, cytopathology and latency characteristics) and genomic 
criteria (conservation of genes and gene clusters, arrangement of gene clusters in relation 
to one another, arrangement of terminal sequences involved in viral genome packaging 
and distribution of nucleotides subject to methylation) [2, 3].  
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Table 1.1.1 | Herpesviridae subfamily characteristics  
Subfamily Characteristics 
Alphaherpesvirinae Host range: Variable.  
Lytic cycle duration: Short, approximately 24 h.  
Cytopathology: Infection disseminates rapidly, resulting in mass cell 
death.  
Latent infections: Established in neurons in peripheral sensory 
ganglia. Viral genomes assume a circular episomal conformation from 
which a limited number of genes are transcribed. 
Betaherpesvirinae Host range: Generally restricted to the species or genus to which the 
host belongs.  
Lytic cycle duration: Long, approximately 72 h.  
Cytopathology: Slow spread of infection from cell to cell in culture. 
Induces enlargement of infected cells (cytomegalia).  
Latent infections: Established in cells of the myeloid lineage (e.g. 
CD34+ hematopoietic progenitor cells, T cells, CD14+ monocytes and 
macrophages). Viral DNA is most commonly maintained as an 
extrachromosomal episome, although some virus in this family 
establish latency by integration into the telomeres of the host 
chromosome. 
Gammaherpesvirinae  
 
Host range: Generally restricted to the same family or order of its 
natural reservoir. Viruses in this subfamily are specific for either B or 
T lymphocytes.  
Lytic cycle duration: Long, approximately 72 h.  
Cytopathology: Can induce lymphoproliferative diseases and 
cancers (e.g. lymphoma, sarcoma).  
Latent infections: Established in B lymphocytes. Contrary to alpha 
and betaherpesvirus, latency is generally the default pathway in cell 
culture. Viral genomes assume a circular episomal conformation from 
which a limited number of genes are transcribed. 
(Adapted from Roizman, 1982) [3, 6-8] 
 
Another characteristic of herpesvirus is the presence of direct or inverted repeat 
sequences greater than 100 bp in their genomes. Herpesvirus genomes can be divided 
according to their structure in six classes, A to F, as depicted in Figure 1.1.  
Genomes of viruses comprising group A feature a large sequence from one 
terminus directly repeated at the other end. In group B, the terminal sequence is directly 
repeated numerous times at both termini, with a variable number of reiterations at both 
Table removed for copyright reasons. Copyright holder is Springer. 
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ends. Group C genomes also have direct terminal reiterations, and additionally possess 
an internal set of direct repeats which is unrelated to the terminal set.  
Group D genomes contain two unique regions, each flanked by inverted repeats. 
In these genomes, the short unique region (S) flanked by inverted repeats are able to 
invert in relation to the long unique sequence (L) and its flanking repeats, thus generating 
two equimolar genome types differing in the orientation of the short unique sequence 
relative to the fixed long component (see Figure 1.1, further detailed in 1.2.2). Group E 
genomes are similar to group D, but contain a sequence that is repeated directly at the 
genome termini (a) and inversely repeated (a’) at the IRL-IRS junction making these 
genomes terminally redundant. Genomes from this group can be found in four equimolar 
genome types, as both the short unique region (S) and long unique sequence (L) invert 
their orientation. Genomes of F group lack direct or inverted repeats [2, 9]. 
 
 
Figure 1.1 | Classes of herpesvirus genome structures  
Long (L) and short (S) unique sequences are shown as horizontal lines. Repeat regions (including 
the terminal repeat sequences TRL/TRS, internal repeat sequences IRL/IRS and terminal 
redundancy a and its inverted copy a’) are shown as rectangles, with arrows depicting their 
orientation. Adapted from Davison, 2007: ‘Comparative analysis of genomes’ [9].   
 
A
B
C
D
E
F
L
L
S
S
TRL IRL IRS TRSa a' a
Figure removed for copyright reasons. Copyright holder is Cambridge University 
Press. 
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1.1.1 Human Herpesvirus  
There are currently nine herpesviruses distributed among the three subfamilies 
of Herpesviridae which are known to infect humans as their primary host (see Table 
1.1.2).  The two human Simplexviruses, Herpes simplex virus 1 and Herpes simplex virus 
2, have approximately 70 % genomic homology and the most common clinical 
manifestations are mucocutaneous infections including gingivostomatitis, herpes 
genitalis, herpetic keratitis, and dermal whitlows. For the other human alphaherpesvirus, 
Varicella-zoster virus (VZV), primary infection causes chickenpox, while reactivation of 
latent virus causes shingles [10].  
 
Table 1.1.2 | Human herpesvirus 
Subfamily Genus Virus 
Alphaherpesvirinae 
Simplexvirus 
(HSV-1/HHV-1) 
(HSV-2/HHV-2) 
Varicellovirus Varicella-zoster virus (VZV/HHV-3) 
Betaherpesvirinae 
Cytomegalovirus Human cytomegalovirus (HCMV/HHV-5) 
Roseolovirus 
Human Betaherpesvirus 6A (HHV-6A) 
Human Betaherpesvirus 6B (HHV-6B) 
Human Betaherpesvirus 7 (HHV-7) 
Gammaherpesvirinae 
Lymphocryptovirus Epstein-Barr virus (EBV/HHV-4) 
Rhadinovirus 
Kaposi’s sarcoma-associated herpesvirus 
(KSHV/HHV-8) 
 
The two gammaherpesviruses, Epstein-Barr virus (EBV) and Kaposi’s sarcoma-
associated herpesvirus (KSHV), are able to induce oncogenesis in the host, and are 
predominantly associated with lymphoproliferative diseases and cancers such as 
lymphomas and sarcomas [10].  
The betaherpesviruses of the Roseolavirus genus, Human Betaherpesvirus 6A 
(HHV-6A), Human Betaherpesvirus 6B (HHV-6B) and Human Betaherpesvirus 7 (HHV-
7), are primarily associated with exanthem subitem (roseola) as well as rejection of 
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transplanted kidneys [10]. Human cytomegalovirus (HCMV) is the focus of this study and 
thus a more comprehensive overview is given in the following sections. 
 
1.2 Human cytomegalovirus 
HCMV is a ubiquitous pathogen that infects the majority of the population 
worldwide by early adulthood [11]. Although approximately 10 % of infected individuals 
develop mononucleosis, in healthy individuals the infection tends to be asymptomatic 
[10]. It is one of the most common infections that lead to serious complications following 
transplantation, due to transmission from the allograft, where the virus reactivates from 
latent infection [12]. In the immunocompromised, HCMV can cause life-threatening 
diseases including pneumonia, hepatitis, retinitis, encephalitis and gastrointestinal 
disease [13]. Congenital HCMV infection is the leading viral cause of birth defects, 
including hearing loss, impaired vision and learning disabilities [14-16]. 
 
1.2.1 Virion structure  
The viral DNA lies within the icosahedral capsid, which is surrounded by a thick 
proteinaceous tegument and sheathed by a lipid envelope derived from host cell 
membrane, with a mature virion (see Figure 1.2.1) ranging from 150 to 200nm in 
diameter [17, 18]. 
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Figure 1.2.1 | The HCMV virion (not to scale) 
 
1.2.1.1 Capsid  
The capsid has an icosahedral structure, with 12 vertices and 20 faces, and is 
composed of 162 capsomeres and 320 triplexes. Capsomeres are termed pentons or 
hexons and consist of five or six major capsid protein UL86 copies respectively. Hexons 
form the edges and faces of the capsid, while one penton is found at each vertex. One of 
the vertices is occupied by a penton consisting of twelve copies of the portal protein 
UL104 with the remaining eleven being UL86 pentamers. The tips of each hexon are 
decorated with six copies of the small capsid protein UL48A [11]. Triplexes are made of 
one subunit of UL46 and two subunits of UL85 [19], and link the capsomeres together 
(see Figure 1.2.1.1).  
Capsid assembly begins in the cytoplasm and is coordinated by the assembly 
protein precursor UL80.5 and the protease precursor UL80a. Both UL80.5 and UL80a 
contain a nuclear localisation signal (NLS), an amino conserved domain through which 
they interact with each other, and a carboxyl conserved domain which promotes binding 
to UL86. Nuclear translocation of UL86 is mediated by interaction with UL80.5 and 
UL80a, while the portal protein contains its own NLS. Triplexes also assemble in the 
cytoplasm and their translocation into the nucleus is enabled by the NLS of UL46. In the 
Capsid
Genome
Envelope
Tegument
Envelope
glycoproteins
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nucleus, combinations of complexes containing UL86, UL80.5 and UL80a associate with 
the triplexes and the portal protein to form procapsids. The protease precursor is then 
activated resulting in elimination of both internal scaffold proteins UL80.5 and UL80a 
and capsid maturation. 
The viral genome is then translocated into the capsid through the UL104 portal 
protein dodecamer via the terminase complex, a molecular motor composed of UL56, 
UL51 and UL89 [20]. Genome packaging generates C capsids, while capsids that lack DNA 
differ on the presence (B capsids) or absence (A capsids) of internal scaffold. 
UL77 and UL93 then form the capsid vertex-specific complex (CVC), a heterodimer 
located exclusively around pentons. In addition to UL52, the CVC aid the terminase 
complex in the DNA packaging and cleavage process [20-25]. The CVC is also thought to 
label DNA-filled mature capsids as ready for nuclear egress and mediate this process by 
interacting with the nuclear egress complex.  
 
Figure 1.2.1.1 | Schematic representation of HCMV capsid organisation 
(A) Surface lattice of the viral capsid, showing the positions of capsomeres and triplexes on one 
face. Major capsid protein UL86 pentons (green) are located in each vertex of the icosahedric 
structure, while UL86 hexons (blue) form the edges and faces of the capsid. Pentons and hexons 
are linked together by triplexes (yellow). (B) Cross section representation of the capsid. Small-
capsid protein UL48A binds to the tips of UL86, forming a layer between the capsid and the 
tegument. Capsid triplex proteins UL85 and UL46 lie on the capsid floor between capsomeres. 
The capsid vertex specific component proteins UL77 and UL93, are located at the vertices, 
forming a linker between the capsid and the large tegument protein UL48. The latter plays a linker 
role for the association of the outer viral tegument to the capsids together with the inner 
tegument protein. Adapted from Viralzone (Swiss Institute of Bioinformatics) [26]. 
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1.2.1.2 Tegument  
Most of the viral proteins present in the virion can be found in the tegument, many 
of which are phosphorylated and carry out diverse functions, from modulating host cell 
signalling at the start of infection to coordinating the last stages of virion assembly [11]. 
Cellular proteins have also been found in the HCMV virion and are thought to be localised 
in the tegument. In addition, viral and cellular RNAs are also packaged within virions [27]. 
The tegument proteins UL50 and UL53 form the nuclear egress complex, allowing 
the capsid to dock onto the nuclear lamina and mediating its egress into the cytoplasm. 
UL50 localizes to the inner and outer leaflets of the nuclear membrane. The nuclear 
matrix protein UL53 interacts with the capsid through the CVC, directing it to the inner 
nuclear membrane by associating with UL50. Phosphorylation of the nuclear lamina is 
performed by the viral kinase UL97, which is recruited to the nuclear membrane by UL50 
and UL53 [28]. Removal of the nuclear lamina barrier allows primary envelopment of the 
capsid with inner nuclear membrane, followed by translocation within the perinuclear 
space, de-envelopment at the outer nuclear membrane and release onto the cytoplasm. A 
subset of tegument proteins can be found in the nucleus, but it is thought that the majority 
of tegument proteins are acquired in the cytoplasm.  
The most predominant proteins found in the HCMV tegument are the large 
tegument protein UL48, the inner tegument protein UL47, the basic phosphoprotein 
UL32 (BPP/pp150), the upper matrix protein UL82 (pp71), and the lower matrix protein 
UL83 (pp65) [29, 30]. The large tegument protein associates with the capsid by binding 
to the CVC. UL47 is added to the tegument by binding to UL48.  The latter is thought to 
mediate the delivery of capsids along microtubules to the nuclear pore complex [31, 32]. 
UL48 has also been shown to have deubiquitinase activity [33].  
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The UL32 phosphoprotein (pp150) forms a filamentous net-like structure that 
surrounds the capsid. It associates with capsid components and promotes their stability 
during translocation from nucleus to cytoplasm. UL96 is added to capsids in the 
cytoplasm and plays a role in stabilisation of UL32-containing capsids [34]. 
The lower matrix protein UL83 is the most abundant tegument protein in virions, 
and localises to the nucleus immediately after viral entry. It has an immunomodulatory 
role during infection counteracting both innate and adaptive immune responses. It 
becomes associated with the virion during the envelopment stage.  
The upper matrix protein UL82 is a sequence homolog of UL83 and similarly 
localises to the nucleus following entry, where it stimulates viral immediate-early (IE) 
transcription. The viral transactivation of UL83 is regulated by two isoforms of another 
tegument protein UL35 which have different temporal expressions and subcellular 
locations. The 75kDa isoform UL35 is expressed late during infection, is packaged into 
the virion and co-operates with UL82 in the activation of IE genes. Contrarily, the 22 kDa 
isoform UL35A is expressed early in infection, localises to the nucleus and promotes 
cytoplasmic UL82 accumulation, decreasing IE gene transcription.  
 The remaining teguments proteins are less abundant virion components and play 
various roles in HCMV infection including immunomodulation (UL23, UL25, UL26, UL45, 
US23, UL76), viral DNA replication/transcription (UL44, UL54, UL57, UL69, UL79, UL84, 
UL112, IRS1, TRS1, US24), modulation of host cell death pathways (UL36, UL38), latency 
(UL76), among others (UL24, US22, UL43, UL72, UL88). 
Finally, the tegument proteins UL94, UL99, UL71 and UL103 locate to the 
cytoplasmic assembly complex and are involved in the last stages of virion maturation. 
The binding partners UL94 and UL99 are required for secondary envelopment, while 
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UL71 is required for final envelopment and binds to UL103, which has been implicated in 
virion egress from the host cell. 
 
1.2.1.3 Envelope  
The lipid envelope derives from the ER-Golgi intermediate compartment or 
endosomal membranes and contains approximately 23 viral glycoproteins. Five 
glycoproteins (gB, gH, gL, gM, gN) form complexes that contribute to attachment and 
entry. gB (UL55) is capable of forming homotrimers and plays a role in initial attachment 
by binding to heparan sulfate proteoglycans as well as membrane fusion [35, 36]. The 
gM:gN complex, encoded by genes UL100 (gM) and UL73 (gN), is also involved in initial 
attachment through binding of gM to heparan sulfate proteoglycans [37, 38]. The 
glycoproteins gH (UL75) and gL (UL115) form a heterodimer which can associate with 
additional proteins to influence attachment to different cell types. The trimeric complex 
gH:gL:gO facilitates entry into fibroblasts, while the pentameric 
gH:gL:UL128:UL130:UL131A is involved in entry into endothelial and epithelial cells 
[39]. UL116 has been shown to compete with gL for binding to gH, yet the function of a 
UL116-gH complex remains unknown [40].  
Not all glycoproteins are involved in cell attachment/entry and instead have 
immunomodulatory roles, for example RL11, RL12, RL13 and UL119-118 can bind to IgG 
[41-43]. The secreted glycoprotein UL22A acts as virally-encoded decoy receptor for CC 
chemokines such as CCL5/RANTES (Regulated and Normal T Cell Expressed and 
Secreted) chemokine [44]. Other immunomodulatory glycoproteins include the viral G 
protein-coupled receptors (GPCR) encoded by US27, US28, UL33 and UL78. The viral 
GPCRs modulate host CXCR4 signalling, with US27 having an enhancing effect while the 
other three impair CXCR4 signalling outcomes [45]. In addition to CXCR4, UL33 and UL78 
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have both been shown to also heteromerize with CCR5 [46]. US27 influences viral spread, 
and may be required for extracellular spreading as deletion of this gene limits the virus 
to direct cell-to-cell spread [47]. US28 is a CC/CX3C chemokine receptor that binds and 
signals in response to multiple host chemokines (e.g. CX3CL1/fractalkine, CCL2/MCP-1, 
CCL5/RANTES, and CCL7/MCP-3) and also plays a role in latency [48-55].  
Additionally, the glycoproteins RL10, UL1, UL4 and UL132 have been identified as 
virion envelope components [56, 57]. 
 
1.2.1.4 Other virion components  
 In addition to the viral genome and proteins it encodes, viral and host mRNAs, as 
well as cellular proteins, lipids and polyamines are also packaged into the virion [58].  
Two small virus-associated RNA molecules (vRNA-1 and vRNA-2) can be found in 
the core of the virion, hybridized to the origin of DNA replication [59] and may act as a 
primer for initiation of DNA replication. Other viral RNAs encoded by the UL21A and 
RL13 genes, as well as the non-protein coding ORFs RL2-5 (RNA2.7), RL7 (RNA1.2) and 
UL106-UL109 (RNA5.0) in addition to at least 14 different small non-coding mature 
microRNAs (miRNAs) have also been found in virion preparations [60, 61]. However 
most of these species may be nonspecifically incorporated into the virion, potentially 
through interactions with several virion proteins [62]. 
Functions of host proteins incorporated into the virions include but are not limited 
to ATP-binding, calcium-binding (e.g. annexin I, annexin V, annexin VI, annexin A2, 
calreticulin), chaperones, cytoskeleton (e.g. α-Actin, β-actin, α-tubulin, β-tubulin), 
cellular enzymes (including several enzymatic catalysers of glycolysis), protein transport 
(e.g. clathrin), signal transduction (e.g. four isoforms of the signal transduction protein 
14-3-3) and transcription-translation control [56].  
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Spermidine and spermine are two types of polyamines which have commonly 
been found in herpesvirus virions. Although polyamines are survival factors implicated 
in the regulation of programmed cell death, these positively charged molecules are 
thought to play a role during genome replication and packaging by neutralizing the 
negatively charged viral DNA, given that inhibition of polyamine biosynthesis inhibits 
virus growth at the level of virion assembly [63]. 
 
1.2.1.5 Non-infectious viral particles  
 During lytic infection, host cells also produce an excess of non-infectious by-
products which can reach a 20:1 ratio to mature infectious virions [29]. These non-
infectious particles can be distinguished from infectious virions using electron 
cryomicroscopy or separated using ultracentrifugation. They are likely to be a 
consequence of defective virion assembly but may also act as decoys for the immune 
system which facilitate survival of the infectious virions within the host [58]. 
 Dense bodies are non-infectious viral particles which consist of a cluster of 
tegument proteins surrounded by the envelope lipid-bilayer but lack a viral capsid. In 
contrast, non-infectious enveloped particles appear to contain a B-capsid, as well as 
tegument and envelope. Both these types of particles are secreted from infected cells and 
do not contain viral DNA [64], suggesting that neither packaging of the genome nor capsid 
assembly are required for viral envelopment and exocytosis.  
 
1.2.2 HCMV genome  
The HCMV genome is approximately 236 kbp. It has E-type configuration 
consisting of two unique regions (UL and US) flanked by inverted repeat segments (a and 
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a’, TRL and IRL, TRS and IRS), resulting in an overall configuration a-TRL-UL-IRL-a’-IRS-US-
TRS-a. The terminal a sequences can recombine with the internal a’ sequence (where the 
prime signal designates reverse orientation) generating four genome isomers (see Figure 
1.2.2).  
A partially duplicated IE gene set conserved in HCMV strains is located in the small 
IRS and TRS repeats (also designated as c and c’), thus the proteins they code (IRS1 and 
TRS1) have domains with nearly identical amino acid sequences. In contrast, the large 
TRL and IRL (also designated as b and b’) repeats appear to be a consequence of extensive 
passage in vitro [11]. 
 
 
Figure 1.2.2 | Organisation and isomerisation of the HCMV genome 
Representation of the four isomers of HCMV genome (not to scale) according to the orientation 
of UL and US regions relative to each other. 
 
1.2.2.1 Cis-acting sequences 
The genome contains cis-acting sequences which are important for cleavage and 
packaging of newly-synthesised viral genomes (pac1 and pac2), DNA replication (oriLyt) 
and RNA transcription.  
Genome packaging is mediated through viral protein recognition of two 
herpesvirus-conserved sequence motifs, pac-1 and pac-2, located in the a sequence at 
each terminus of the viral genome [65]. These pac elements are recognized by the 
A B UL USAB AC C
A B UL USAB AC C
A B UL USAB AC C
A B UL USAB AC C
25 
 
terminase complex to both translocate the viral DNA into a capsid and signal cleavage 
once a genome-length is reached. The terminase subunit UL56 binds to AT-rich regions 
in the pac sequences while the subunit UL89 cleaves the genome producing ends at the 
location of pac1 and pac2 with single overhanging 3´-nucleotides. 
The origin of DNA synthesis, oriLyt, is located in a position conserved in all 
characterized betaherpesviruses, between the genes UL57 and UL69. It is approximately 
1.5 kbp and has several features, including a pyrimidine-rich sequence, reiterated 
elements, direct and inverted repeats, transcription factor-binding sites and RNA-DNA 
hybrids formed with vRNA-1 and vRNA-2. 
Two other types of cis-acting sequences present in the viral genome include 
transcription enhancers and promoters that are activated at different times throughout 
infection and regulate the activity of host cell RNA polymerase II machinery. HCMV genes 
have individual promoters, except for a small subset of genes that are expressed by 
splicing from a shared 5’ leader sequence (e.g. IE1/UL123 and IE2/UL122). 
 
1.2.2.2 Gene products 
HCMV encodes for 171 canonical genes that are present in all clinical isolates and 
are likely to code proteins (see Figure 1.2.2.2 and Table 1.2.2.2). A variety of functions 
has been assigned to most of these canonical proteins including: modulation of 
transcription, protein synthesis, immune response and host cell cycle; viral tropism, DNA 
replication, virion assembly/maturation/egress, latency, apoptosis inhibition and 
cellular trafficking [66]. Ribosome profiling studies have identified 751 translated ORFs, 
yet it is unclear whether these encode for functional transcripts [67].  
The HCMV genome contains 40 core genes, which are shared among alpha, beta 
and gammaherpesvirus and are presumed to have been inherited from a common 
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ancestor. Similarly, it contains 7 genes which are shared among beta and 
gammaherpesvirus only, thus termed sub-core. Most core genes are essential for viral 
growth and are involved in vital processes such as DNA replication, packaging, capsid 
structure and assembly. Sub-core genes are required for the transcription of late 
transcripts. The remaining non-core canonical genes are grouped into gene families 
according to the likelihood of arising from gene duplication, although the proteins they 
code have different functions. Besides gene duplication, acquisition of genes from the cell 
or from other viruses has played a role in increasing the coding capacity of HCMV.  Gene 
capture is likely to have occurred by insertion of a cDNA copy of a cellular mRNA or pre-
mRNA into the viral genome, since most of the cellular homolog genes lack introns. 
Additional ORFs encode non-coding RNAs including the four long non-coding 
RNAs (such as RNA2.7, RNA1.2, RNA4.9 and RNA5.0), at least 23 miRNAs most of which 
associate with the RNA-induced silencing complex, and antisense transcripts which are 
transcribed antisense to coding regions. The majority still has unclear functions, however 
cellular and viral targets for some of these RNA molecules have been identified, hinting 
that they may be involved in promoting changes in the infected cell to favour lytic 
infection [68]. 
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Figure 1.2.2.2 | Genetic map of HCMV Merlin genome 
Protein-coding regions are indicated by coloured arrows grouped in gene families as depicted by 
the key, with gene nomenclature below. UL72 is both a member of the deoxyuridine 
triphosphatase-related protein (DURP) gene family and a core gene. Introns are shown as narrow 
white bars. The UL and US prefixes have been omitted from UL1–UL150 and US1–US34A. Colours 
differentiate between genes on the basis of conservation across the α-, β- and γ-herpesvirinae 
(core genes) or between the β- and γ-herpesvirinae (sub-core genes). Long non-coding RNAs, the 
origin of lytic replication (oriLyt) and  the RL and RS regions (which contain the ‘a’ sequence as a 
direct repeat at the genome termini and as an inverted repeat internally) are indicated by 
coloured boxes. Adapted from Dolan et al (2004) and Gatherer et al (2011) [69, 70]. 
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Table 1.2.2.2 | Canonical protein coding genes in HCMV Merlin strain 
Gene Protein name Gene Protein name Gene Protein name 
RL1 IRL1, HKLF1 UL51 UL51, TRM2 UL131A UL131A 
RL5A RL5A UL52 UL52 UL132 UL132, gp42 
RL6 RL6 UL53 UL53, NEC1 UL133 UL133 
RL8A RL8A UL54 UL54 DPOL UL135 UL135 
RL9A RL9A UL55 UL55, gB, gp116, gp58 UL138 UL138 
RL10 RL10, gpTRL10 UL56 UL56, TRM1 UL139 UL139 
RL11 RL11, gpTRL11, gp34 UL57 UL57, SSB, p130 UL140 UL140 
RL12 RL12, gpTRL12, gp95 UL69 UL69, MRE UL141 UL141, gpUL141 
RL13 gpTRL13, RL13/14 UL70 UL70, Primase UL142 UL142 
UL1 UL1, gp1 UL71 UL71, CEF1 UL144 UL144 
UL2 UL2 UL72 UL72 UL145 UL145 
UL4 UL4, gp48 UL73 UL73, gN UL146 UL146, vCXCL1 
UL5 UL5 UL74 UL74, gO, gp125 UL147 UL147, vCXCL2 
UL6 UL6 UL74A UL74A UL147A UL147A 
UL7 UL7 UL75 UL75, gH, gp86 UL148 UL148 
UL8 UL8 UL76 UL76 UL148A UL148A 
UL9 UL9 UL77 UL77, CVC2 UL148B UL148B 
UL10 UL10 UL78 UL78 UL148C UL148C 
UL11 UL11 UL79 UL79 UL148D UL148D 
UL13 UL13 UL80 UL80, UL80a, pPR, p38 UL150 UL150 
UL14 UL14 UL80.5 UL80.5, pAP UL150A UL150A 
UL15A UL15A UL82 UL82, pp71 IRS1 IRS1 
UL16 UL16, gpUL16 UL83 UL83, pp65 US1 US1 
UL17 UL17 UL84 UL84 US2 US2 
UL18 UL18, gpUL18 UL85 UL85, TRI2, TRX2 US3 US3 
UL19 UL19 UL86 UL86, MCP US6 US6 
UL20 UL20 UL87 UL87 US7 US7 
UL21A UL21 UL88 UL88 US8 US8 
UL22A UL21.5 UL89 UL89, TRM3 US9 US9 
UL23 UL23 UL91 UL91 US10 US10 
UL24 UL24 UL92 UL92 US11 US11 
UL25 UL25, pp85 UL93 UL93, CVC1 US12 US12 
UL26 UL25 UL94 UL94, CEP2 US13 US13 
UL27 UL27 UL95 UL95 US14 US14 
UL29 UL29/28 UL96 UL96 US15 US15 
UL30 UL30 UL97 UL97, VPK US16 US16 
UL30A UL30A UL98 UL98, NUC US17 US17 
UL31 UL31 UL99 UL99, CEP3, pp28 US18 US18 
UL32 UL32, BPP, pp150 UL100 UL100, gM US19 US19 
UL33 UL33 UL102 UL102, HEPA US20 US20 
UL34 UL34 UL103 UL103, CEP1 US21 US21 
UL35 UL35 UL104 UL104, Portal protein US22 US22 
UL36 UL36, vICA UL105 UL105, Helicase US23 US23 
UL37 UL37, vMIA, gpUL37 UL111A UL111A, vIL-10 US24 US24 
UL38 UL38 UL112 UL112-113 US26 US26 
UL40 UL39 UL114 UL114 US27 US27 
UL41A UL41A, UL41.5 UL115 UL115, Gl US28 US28 
UL42 UL42 UL116 UL116,  US29 US29 
UL43 UL43 UL117 UL117 US30 US30 
UL44 UL44, VPAP, PPS, p52 UL119 gp68, UL119-118 US31 US31 
UL45 UL45 UL120 UL120 US32 US32 
UL46 UL46, TRI1, TRX1 UL121 UL121 US33A US33A 
UL47 UL47, ITP UL122 UL122, IE2, IE-86 US34 US34 
UL48 UL48, LTG UL123 UL123, IE1, IE-72 US34A US34A 
UL48A UL48A, SCP, UL48.5 UL124 UL124 TRS1 TRS1 
UL49 UL49 UL128 UL128   
UL50 UL50, NEC2 UL130 -   
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1.2.2.3 Viral DNA replication 
Viral DNA replication takes place in the nucleus of infected cells, with peak 
production approximately around 24 h post-infection. The mechanism is not completely 
understood, but several viral proteins and regions in the viral genome have been found 
to play a role in this process. 
Genomes isolated from virions are linear, yet the viral DNA circularises once it is 
delivered to the nucleus and replication occurs in a rolling circle mechanism, generating 
tandemly linked copies. As mentioned in 1.2.2.1, these are cleaved into genome units by 
the viral terminase during encapsidation. 
Synthesis of new genome copies initiates at the lytic origin of replication, oriLyt, 
which contains two regions that are essential to viral DNA replication. Essential Region I, 
contains a bidirectional promoter and pyridine-rich sequence termed the Y-block. 
Essential Region II, comprises an RNA-DNA hybrid structure containing a vRNA-2 binding 
site and an adjacent RNA stem-loop, and is enriched in direct and inverted repeat 
sequences as well as transcription factor-binding sites.  
Initiation of DNA synthesis is dependent on the formation of a complex between 
UL84 and IE2-p86 (encoded by UL122), which binds to and activates the oriLyt promoter. 
Binding of UL84 to IE2-p86 disrupts its gene expression transactivation activity.  
Additionally, UL84 also binds the RNA stem-loop and acts to change its conformation 
[71]. 
The UL112-113 ORF encodes four phosphoproteins (pp34, pp43, pp50, pp84) 
which are produced via alternative mRNA splicing and form a complex that is thought to 
mediate assembly of the viral replisome. In complex with the UL112-113 proteins and 
IE2-p86, UL84 recruits the polymerase processivity subunit UL44, which recruits the 
other replication fork proteins: the DNA polymerase catalytic subunit UL54, the single-
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stranded DNA-binding protein UL57, and the heterotrimeric helicase-primase complex 
consisting of the helicase UL105, the primase UL70 and a helicase-primase associated 
factor UL102. UL44 also interacts with the alkaline nuclease UL98 and the DNA 
glycosylase UL114, which appears to be important for efficient DNA synthesis.  
Other viral proteins encoded by UL36 (vICA), UL37 (vMIA), IRS1 and TRS1 are not 
involved in the replication compartment but support HCMV DNA replication by 
modulating the host cell environment. Additionally, cellular factors such as the oriLyt-
binding C-EBP and the cell-viability promoting hnRNP-K are necessary for viral DNA 
synthesis.  
 
1.2.3 Lytic lifecycle  
HCMV initiates infection by binding to heparin sulphate proteoglycans on the cell 
surface [35]. Following initial attachment, interactions between gB and cellular integrins 
α2β1, α6β1 and αVβ3 are thought to be required [72]. For fibroblast cells, a trimeric 
complex gH:gL:gO facilitates entry, in addition to gB, and the viral envelope fuses with the 
cellular membrane. For endothelial and epithelial cells, the pentameric complex 
gH:gL:UL128:UL130:UL131A mediates entry via endocytosis [39]. Once the nucleocapsid 
is released into the cytoplasm, tegument proteins aid its translocation towards the 
nucleus via microtubules. There it interacts with nuclear pores in order to release the 
viral genome into the nucleus. Other tegument proteins play a role in increasing efficiency 
of IE gene expression [73].  
Viral gene expression follows a phasic pattern, with IE genes being the first to be 
expressed. IE gene expression is dependent on pre-formed host and viral machinery as 
well as the tegument protein pp71 (UL82) which functions as a transactivator. The major 
IE gene, transcribed from the major immediate early promotor (MIEP), encodes two 
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predominant nuclear phosphoproteins, IE1-p72 (from gene UL123) and IE2-p86 (from 
gene UL122). Together, these proteins reverse epigenetic repression, induce expression 
of E and L genes, self-regulate IE gene expression and contribute to the switch between 
latency and reactivation. The E genes are necessary for viral DNA replication, which starts 
at approximately 14h post-infection. Their activation requires expression of IE genes. 
Once DNA replication has been initiated, the E-dependent L gene expression peaks. These 
proteins have mostly structural functions (capsid and tegument components) and their 
products control capsid maturation, DNA encapsidation, virion maturation and egress 
[11].  
Virion assembly begins in the nucleus. Firstly, the capsid is assembled (described 
in 1.2.1.1) and the genome is encapsidated. Initial components of the tegument are added 
to the capsid, forming an inner tegument that provides stability during nuclear 
translocation and directs trafficking to sites of envelopment in the cytoplasm. Then the 
nuclear egress complex, comprised by UL50 (NEC1) and UL53 (NEC2), mediates 
translocation of the nucleocapsid to the cytoplasm by recruiting kinases that disrupt the 
nuclear lamina. Once in the cytoplasm, the secretory apparatus termed the assembly 
complex mediates final tegumentation and envelopment. The mature virion is then 
transported to the cell surface in small vesicles, exiting the cell via exocytosis.  
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Figure 1.2.3 | Overview of the human cytomegalovirus life cycle 
(A) A virion initiates infection by attaching to the cell surface, followed by entry via fusion of the 
viral envelope with the plasma membrane or endocytosis. Tegument proteins and the 
nucleocapsid are released into the cytosol. (B) The nucleocapsid is translocated towards the 
nucleus, along cytoplasmic microtubules. The viral genome is released into the nucleus where a 
temporal cascade of gene expression is activated: firstly immediate early (IE) genes, followed by 
delayed early (DE) genes, which initiate viral genome replication, and late (L) genes. (C) 
Translation of the structural virion components initiates assembly of viral capsid in the nucleus. 
The viral genome is then translocated into the capsid, followed by nuclear egress and acquisition 
of tegument proteins in the cytosol. These particles are then trafficked to the viral assembly 
complex (AC) which contains components of the endoplasmic reticulum (ER), Golgi apparatus, 
and endosomal machinery. There they acquire more tegument proteins and a viral envelope by 
budding into intracellular vesicles at the AC. (D) Mature virions are released along with non-
infectious dense bodies through exocytosis. Figure and figure legends were adapted from (Jean 
Beltran & Cristea, 2014) and modified by Abdul-Aleem Mohammad. Reprinted from Abdul-Aleem 
Mohammad, 2017: “Human Cytomegalovirus: From Novel Strain, miRNAs to Interplay with 
Breast Cancer”. [74, 75] 
 
  
Figure removed for copyright reasons. Copyright holder is Abdul-Aleem Mohammad. 
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1.2.4 Viral latency  
Like all herpesvirus, HCMV is able to persist within the host by establishing a 
generally asymptomatic, lifelong infection. Although viral DNA can be detected, 
immediate early (IE) gene expression is suppressed and no infectious virions are 
produced [76].  Cells of the myeloid lineage, including CD14+ monocytes and their CD34+ 
progenitor, are well established sites of latent infection, however cell differentiation 
triggers viral reactivation and lytic replication [77-79].  
Similarly to other herpesvirus, gene expression during HCMV latency was initially 
thought to be restricted to a subset of viral genes and thus different from the lytic 
infection transcriptional programme [80]. In addition, different isoforms of viral 
transcripts have been shown to be expressed during latency [81, 82]. Two recent studies 
of the viral latent transcriptome have shown a broader pool of transcripts which largely 
resembles a late stage of lytic infection, although at lower expression level [83, 84]. 
 
1.2.5 Transmission and tropism 
Transmission requires direct contact with infected bodily fluids (e.g. saliva, breast 
milk, urine and genital secretions) [85, 86]. HCMV can be vertically-transmitted from an 
infected mother to an embryo, fetus or baby. Horizontal transmission occurs 
predominantly by contact with infected children (especially in childcare centres), 
through sexual activity in adults [87], and via blood transfusion and cells, tissues or organ 
transplantation from seropositive donors [11].  
The virus is able to infect a wide range of cells, including parenchyma and 
connective tissue of any organ, as well as several hematopoietic cell types. Infection of 
endothelial cells and hematopoietic cells facilitate systemic spread within host while 
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infection of epithelial cells in salivary glands, kidney and gastrointestinal tract likely 
contributes to inter-host transmission, by viral shedding into body fluids. Infection of 
ubiquitous cell types such as fibroblasts and smooth muscle cells enable efficient 
proliferation [88].  
A number of immortalised cell lines (glioblastoma, monocytic) and primary cell 
cultures (skin and lung fibroblasts, vascular smooth muscle cells, vascular endothelial 
cells, retina pigment epithelial cells, placental trophoblasts, hepatocytes and kidney 
epithelial cells, monocyte-derived macrophages and dendritic cells, neuronal and glial 
brain cells) support a complete viral replication cycle [88].  
Viral tropism varies among HCMV strains, however skin and lung fibroblasts are 
the standard cell type for isolation and propagation from patient samples and the most 
efficient progeny producers [11]. 
 
1.2.6 Strains of HCMV 
There are two types of HCMV strains: clinical isolates that have been passaged 
minimally in fibroblasts and laboratory strains that have been extensively passaged and 
adapted to growth in fibroblasts [89]. 
The most commonly used lab-adapted strains are AD169 and Towne [90], which 
was passaged 125 times in vitro in order to develop an attenuated vaccine [91]. High-
passage led to the development of mutations that affected several genes in AD169 (RL5A, 
RL13, UL36 and UL131A) and Towne (RL13, UL1, UL40, UL130, US1 and US9). In 
addition, these high-passage strains differ from wild-type HCMV as the UL/b’ region has 
been replaced. A 15 kbp deletion in AD169 resulted in the absence of genes between 
UL132-IRS1 and their replacement with a duplication of UL/b, containing copies of TRL1-
14 termed as IRL1-14. Similarly, in Towne, a 13 kbp deletion in UL/b’ replaced genes 
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between UL148-IRS1 with a duplication of UL/b containing copies of TRL1-14 [92]. 
Furthermore, variants of each strain are generated as they are passaged in different 
laboratories accumulating diverging mutations since their initial isolation. 
Another commonly used lab-strain, TB40/E, has been reported to possess the 
broad cell tropism of a clinical isolate and the high titre growth of a cell culture adapted 
strain [93, 94]. However, this strain has been shown to be genetically and phenotypically 
heterogeneous, with more than one virus involved in its derivation, thus complicating 
correlation between genotype and phenotype [69].  
In 1996, Cha et al., showed that the low passage strain Toledo had a segment 
inversion which disrupted at least UL128 [95]. Several other low passage strains have 
also been shown to contain disruptions in UL128, UL130 and UL131A [96] or genes in the 
RL11 family, a consequence of adaptation to fibroblast cell culture.  
Given that passage of virus rapidly causes adaptive mutations, no laboratory 
strain can be assumed to be genetically intact as any viral gene in a cultured stock could 
be mutated and this fact could go unrecognized, making it easy to overlook loss of gene 
function [90]. This led to the cloning of the genome of several HCMV strains onto bacterial 
artificial chromosomes (BAC) to generate clones where each genome can be maintained 
without acquiring additional mutations, as well as facilitating their genetic manipulation 
to match the sequence in the clinical isolate. Many of these BAC clones incorporated an 
element of the vector cassette within the US region replacing several viral genes with 
immunomodulatory function [97]. 
The genome sequence of HCMV strain Merlin is designated the reference HCMV 
sequence by the National Center for Biotechnology Information [69]. A recombinant 
version (RCMV 1111) of this strain was cloned into a BAC and repaired to match the viral 
sequence of the original clinical isolate from which it derived. Given that restoration of 
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RL13 and UL128 impairs growth in fibroblasts, RCMV 1111 contains point mutations in 
these two genes to relieve selective pressure [98]. 
 
1.2.7 Immune response and modulation 
 
1.2.7.1 Innate immune response 
With an intricate network of activating and inhibiting receptors, NK cells are 
crucial to controlling HCMV infection [99, 100] via direct cytotoxicity (either antibody-
dependent or via perforin and granzyme) as well as the production of cytokines and 
chemokines such as interferon-gamma and tumour necrosis factor alpha [101]. 
Binding of HCMV envelope glycoproteins to cellular receptors trigger signalling 
cascades that result in the activation of cellular transcription factors such as NFκ-B, Sp1, 
and interferon regulatory factor 3 (IRF3) [102-105]. The toll-like receptor 2 (TLR2) 
recognises glycoproteins gB and gH and activates NFκ-B signalling resulting in the 
production of inflammatory cytokines such as IL-6 and IL-8 [104, 106]. The Z-DNA 
binding protein 1 (ZBP1) detects HCMV DNA and activates IRF3 signalling, triggering 
interferon type I production and expression of interferon-stimulated genes (ISGs) [107]. 
The PML-nuclear body constituents Daxx, Sp100 and PML proteins have been shown to 
repress expression of HCMV IE genes in an interferon-inducible manner [108-111]. 
The catalytic activity of the ISG-encoded 2’-5’ oligoadenylate synthase (OAS) 
results in the activation of RNase L, leading to the degradation of single-stranded mRNA 
and rRNA [112]. Upon recognition of dsRNA, the ISG-encoded protein kinase R (PKR) 
halts protein synthesis by phosphorylating the eukaryotic initiation factor 2α (eIF2α) 
[112]. Together, OAS and PKR create an antiviral environment that prevents the virus 
from translating its proteins.  
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1.2.7.2 Adaptive immune response 
An antigen specific immune response is elicited by antigen presenting cells (APCs) 
upon processing of viral particles. Antigens are displayed on the surface of APCs by the 
major histocompatibility complex (MHC) class II molecules to CD4+ T cells; and in the 
surface of all nucleated cells by class I molecules to CD8+ T cells, generating a specific 
subset to a range of viral epitopes. These cells restrain viral replication and are eventually 
maintained as long term memory T cells [113, 114]. HCMV-specific CD4+ and CD8+ T cells 
secrete cytokines (such as IFN-γ) to regulate the immune response in addition to 
expressing and releasing the cytolytic proteins granzyme and perforin onto the 
cytoplasm of infected cells upon recognition of vira antigens, triggering apoptosis [115-
121].   
B cells also play a role in controlling HCMV infection by producing antibodies 
against viral proteins such as the envelope glycoproteins (e.g. gB, gH and gL) and virion 
tegument proteins (e.g. UL32/pp150 and UL83/pp65) [122-127].  
  
1.2.7.3 Immune evasion 
HCMV has developed several strategies to counteract the actions of the host 
immune system. Modulation of MHC class I and II molecules by viral transcripts US2, US3, 
US6, US10, US11, UL82 (pp71), UL83 (pp65) disrupt antigen processing and presentation 
[128]. Furthermore, the miRNA miR-US4.1 downregulates ERAP-1, inhibiting viral 
peptide trimming for MHC Class I peptide presentation and consequently decreasing the 
susceptibility of infected cells to HCMV-specific cytotoxic T lymphocytes [129]. 
Multiple viral proteins are involved in the inhibition of NK cell-mediated killing 
[130]. The viral MHC I homolog UL18 binds the inhibitory receptor LIR1 on NK cell 
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surface [131]. UL142, also an MHC I homolog, promotes downregulation of MICA, a ligand 
for activating receptor NKG2D [132]. The glycoprotein UL40 upregulates HLA-E, which is 
a ligand for the inhibitory complex CD94/NKG2A on NK cells [133]. Tegument protein 
UL83/pp65 binds activating receptor NKp30, causing its dissociation from CD247 and 
repressing the NK activating ability of this complex [134]. UL16 has been shown to 
sequester MICB, ULBP1 and ULBP2 in the ER, preventing their binding to the NK 
activating receptor NKG2D [135-137]. The UL/b’ region has been shown to encode for 
transcripts that protect from NK cell attack [138]. Besides UL142, another gene from the 
UL/b’ region, UL141 has been shown to repress NK cell cytotoxicity by sequestering 
CD155 in the ER, which is a ligand for activating receptors CD226 and CD96 [138]. The 
miRNA miR-UL112 targets MICB mRNA suppressing cell surface expression and 
preventing this ligand from activating the natural killer cell receptor NKG2D [139]. 
To evade complement-mediated lysis, HCMV incorporates complement control 
proteins CD55 and CD59 into its virion, which are able to inhibit various stages of the 
complement cascade [140]. Additionally, two viral Fc gamma receptor homologs, 
encoded from genes RL11 and UL119-118 have been shown to serve as a receptor for IgG 
and thus may be involved in evading complement activation and antigen-dependent cell-
mediated cytoxicity [141].  
Modulation of the IFN signalling pathway is achieved through the 72kDa 
immediate early 1 protein (IE1) and 86kDa immediate early protein 2 (IE2). IE1 binds 
STAT1 and STAT2 preventing the transcriptional activator ISGF3 from binding to the ISG 
promoter [142]. IE2 represses transcription of IFN-β and CCL5 through binding to the 
transcription factor NFκB [143]. The miRNA miR-UL148D also targets CCL5 by inducing 
degradation of its mRNA, preventing its translation into a T-cell chemoattractant [129].  
39 
 
Viral proteins TRS1 and IRS1 can suppress block the OAS and PKR pathways, preventing 
activation of RNase L and protein synthesis shutoff [144]. 
The virally encoded interleukin-10 homolog, UL111A, mimics the function of this 
immunosuppressive cytokine, downregulating IFNγ and TNFα and decreasing the 
expression of MHC class I and II molecules [145, 146]. Additionally, UL111A can inhibit 
cytokine production via activation of the phosphatidylinositol 3-kinase/Akt pathway 
[147]. The viral GPCR homologs US27 and US28 bind and internalise cytokines, removing 
them from the extracellular environment [148, 149]. UL144 is able to inhibit T-cell 
proliferation in vitro and induce CCL22 expression, a TH2 chemoattractant, to subvert 
TH1 response [150, 151]. The latency-associated UL138 has been shown to induce 
TNFR1 hyper-responsiveness, this is thought to contribute to contribute to HCMV 
reactivation by re-initiation of transcriptional programmes leading to lytic infection [152, 
153]. 
 
1.2.8 Antiviral treatment 
Several antiviral therapies have been approved to treat HCMV infection, having 
been shown to eliminate or reduce viremia and viral shedding in immunocompromised 
adults [11]. The majority of these compounds target the DNA polymerase UL54 and are 
accompanied by significant toxicity, except for the recently approved Letermovir (see 
Table 1.2.8). Maribavir, another antiviral drug targets the viral kinase UL97 but is still 
being tested. However, therapeutic agents targeting viral proteins are subject to the 
development of resistant mutations, rendering them ineffective. Vaccines against HCMV 
are still in development [154].    
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Table 1.2.8 | Antiviral agents approved for treatment or prevention of HCMV infection in 
immunocompromised adults 
Antiviral agent Inhibits/targets Major toxicity 
Ganciclovir DNA polymerase UL54 Hematologic 
Valganciclovir DNA polymerase UL54 Hematologic 
Foscarnet DNA polymerase UL54 Renal 
Cidofovir DNA polymerase UL54 Renal neutropenia 
Acyclovir DNA polymerase UL54 Neurotoxicity 
Letermovir UL56 subunit of Terminase complex   
Adapted from Mocarski et al, 2013: ‘Cytomegaloviruses’. [11, 154] 
1.3 Proteomics as a tool for studying viral infection 
 Viruses require a living host cell for replication. Their replicative cycle relies on 
host-pathogen interactions which have been adapted throughout millions of years of co-
evolution with their host. Although viral replication strategies may differ, host-pathogen 
interactions occur regularly throughout the virus lifecycle and underpin processes such 
as cell entry, recruitment of intracellular machinery for trafficking and replication as well 
as subversion of the immune system. Thus, understanding the molecular basis for the 
biological processes that take place throughout the viral life cycle inside the host is 
necessary for the development of means to prevent and treat disease caused by these 
pathogens.  
 In the last decade, genomic, transcriptomic, proteomic and metabolomics 
approaches have emerged as powerful and effective tools, often in a complementary 
manner, in basic, translational and clinical research. For example, a study by Soderholm 
et al (2016) compiled data from transcriptomics, metabolomics, proteomics (using 
iTRAQ technology, a type of isobaric tags that allows up to 8-plex analysis) and 
phosphoproteomics, providing a complete analysis of gene regulation during Influenza A 
infection [155].  
Proteomics, the large-scale study of the proteome of a biological system, provides 
sensitive protein detection and quantification. Proteomics approaches have been 
developed to study modulation of protein abundance, spatial organisation of the 
Table removed for copyright reasons. Copyright holder is WOLTERS KLUWER HEALTH. 
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proteome, pathogen-induced post-translational regulation and mapping host–pathogen 
protein interaction networks. In addition to allowing the study of thousands of proteins 
in a single experiment, through the use of sample labelling methods such as stable isotope 
labelling of amino acids in cell culture (SILAC) [156] or tandem-mass tagging (TMT) 
labelling [157], proteomics allows analysis of up to 3 or 16 samples (respectively) in 
tandem. 
 
1.3.1 Proteomic studies of HCMV infection 
To study HCMV infection, five kinds of proteomic approaches (briefly summarised 
below) have been applied: 
 
(a) Studies of the virion 
(b) Temporal studies of viral and host protein changes throughout infection 
(c) Studies of post-translational modifications by viral infection 
(d) Studies of changes of viral and host proteins in space during infection 
(e) Studies of individual viral-host protein interactions 
 
In 2004, Varnum et al., employed mass spectrometry to identify proteins present 
in the particles of virions from HCMV AD169 strain [56]. This was extended by Buscher 
et al (2015), using proteomics to examine molar ratios of proteins in virions from 
different laboratory strains, suggesting that most proteins were in fact present in similar 
ratios across the strains studied [158].  
In 2013, Weekes et al studied the regulation of the plasma membrane (PM) 
proteome by UL138 during latent HCMV infection and identified the regulation of the 
multidrug-resistance protein 1 (MRP1) [159]. This study employed PM profiling, a 
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technique that combined enrichment of oxidated and aminooxy-biotinylated sialylated 
PM proteins with SILAC-based quantitation to allow sample multiplexing [160]. In 2014, 
Reyda et al used label-free quantification to study protein relative abundance over three 
time-points of infection with two HCMV AD169-derived strains, in addition to performing 
proteomics on purified virions from these strains [161]. In the same year, a study by 
Weekes et al, analysed changes in PM and whole cell proteins during the course of HCMV 
Merlin strain infection. Using the multiplexing capacity of TMT tags, it provided a 
comprehensive quantification of over 8000 whole cell lysate proteins (WCL) and 1200 
PM proteins throughout the course of HCMV infection, with 4 time points for PM and 8 
time points for WCL. This study reported on the HCMV-induced modulation of cellular 
pathways and regulation of specific protein families, including proteins important in NK 
and T-cell recognition, and innate immunity. Additionally, it confirmed the identification 
of a subset of new viral ORFs, some of which had been previously identified by ribosomal 
profiling [67], as well as grouping viral proteins into five classes according to their 
profiles of relative abundance throughout infection. This was the first multiplexed study 
of viral proteomics using MS3/TMT technology and paved the way for several temporal 
viromic studies [162]. Another multiplexed approach by Nightingale et al (2018), used 
three orthogonal proteomic/transcriptomic screens to identify putative HCMV 
restriction factors on the basis of pathogen-induced degradation by the proteasome or 
lysosome early during infection. This degradation dataset was then combined with a 
comprehensive panel of HCMV gene block deletion mutants to predict the viral genes 
targeting more than 250 host proteins [163]. 
During infection, modulation of gene expression and function can also be 
regulated through post-translational modifications, such as phosphorylation and 
ubiquitination. The most abundant virion protein, UL83 plays a role in immune evasion 
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by inhibiting IFI16-mediated DNA-sensing [164]. A study by Li et al. (2013), showed that 
UL83 is phosphorylated in multiple sites by host kinases in order to interfere with its 
immune evasion function [165]. Moreover, the virus can also modulate phosphorylation 
of host proteins. Using SILAC, Oberstein et al. (2015), analysed UL97-induced changes on 
the cellular phosphoproteome [166]. In 2012, Sinigalia et al, showed that the viral DNA 
polymerase processivity factor UL44 has multiple sites for small ubiquitin-related 
modifier (SUMO) and is SUMOylated, enhancing viral replication [167].  
During infection viral proteins are shuttled to the appropriate cellular 
compartments either to play a role in replication or for virion assembly [168]. Often, the 
pathogen also induces changes in the pools of specific host proteins, either through 
retention in a cellular compartment or shuttling to another subcellular location. In 2016, 
Beltran et al used a combination of density-gradient fractionation of organelles and MS2-
level TMT proteomics to identify the spatial dynamics of proteins throughout the course 
of infection with HCMV AD169 strain [169]. This so-called spatial proteomics provided 
data on the subcellular localisation of individual viral proteins through the course of 
infection, and how HCMV may induce host proteins to translocate from one compartment 
to another.  
Studies of individual protein-protein interactions are the most commonly used to 
elucidate the contribution of numerous viral protein for infection [170-174]. The most 
common affinity-purification (AP-MS) approaches involve heterologous expression of 
viral proteins tagged with an epitope for immunoprecipitation or expression of virally 
encoded tagged protein. However, this is normally done for individual proteins and a 
large-scale analysis of protein-protein interactions during HMC infection had not yet 
been done. 
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1.3.2 Affinity-purification mass spectrometry 
 Affinity-purification mass spectrometry (AP-MS) allows the identification of 
proteins interacting with a given bait. To achieve this, clarified cell lysates are incubated 
with antibodies conjugated to a resin (agarose, sepharose, magnetic beads) and protein 
complexes are isolated. Proteins are then digested into peptides, separated through 
liquid-chromatography and analysed by tandem mass spectrometry.  
While label-free quantitation is the most common, multiplex analysis can be 
achieved via the use of SILAC or isobaric tag technologies (TMT, iTRAQ). Moreover, there 
are several approaches that employ the use of epitope tagged proteins for the study of 
interactions, such as cellular overexpression of tagged viral proteins or infection with 
virus that encodes a tagged bait. 
In addition to HCMV, several studies have applied this technology to identify 
interactors to epitope-tagged proteins of other virus such as HSV-1, KSHV, HPV, Human 
respiratory syncytial virus, Influenza, Dengue virus, Sindbis virus, Ebola virus and HIV 
and West Nile virus [175-183]. For a small subset of virus, such as HCV, Ebola, HIV and 
KSHV, this approach has been used to generate a complete or near-complete map of 
interactions for all viral proteins [184-187]. 
A drawback to this approach is the identification of unspecific interactions, yet 
truly specific interactions may be singled out via comparison to appropriate controls 
which allow the establishment of a background of common contaminants. To aid this 
process, a repository of contaminants for AP-MS data has been compiled from negative 
controls of multiple AP-MS studies to increase background coverage [188]. 
 To distinguish the interactions that are most likely to be true from the non-specific 
contaminants, these AP-MS datasets are usually analysed using filtering tools with 
algorithms that score all the putative interactors. For example, in 2015 Huttlin et al. 
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published a fraction of the human interactome. AP-MS analysis was used for 2,594 baits 
and all detected interactions were then scored using the algorithm from CompPASS. 
Through comparison of the AP-MS samples being analysed in tandem, CompPass 
identified 23,744 interactions involving 7,668 proteins [189]. These were then compiled 
into the BioPlex Network (https://bioplex.hms.harvard.edu/). CompPASS measured 
enrichment of each protein for each IP in comparison to other unrelated AP-MS data and 
its algorithm features several scoring metrics that altogether take into account protein 
abundance, detection frequency and reproducibility amongst replicates. 
 
1.4 Project aims 
The many proteomic approaches employed to study the biology of HCMV infection 
have provided information on how the abundance and location of cellular and viral 
proteins changes during infection. This may allow the prediction of potential interactions 
that explain patterns of gene regulation, by juxtaposing cellular and viral protein profiles. 
Given the number of canonical and non-canonical ORFs encoded by HCMV, identifying 
which viral protein is responsible for a given modulation of cellular factors may prove to 
be labour intensive [67, 163]. Furthermore, certain cellular proteins may be targeted by 
more than one viral factor [130, 190-192].  
To deepen our understanding of the molecular mechanisms underlying the 
changes observed during HCMV infection, this project aimed to identify viral-viral and 
viral-human protein interactions in cells infected with HCMV.  
An analysis of HCMV protein interactions can be achieved by generating stable cell 
lines that overexpress each of the 171 canonical proteins tagged with a V5 epitope. 
Additionally, two uncharacterised ORFs, ORFL147C and ORFS343C.iORF1 (referred to 
from here on as ORFS343C) which have been identified in previous proteomics studies 
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and by ribosomal profiling will be included based on the relative of these polypeptides to 
other HCMV proteins (see Figure 1.4) [193]. 
 
 
Figure 1.4 | Abundance of canonical and non-canonical HCMV ORFs quantified by 
proteomics from the whole cell lysate analysis   
The intensity-based absolute quantification (IBAQ) method was adapted to generate normalised 
average IBAQ values for proteins quantified in two analysis of whole cell lysates from HCMV 
infection at 24, 48 and 72 h PI [162, 194]. Error bars represent the range of values for each 
protein. ORFL147C was the most abundant non-canonical ORF, and ORFS343C.iORF1 was one of 
the least abundant non-canonical ORFs (shown in red). Both were included as baits in the 
interactome. Adapted from Nobre et al (2019) [193].  
 
 
These cell lines can subsequently be infected with low-passage Merlin strain 
HCMV. Lysates will then be collected at a singular time-point of infection to guarantee a 
similar background for the analysis, and protein complexes will be isolated through 
immunoprecipitation. Proteins that interact with the V5-tagged bait will be identified 
through mass spectrometry and through the use of the CompPass platform [195]. 
Potential interactors will be scored according to their enrichment, abundance, detection 
frequency and reproducibility in order to remove contaminants [189]. 
 Thus, project aims were as follows: 
- To generate the necessary resources for the assembly of a network of  HCMV 
protein interactions in infected cells; 
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- To adapt and optimise the AP-MS protocol employed by Huttlin et al (2015); 
- To validate a subset of novel findings. 
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2 | Materials and Methods 
Parts of the work presented in this chapter have been published in a similar form in eLife 
(Nobre et al., 2019). Collaborative work is acknowledged under the header of each section, 
as well as in the following chapters and appendices. 
 
2.1 Solutions 
Complete medium:  Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich) with 10 
% (v/v) Foetal bovine serum (Sigma-Aldrich), 100 IU/mL 
penicillin and 0.1 mg/mL streptomycin (Sigma-Aldrich). 
 
Digitonin lysis buffer: 1 % (w/v) Digitonin (Merck Millipore) in Tris-buffered saline 
(Sigma) with Roche protease inhibitor cocktail (1 tablet/10 
mL). 
 
DTT: A stock solution of 1 M was made by dissolving 1 g of DTT in 
6.5 mL of HPLC grade H2O. The stock solution was diluted to 
100 mM with 200 mM HEPES pH 8.5. 
 
Freezing medium:  90 % Foetal bovine serum (Sigma-Aldrich) and 10 % (v/v) 
dimethyl sulphoxide (Sigma-Aldrich). 
 
Guanidine lysis buffer: 9 mL of 8 M Guanidine Hydrochloride were diluted with 3 mL 
200 mM HEPES pH 8.5 to give final 6 M Guanidine / 50 mM 
HEPES pH 8.5. 
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HEPES buffer: 8 mL 1 M HEPES stock diluted with 32 mL HPLC-grade H2O. 
pH was adjusted to 8.5 with the necessary amount of 1 M 
NaOH 
 
Hydroxylamine: A 50% stock solution (Thermo Fisher Scientific) was diluted 
to 5 % Hydroxylamine in 200 mM HEPES pH 8.5. 
 
IAA: Iodoacetamide (Sigma-Adrich) was dissolved in 200 mM 
HEPES pH 8.5 to a final concentration of 500 mM. 
 
LysC: The contents of a 10 AU vial (Wako) were dissolved in 2 mL 
of HPLC grade water. 
 
MCLB buffer:  50 mM Tris pH 7.5, 300 mM NaCl, 0.5 % (v/v) NP-40, 1 mM 
DTT and Roche protease inhibitor cocktail (1 tablet/10 mL). 
 
PBS:  for cell culture was purchased from Sigma-Aldrich. 
PBST:   PBS with 0.2 % (v/v) Tween-20 (NBS Biologicals). 
 
Protein Loading Dye (6X):  Tris 375 mM pH 6.8, 12 % (w/v) Sodium dodecyl sulphate 
(SDS), 30 % (v/v) glycerol, 0.6 M DTT, 0.06 % (w/v) 
bromophenol blue. 
 
RIPA buffer (1X): For cell lysis was purchased from CST as a 10X stock and 
diluted to 1X using distilled H2O. The 1X working solution 
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contains 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1 % (v/v) NP-40, 1 % (v/v) sodium 
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 μg/mL leupeptin. One 
tablet of Roche protease inhibitor cocktail was added to 10 
mL of 1X RIPA buffer. 
 
TAE buffer: For agarose gel electrophoresis was purchased from CIMR 
media kitchen. 
 
TMT reagent: Vials containing 0.8 mg of TMT label were re-suspended in 
43 µL anhydrous acetonitrile. 
 
Trypsin: For cell culture was purchased from Sigma-Aldrich. 
 For proteomics, the contents of a 100 µg vial (Thermo Fisher 
Scientific) were dissolved in 3 mL 200 mM HEPES pH 8.5. 
 
Semi-dry transfer buffer: 10X stock – 360 g Glycine, 75 g Tris Base, 9.25 g SDS, distilled 
H2O to 2.5 L; Working solution – 0.1 L 10X stock, 0.2 L 
Methanol, 0.7 L ddH2O.                        
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2.2. Cell Culture 
2.2.1 Established cell lines 
Human foetal foreskin fibroblast cells immortalised with human telomerase 
reverse transcriptase (HFFF-TERT, male), as described in [196], were kindly provided by 
Dr. Peter Tomasec (School of Medicine, Cardiff University). HEK293T cells (female) were 
kindly supplied by Professor Paul Lehner (Department of Medicine, Cambridge 
University). 
 
2.2.2 Cell culture conditions 
Cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10 % (v/v) foetal bovine serum (FBS), and 100 IU/mL penicillin / 0.1 
mg/mL streptomycin, referred to from here on as complete medium. Cell lines were 
generally maintained in a 175 cm2 tissue culture flask (Falcon). All cells were incubated 
in a static incubator (Binder) at 37 °C and 5 % CO2. 
 
2.2.3 Cell line passage 
Confluent layers of cells were passaged by removing the medium in the tissue 
culture flask, followed by washing the adherent layer with PBS and incubating cells with 
6 mL Trypsin-EDTA (Sigma-Aldrich) until they detached from the surface of the culture 
vessel. Once the cells were in suspension, 4 mL of new complete medium was added and 
cells were split between 1:5 and 1:10, into 175 cm2 tissue culture flasks containing new 
complete medium. 
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2.2.4 Cell counting 
A 10 μL aliquot of the cell suspension was counted on a bright line 
haemocytometer (Heinz Herenz) using bright-field microscopy. The total number of cells 
was calculated using the following formula: 
Total number cells/ mL = (Number cells in grid) x 104 
 
2.2.5 Stable cell line generation 
To generate lentiviral particles, 1.5x105 HEK293T cells were plated in each well of 
a 12-well plate, 24 h prior to transfection. Cells were then transfected with 500 ng of 
plasmid DNA combined with 140 ng of a mixture of lentiviral packaging plasmids (VSVG, 
TAT1B, MGPM2, CMV-Rev1B, combined in a 1:1:1:1 ratio). The recombinant DNA mixture 
was diluted in 100 μL Opti-MEM Reduced Serum Medium (Thermo Fisher Scientific) and 
3 μL TransIT-293 transfection reagent (Mirus) and incubated for 30 min at room 
temperature (RT). The mixture was then added dropwise to the cells and incubated at 37 
°C, 5 % CO2 for 24 h. After incubation, 90 % of the transfection media was replaced with 
complete medium. Lentiviral supernatant was harvested 48 h post-transfection and cell 
debris was removed with a 0.22 μm filter.  
HFFF-TERT cells were plated at 1.25x105 cells/well in a 12-well plate, 24 h prior 
to transfection. These cells were then transduced with the lentiviral supernatant for 48 h 
and then subjected to antibiotic selection with complete medium containing 1 μg/mL 
Puromycin for two weeks. 
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2.2.6 Cryopreservation 
A cell suspension from a confluent 175 cm2 tissue culture flask was generated as 
described in 2.2.3 and centrifuged at 400 x g, RT for 5 min. After discarding the 
supernatant, the cell pellet was re-suspended in 4 mL of freezing medium (90 % FBS and 
10 % (v/v) dimethyl sulphoxide (DMSO). Aliquots of 1 mL were placed in cryovials 
(Greiner) and stored in a Mr Frosty freezing container (Nalgene). The freezing container 
was kept at -70 °C for 24 h and then transferred into the liquid nitrogen storage. 
Once necessary, cells were recovered from storage, thawed in a 37 °C waterbath 
(VWR) and transferred into a 50 mL tube containing 9 mL of complete medium. Cells 
were centrifuged at 400 x g, RT for 5 min. After discarding the supernatant, the pellet was 
re-suspended in 20 mL of complete medium and transferred into a 175 cm2 tissue culture 
flask to be incubated at 37 °C, 5 % CO2. 
 
2.2.7 Transient transfection 
HEK293T cells were plated at 7.5 x 105 cells/well in a 6-well plate, 24 h prior to 
transfection. A total of 2.5 µg plasmid DNA was diluted in 250 μL Opti-MEM Reduced 
Serum Medium (Thermo Fisher Scientific) and 7.5 μL TransIT-293 transfection reagent 
(Mirus). The mixture was incubated for 30 min at RT, then added dropwise to the cells 
and incubated at 37 °C, 5 % CO2 for 48 h. 
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2.3 HCMV 
2.3.1 Propagation of HCMV strains 
All HCMV strains were propagated in HFFF-TERT cells. A list of HCMV strains used 
in this study can be found in Table 2.3.1. A stock of RCMV 1111 strain was provided by 
Dr. Pete Tomasec, while stocks of RMCV 2582 and RCMV 2697 were provided by Dr. 
Richard Stanton (School of Medicine, Cardiff University). Whole-genome consensus 
sequences of passage 2 of all recombinant viruses were derived using the Illumina 
platform as described in [190]. 
For each viral stock, cells were cultured in five to ten 175 cm2 tissue culture flasks 
until they reached 80 % confluency. Cells were then infected with an aliquot of a low-
passage stock of the HCMV strain to be propagated, at a multiplicity of infection (MOI) 
0.0025 in 10 mL of serum-free DMEM. Infection was carried out for 2 h, at 37 °C, 5 % CO2 
in an incubator containing a rocker platform (Stuart). At the end of the incubation period, 
the serum-free DMEM was replaced with complete medium. Cells were monitored for 
cytopathic effect (CPE) and complete medium was replaced as required. Once 60 % CPE 
was observed, media was removed for HCMV purification (as described below in 2.3.2). 
Complete media was kept and replaced every two days, until the majority of cells had 
been lysed. 
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Table 2.3.1 | List of HCMV used in this study 
Laboratory 
designation 
Description 
RCMV 1111 Merlin BAC derived virus (Stanton et al, 2010) 
RCMV 2582 
HCMV expressing rGFP from a P2A self-cleaving peptide at the 3’-end of the 
UL36 coding region generated by recombineering the strain Merlin BAC 
(RCMV 1111) [193].  
RCMV 2697 
ORFL147C mutant generated by recombineering RCMV 2582. Substitutions 
were introduced into three in-frame ATG codons at or near the 5’-end of 
ORFL147C, in such a way that the coding potential of UL56, with which 
ORFL147C overlaps extensively in another reading frame, was unaffected 
[193]. 
 
2.3.2 Purification of viral stocks 
Immediately after harvest, media from HCMV infections was centrifuged in sterile 
250 mL Sorvall bottles (Sorvall) at 10,000 rpm, 35 °C for 2 h in an Avanti JXN-26 
centrifuge (Beckman Coulter), using a pre-warmed JLA-16.250 rotor. After discarding the 
supernatant, the pellet was re-suspended in 1 mL complete medium pre-warmed at 37 
°C, aspirated through a 21 gauge needle to disrupt pellet aggregates and stored at -80 °C. 
Once the infection of the propagation culture was complete, all 1 mL aliquots from 
harvests of the same propagation were thawed, pooled and spun at 10,000 rpm, RT for 5 
min in a benchtop microcentrifuge (Eppendorf) to remove cell debris. The pooled 
supernatant was dispensed in 100 µL aliquots and kept at -80 °C until required. Titres of 
HCMV stocks were calculated by titration as described below in 2.3.3. 
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2.3.3 Viral titration 
HFFF-TERT cells were seeded at 1.5x105 cells/well in a 12-well plate and 
incubated at 37 °C, 5 % CO2. The following day, cells were infected with 4-fold serial 
dilutions (1:16, 1:64, 1:256, 1:1024, 1:4096, 1:16348; in duplicate) in serum-free DMEM 
in a total of 300 µL/well. Infections were carried out for 2 h, at 37 °C, 5 % CO2, in an 
incubator containing a rocker platform. After the incubation period, serum-free DMEM 
was replaced by complete medium and incubated for 24 h. Cells were processed as 
described in 2.7 and analysed by Flow Cytometry. The values for each dilution’s 
duplicates were averaged to give infectious titres as either IE1 or GFP-forming units/mL. 
 
2.3.4 Infection for assays  
For each assay, HFFF-TERT cells were seeded approximately at 4x104 cells/ cm2, 
24 h prior to infection. The culture media was replaced with virus inocula (in serum-free 
DMEM), in a minimal volume of media according to the surface area of the tissue culture 
vessel. Cells were incubated with viral inoculums for 2 h, at 37 °C, 5 % CO2, in an incubator 
containing a rocker platform. Post-incubation, the inoculum was replaced with warm 
complete medium and cells were cultured for the necessary amount of time according to 
the assay’s purpose. 
For a subset of experiments, cells were incubated with dexamethasone in serum-
free medium 24 h prior to viral infection. This alternative method is explained in more 
detail in the relevant sections 2.9.1.1 and 2.10. 
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2.3.5 Viral growth curve 
1x106 HFFF-TERT cells were seeded into 25 cm2 tissue culture flasks 24 h prior to 
infection. The following day, cells were infected with HCMV at MOI 1, as described in 
2.3.4. Starting at day 2 and then every subsequent two days, the whole supernatant from 
the culture was taken and replaced with new complete medium of equal volume. The 
supernatant was centrifuged at 400 x g, RT for 10 min to pellet any cells in suspension 
and frozen in 1 mL aliquots at -80 °C.  Aliquots were then titred in HFFF-TERT cells, as 
described in 2.3.3, to estimate the amount of virus present in the supernatant. 
  
2.4. Molecular Biology 
 
2.4.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify DNA fragments employing 
the PfuUltra II Fusion HS DNA Polymerase (Agilent) in the manufacturer’s buffer 
(containing Magnesium to a final concentration of 2 mM), 50 mM dNTP mix and 1 μM of 
each primer (designed according to template and ordered from Sigma-Aldrich). 
Thermocycling conditions were as follows: 
1. 95 °C for 2 min 
2. 95 °C for 20 sec 
3. Lowest primer melting temperature -5 °C for 20 sec 
4. 72 °C for 15 sec/kilobase pair (kbp) 
5. 72 °C for 3 min 
  Steps 2 to 4 were repeated for 25 to 30 cycles depending on template type. 
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2.4.2 Agarose gel electrophoresis 
Electrophoresis was performed to separate DNA fragments based on size using a 
0.7 % (w/v) TAE agarose gel containing SYBR Safe (1:10,000). DNA samples were mixed 
with 6X Gel Loading Dye (NEB) prior to loading into the wells of the pre-casted agarose 
gel. Molecular weight-size markers (1 kbp DNA ladder or 100 bp DNA ladder, NEB) were 
run in parallel to estimate sample DNA fragment sizes. Gels were run at 70-90 V for 30-
45 min, before visualisation with an UV transiluminator.  
 
2.4.3 DNA purification from an agarose gel 
Following agarose gel electrophoresis, selected DNA bands were excised from the 
gel using a scalpel and transferred to a 1.5 mL tube. DNA was then purified using the 
QIAquick Gel Extraction Kit (QIAGEN). Gel slices were dissolved in three times their 
weight of QG buffer (100 mg ~ 100 μL) at 50 °C for 10 min. One gel volume of isopropanol 
was added to the sample once the agarose was fully dissolved. The mixture was 
transferred to a QIAquick spin column placed in a collection tube, 800 μL at a time, and 
centrifuged for 1 min at 13,000 rpm. After discarding the flow-through, the column was 
washed with 0.75 mL PE buffer and centrifuged for 1 min at 13,000 rpm. The flow-
through was once again discarded and the column centrifuged for an additional 1 min to 
remove residual buffer. A QIAquick column was placed in a new 1.5 mL tube and allowed 
to incubate for 1 min with 50 μL EB buffer before centrifugation for 1 min at 13,000 rpm 
to elute the DNA. Purified DNA was kept at -20 °C until necessary. 
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2.4.4 Gateway cloning 
 Gateway cloning (see Figure 2.4.1) allows transfer of selected DNA sequences in 
between vectors using lambda recombination, which is catalysed by a mixture of the 
integrase (Int) and excisionase (Xis) enzymes from bacteriophage λ in combination with 
the E. coli Integration host factor protein (IHF). These enzymes bind to unique sites (att), 
bring the target sites together, cleave them and covalently attach the DNA.  
 
 
Figure 2.4.1 | Gateway cloning schematic  
A gene of interest is cloned into a donor vector (pDONR223) in a BP reaction generating an entry 
clone. This step is catalysed by the BP Clonase enzyme mix (Integrase from bacteriopaghe λ and 
E. coli Integration host factor protein). The transgene is then transferred into an expression clone 
in a LR reaction, catalysed by the LR Clonase enzyme mix (Integrase and Excisionase from 
bacteriopaghe λ in addition to the E. coli Integration host factor protein). Adapted from 
manufacturer’s manual. 
 
 
PCR products or double-stranded DNA fragments containing flanking attB 
sequences were cloned into the pDONR223 entry vector (see Figure 2.4.2), then the 
lentiviral destination vector pHAGE-pSFFV (see Figure 2.4.3), using Gateway cloning 
(Thermo Scientific).  
The BP reaction was performed using 0.4 μL BP clonase II enzyme mix (containing 
the enzyme in its reaction buffer), 0.2 μL pDONR223 (150 ng/μL), 0.5 μL attB insert DNA 
(15-150 ng), 0.9 μL Tris-EDTA buffer (TE) pH 8.0 and incubated overnight (O/N) at RT.  
GENE
attB
attB
+ ccdB
attP
attP
GENE
attL
attL
BP Clonase Mix
(Int, IHF)
GENE
attL
attL
+ ccdB
attR
attR
GENE
attB
attBLR Clonase Mix
(Xis, Int, IHF)
pDONR223 pDONR223
pHAGE-SFFV pHAGE-SFFVpDONR223
B
P
 r
e
ac
ti
o
n
LR
 r
e
ac
ti
o
n
Donor vector Entry clone
Entry clone Destination vector Expression clone
+ ccdB
attR
attR
By-product
+ ccdB
attP
attP
By-product
Figure removed for copyright reasons. Copyright holder is INVITROGEN. 
60 
 
The LR reaction was performed using 0.4 μL LR clonase, 0.2 μL pHAGE-pSFFV (150 
ng/μL), 0.4 μL TE buffer pH 8.0, 1 μL entry clone (generated by the BP reaction) diluted 
1:5 in TE and incubated overnight (O/N) at RT.  
Following O/N incubation, both BP and LR reactions were incubated with 0.3 μL 
Proteinase K for 10 min at 37 °C, then incubated for 1 min on ice, before transformation 
into competent bacterial cells. 
 
 
 
Figure 2.4.2 | pDONR223 vector map 
Gateway Entry vector containing a T7 promoter, Spectinomycin resistance marker and a pBR322 
origin of replication. The Gateway attP1/attP2 sites allow the replacement of the ccdB toxin 
coding sequence and the chloramphenicol acetyltransferase resistance marker (CAT/CamR), 
with an insert containing gateway attB1/attB2 flanking sequences, via a BP reaction.  
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Figure 2.4.3 | pHAGE-SFFV vector map 
Gateway Destination vector containing the lentiviral HIV-1 Ψ, RRE, cPPT and LTR sequences. The 
Gateway attR1/attR2 sites allow the replacement of the ccdB toxin coding sequence as well as the 
chloramphenicol acetyltransferase resistance marker (CAT/CamR) and its promoter, with an 
insert containing gateway attL1/attL2 flanking sequences, via an LR reaction. Expression of the 
insert is driven by the SFFV promoter and would contain the FLAG and HA sequences (with a 
short linker in between) unless a stop codon were placed at the 3’ end of the insert. Other features 
include an internal ribosomal entry site (IRES), the Woodchuck Hepatitis Virus 
Posttranscriptional Regulatory Element (WPRE), an origin of replication (ORI), lac promoter and 
operator, SV40 promoter-enhancer sequences and ampicillin and puromycin antibiotic selection 
markers. 
 
2.4.5 Bacterial transformation 
Aliquots of Gold Alpha-Select Chemically Competent Cells (Bioline) were thawed 
on ice and 20 μL were mixed into each cloning reaction. The mixture was incubated on 
ice for 20 min, followed by heat-shock at 42 °C for 45 sec in a waterbath (Grant). After 
incubating for 1 min on ice, 200 μL Luria-Bertani (LB) medium were added and the 
reaction was incubated for 1 h at 37 °C, 350 rpm. The mixture was then plated on a 
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LB/Agar plate containing an appropriate antibiotic for selection of bacterial 
transformants. 
 
2.4.6 Small-scale plasmid DNA preparation 
Small-scale isolation of plasmid DNA from bacterial cultures was performed using 
a QIAprep Spin Miniprep kit (QIAGEN) and the proprietary reagents therein. Bacterial 
transformants were grown O/N at 37 °C, shaking at 350 rpm in 4 mL LB containing 
antibiotic for selective pressure. From this culture, 3 mL were pelleted by centrifugation 
at 8,000 rpm, RT for 3 min. The pellet was re-suspended in 250 μL buffer P1 and 
transferred to a 1.5 mL tube. The cells were lysed by adding 250 μL of buffer P2 and 
incubating for 5 min at RT. The reaction was neutralised with 350 μL buffer N3, mixed 
several times by inversion and centrifuged at 13,000 rpm, RT for 10 min. The supernatant 
was transferred to a QIAprep spin column placed in a collection tube and centrifuged at 
13,000 rpm, RT for 1 min. After discarding the flow-through, the column was washed with 
0.5 mL PB buffer and centrifuged at 13,000 rpm, RT for 1 min. The flow-through was 
discarded again and the column was washed with 0.75 mL PE buffer followed by 
centrifugation at 13,000 rpm, RT for 1 min. After discarding the flow-through, the column 
was centrifuged at 13,000 rpm, RT for 1 min to remove residual buffer. The column was 
transferred to a new 1.5 mL tube and incubated with 50 μL EB buffer for 1 min, before 
DNA elution by centrifugation at 13,000 rpm, RT for 1 min. 
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2.4.7 Large-scale plasmid DNA preparation 
For transient transfection, large-scale preparation of plasmid DNA was required. 
This was performed using the QIAgen Plasmid MAXI kit (QIAGEN). For this procedure, a 
colony of bacterial transformants was used to inoculate 250 mL LB and incubated O/N at 
37 °C, shaking at 350 rpm. Bacterial cells were pelleted by centrifugation at 6000 x g at 4 
°C for 15 min using 250 mL Sorvall centrifuge bottles (Sorvall) and SLA1500 rotor. The 
pellet was re-suspended in 10 mL P1 buffer and cells were lysed by adding 10 mL P2 
buffer, mixing by inversion and incubating at RT for 5 min. The reaction was neutralised 
with 10 mL of ice-cold buffer P3, mixed by inversion, poured into the barrel of a QIAfilter 
Cartridge containing a screw cap on the outlet nozzle and incubated for 10 min, RT. 
During this incubation, a QIAGEN-tip was equilibrated with 10 mL QBT buffer, allowing 
the column to empty by gravity flow. At the end of the incubation, the screw cap was 
removed from the QIAfilter Cartridge and a plunger was inserted, allowing the cell lysate 
to be filtered by gravity flow into the previously equilibrated QIAGEN-tip. The tip was 
washed twice with 30 mL QC buffer and DNA was eluted into a 50 mL tube with 15 mL 
QF buffer. DNA was precipitated with 10.5 mL RT isopropanol and the solution was mixed 
and centrifuged at 15,000 x g, 4 °C for 30 min. The supernatant was carefully removed 
and the DNA pellet washed with 5 mL RT 70 % (v/v) ethanol, followed by centrifugation 
at 15,000 x g for 10 min. After decanting the supernatant, the pellet was air-dried for 10 
min. DNA was re-suspended in 100 μL TE buffer.  
 
2.4.8 Nucleic acid sample quantification 
Concentration of nucleic acids for DNA and RNA samples was determined by 
reading absorbance at 260 nm using a NanoDrop Spectrophotometer (Fisher Scientific). 
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Sample purity was estimated by calculating a ratio between the reading at 260, 230 and 
280 nm. 
 
2.4.9 Glycerol stock generation 
Glycerol stocks for selected plasmids were made by mixing equal volumes of an 
O/N bacterial culture and 80 % (v/v) glycerol (sterile) in a Nunc CryoTube (Merck). 
Glycerol stocks were stored at -70 °C. 
 
2.5 Construction of the expression vector library 
A library of recombinant adenovirus expression vectors containing coding sequences 
for a large subset of HCMV proteins was generated by Dr. James Davies and Dr. Sepehr 
Seirafian (School of Medicine, Cardiff University). Cloning of CUL4A-HA, TRIM22-HA, 
MBNL1-HA, CELF1-HA as well as site-directed mutagenesis to generate the UL25-N625-V5 
and NCK1-HA mutants were performed by Dr. Katie Nightingale (Department of Medicine, 
University of Cambridge). 
 
2.5.1 Genes cloned from recombinant adenoviral vector library 
The majority of HCMV genes and the GFP control were cloned from a library of 
recombinant adenoviral vectors (rAdv), which was kindly provided by Professor Gavin 
Wilkinson’s group (School of Medicine, Cardiff University). Primers were designed to 
recognise the 3’ end of the CMV promoter encoded within the rAdv (‘rAdv fwd’) and the 
3’ end of the V5 tag (‘rAdv rev’). Both primers were flanked by four guanine residues, 
followed by Gateway attB1 (forward) or attB2 (reverse) sequences (highlighted in blue 
in the sequences of rAdv forward/reverse primers in Table 2.5.1). 
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Table 2.5.1 | Primer sequences for cloning and plasmid DNA sequencing 
Primer Sequence (5’-3’) PCR template 
rAdv fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTGAAGACACCGGGACCGATC rAdv library 
rAdv rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTACGTAGAATCAAGACCTAGGAG
C 
rAdv library 
No bait oligo 1 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCCAGGCGAGAACGTGTGCGTGGA
CAAGCGAGCAGCATACGAACCCAGCTTTCTTGTACAAAGTGGTCCCC 
- 
No bait oligo 2 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCGTATGCTGCTCGCTTGTCCACG
CACACGTTCTCGCCTGGGAGCCTGCTTTTTTGTACAAACTTGTCCCC 
- 
US9 fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGATCCTGTGGTCCCCG HCMV Merlin BAC 
US9 rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTATCGTCTTTAGCCTCTTCTTCC 
HCMV Merlin BAC 
UL20 fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCTCGGGATACGGGCTATG HCMV Merlin BAC 
UL20 rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTTGCTGGCATGCAGACCACC 
HCMV Merlin BAC 
UL48-H1 fwd 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGAAAGTCACACAGGCCAGCTGC
C 
HCMV Merlin BAC 
UL48-H1 rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTGGGCAGGGCTCCCTCGTTGG 
HCMV Merlin BAC 
UL48-H2 fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGAACCCACGGAAACCGCAGGC HCMV Merlin BAC 
UL48-H2 rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTCAAAAGATAGAGAAACCGCATGT
GTTG 
HCMV Merlin BAC 
UL80.5 fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGTCGCACCCTCTGAGTGC HCMV Merlin BAC 
UL80.5 rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTCTCGAGCTTATTGAGCGCAGC 
HCMV Merlin BAC 
UL112 fwd 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGATCTGCCTACTACCG cDNA of HFFFs 
infected with 
HCMV (72h) 
UL112 rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTATCGTCGAAAAACGCCGCG 
cDNA of HFFFs 
infected with 
HCMV (72h) 
UL132 fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCCGGCCCCGCGGGGTC HCMV Merlin BAC 
UL132 rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTGTCGTACTCGGGATCTCTGAGCG
AG 
HCMV Merlin BAC 
RL8A fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCCTCACGGCCATCTCC HCMV Merlin BAC 
RL8A rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTGCTAAAAACAGCGGACAGTCC 
HCMV Merlin BAC 
RL9A fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGTCTCTAGATGCCGCCAGC HCMV Merlin BAC 
RL9A rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTGAGAAACAGCACGTAGGTCAGG 
HCMV Merlin BAC 
IRS1 fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGCCCAGCGCAACGGC HCMV Merlin BAC 
IRS1 rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAG
GAGCGGGTTAGGGATTGGCTTACCAGCGCTATGATGAACGTGGTGAGGGGCG 
HCMV Merlin BAC 
M13 fwd GTAAAACGACGGCCAG - 
M13 rev CAGGAAACAGCTATGAC - 
SFFVp seq CGCGCCAGTCCTCCGATTG - 
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Templates were amplified by PCR using the generic primers above and the 
product was inserted into pDONR223, then pHAGE-pSFFV using Gateway Cloning as 
described in 2.4.4. The resulting lentiviral template expresses a C-terminally V5-tagged 
gene under the control of a SFFV promoter, with the six base-pair linker region ‘AGCGCT’ 
between the 3’ end of the gene and the tag.  
For UL48 it was not possible to generate a cell line expressing the full-length 
construct, likely due to inefficient transduction caused by the length of the transgene (6.7 
kbp). To enable cloning of UL48 in two segments without splitting protein secondary 
structures, the coding sequence was analysed using the YASPIN Secondary Structure 
Prediction tool from the Centre for Integrative Bioinformatics VU (Vrije Universiteit 
Amsterdam) [197] (see Appendix A). The gene was divided into two segments, one of 4.5 
kbp (1-1504 aa) terminating in a stop codon (UL48-H1), and one of 2.2 kbp (1505-2241 
aa), with an additional start codon (UL48-H2). Both segments were cloned as described 
above (primers provided in Table 2.5.1) and stably expressed in separate cell lines. 
 
2.5.2 Genes cloned from HCMV Merlin BAC or cDNA template 
For HCMV genes amplified from the HCMV Merlin BAC, primers were designed to 
recognize the 5’ end (forward) and the 3’ end (excluding the stop codon, reverse) of each 
gene. In addition to the gene specific sequence, the reverse primer also contained the six 
base-pair linker region ‘AGCGCT’, followed by the coding sequence for the V5 tag and a 
stop codon. Both primers were flanked by four guanine residues, followed by Gateway 
attB1 (forward) or attB2 (reverse) sequences. Cloning methods and structure of the 
resulting lentiviral vector were as described in 2.5.1. Primers for gene cloning from the 
HCMV Merlin BAC are provided in Table 2.5.1. 
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HCMV genes cloned from cDNA generated from HCMV infected primary HFFF cells 
were amplified with primers designed similarly to primers used for cloning from the 
Merlin BAC. Primer sequences for these genes are provided in Table 2.5.1.  A diagram of 
the primer design for HCMV genes cloned from the Merlin BAC or cDNA from HCMV 
infected primary HFFF cells is shown in Figure 2.5.2. 
 
US9 coding sequence 3’: 5’-ATGATCCTGTGGTCCCCG-3’ 
US9 coding sequence 5’ (reverse complement): 5‘-ATCGTCTTTAGCCTCTTCTTCC-3’ 
 
attB1: 5’-ACAAGTTTGTACAAAAAAGCAGGCT-3’ 
Reverse complement of attB2: 5’- ACCACTTTGTACAAGAAAGCTGGGT-3’  
 
Linker: 5’-AGCGCT-3’ 
V5 tag: 5’-GGTAAGCCAATCCCTAACCCGCTCCTAGGTCTTGATTCTACGTAA-3’ 
Stop codon: 5’-TAA-3’ 
 
Reverse complement of Linker + V5 tag + Stop codon: 
5'-TTATTACGTAGAATCAAGACCTAGGAGCGGGTTAGGGATTGGCTTACCAGCGCT-3' 
 
US9 Primer fwd: 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTATGATCCTGTGGTCCCCG-3’ 
US9 Primer rev: 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAGGAGC 
GGGTTAGGGATTGGCTTACCAGCGCTATCGTCTTTAGCCTCTTCTTCC-3’ 
 
Figure 2.5.2 | Diagram of primer design for HCMV genes cloned from the Merlin BAC or 
cDNA from HCMV infected primary HFFF cells 
 
2.5.3 Synthesized genes 
The coding sequences of the canonical HCMV genes UL55, UL56, UL128, UL131A, 
UL150A and non-canonical ORFL147C and ORFS343C were synthesized as double-
stranded DNA fragments (gBlocks®, Integrated DNA Technologies). Each fragment 
comprised the viral gene (without a stop codon), succeeded by the six base-pair linker 
region ‘AGCGCT’, the coding sequence for the V5 tag then the stop codon. The fragments 
had flanking Gateway attB sequences allowing cloning into pDONR223 as described in 
2.4.4. 
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N-terminally V5-tagged UL42 was synthesized as double-stranded DNA fragment 
(gBlocks®, Integrated DNA Technologies). The fragment comprised a start codon 
succeeded by the coding sequence for the V5 tag, followed by the six base-pair linker 
sequence ‘AGCGCT’ and the viral gene (including its start and stop codon). The fragment 
had flanking Gateway attB sequences allowing cloning into pDONR223 using the gateway 
cloning method. 
 
2.5.4 pHAGE-pSFFV vector control 
To generate an empty vector control, two complementary oligonucleotides (‘No 
bait’ oligonucleotides 1 and 2, Table 2.5.1) were designed to code for a random sequence 
of 14 aa, which featured neither a Methionine nor the V5 tag, with flanking Gateway attB 
sequences and four guanosine residues allowing cloning into pDONR223. To produce a 
double-stranded insert, the oligonucleotides were annealed at 95 °C for 10 min. The 
reaction was cooled down to 25 °C at approximately 5 °C/ min using a Thermomixer 
(Eppendorf). The solution was diluted 1:10 for the BP reaction, for a final concentration 
of 1 μM. 
 
2.5.5 Cloning of human genes 
The coding sequences for NEDD4L, CUL4A, TRIM22, NCK1, MBNL1 and CELF1 
were amplified from plasmids containing the template, using primers designed to 
recognize the 5’ end (forward) and the 3’ end (excluding the stop codon, reverse) of the 
gene (see Table 2.5.5). The reverse primer also contained the fifteen base-pair linker 
region ‘TCGGCCGCTGGAGGA’, followed by the coding sequence for the HA tag and a stop 
codon. Both primers were flanked by four guanine residues, followed by Gateway attB1 
(forward) or attB2 (reverse) sequences allowing cloning into pDONR223 and 
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subsequently pHAGE-SFFV, as described in 2.4.4. The same strategy was used to clone 
TRIM22, but instead of amplifying the template from a plasmid, cDNA of HFFF-TERT cells 
stimulated with IFNα2a (1000 U for 24 h) was used. 
The coding sequences of CNOT2 and LRFN3 were cloned from a gateway entry 
vector (see Table 2.5.5) into pHAGE-SFFV by performing an LR reaction. Lentiviral 
plasmids containing the coding sequences of CNOT7 and NEDD4 were purchased from 
Harvard’s PlasmID or Addgene collections. Lentiviral expression vectors were then used 
for transient transfection of HEK293T cells.  
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Table 2.5.5 | Templates and primers for human gene cloning 
Gene name 
Forward primer 
(5'-3') 
Reverse primer 
(5'-3') 
Template Source 
CNOT2 - - pDONR223-CNOT2 
Harvard PlasmID 
HsCD00080019 
CNOT7 - - pHAGE-CNOT7 
Harvard PlasmID 
HsCD00453329 
NEDD4 - - 
PHAGE-P-CMVt-N-
HA Nedd4 wt 
Addgene 
24124 
NEDD4L 
GGGGACAAGTTTGTA 
CAAAAAAGCAGGCTA 
TGGCGACCGGGCTCG 
GGG 
GGGGACCACTTTGTA 
CAAGAAAGCTGGGTC 
TAGGCGTAGTCGGGC 
ACGTCGTAGGGGTAT 
CCTCCAGCGGCCGAC 
ACCCCTTCAAATCCT 
TGAGCATTTTCCACG 
pCMV-SPORT6-
NEDD4L 
Harvard PlasmID 
HsCD00337956 
LRFN3 - - pDONR221-LRFN3 
Harvard PlasmID 
HsCD00041564 
CUL4A 
GGGGACAAGTTTGTA 
CAAAAAAGCAGGCTA 
TGGCGGACGAGGCCC 
CG 
GGGGACCACTTTGTA 
CAAGAAAGCTGGGTT 
TAAGCGTAATCTGGA 
ACATCGTATGGGTAA 
GCGCTGGCCACGTAG 
TGGTACTGATTC 
pOTB7-CUL4A  
Harvard PlasmID 
HsCD00325140 
TRIM22 
GGGGACAAGTTTGTA 
CAAAAAAGCAGGCTA 
TGGATTTCTCAGTAA 
AGGTAGACA 
GGGGACCACTTTGTA 
CAAGAAAGCTGGGTA 
GGAGCTCGGTGGGCA 
CACAGTCATG 
cDNA of HFFF-TERT 
cells stimulated with 
IFNα2a 
- 
MBNL1 
GGGGACAAGTTTGTA 
CAAAAAAGCAGGCTA 
TGGCTGTTAGTGTCA 
CACC 
GGGGACCACTTTGTA 
CAAGAAAGCTGGGTT 
TAAGCGTAATCTGGA 
ACATCGTATGGGTAA 
GCGCTCTACATCTGG 
GTAACATACTTG 
pDONR221-MBLN1  
Harvard PlasmID 
HsCD00079833 
CELF1 
GGGGACAAGTTTGTA 
CAAAAAAGCAGGCTA 
TGAACGGCACCCTGG 
ACCAC 
GGGGACCACTTTGTA 
CAAGAAAGCTGGGTT 
TAAGCGTAATCTGGA 
ACATCGTATGGGTAA 
GCGCTTCAGTAGGGC 
TTGCTGTCATTC 
pDONR221-CUGBP1  
Harvard PlasmID 
HsCD00039403 
NCK1 
GGGGACAAGTTTGTA 
CAAAAAAGCAGGCTA 
TGGCAGAAGAAGTGG 
TGGTAG 
GGGGACCACTTTGTA 
CAAGAAAGCTGGGTT 
TAAGCGTAATCTGGA 
ACATCGTATGGGTAA 
GCGCTTGATAAATGC 
TTGACAAGATATAAT 
TTTTC 
pENTR223-NCK1  
Harvard PlasmID 
HsCD00370605 
NCK1 SH3-
1 W38K 
GGAATTTCGAACTCG 
CCACTTGGACTTAGA 
ATCATCCAGA 
TCTGGATGATTCTAA 
GTCCAAGTGGCGAGT 
TCGAAATTCC 
pHAGE-NCK1-HA - 
NCK1 SH3-
2 W143K 
TTGTAGCTACCACGC 
CACTTCCCATCACTG 
CATTTCTC 
GAGAAATGCAGTGAT 
GGGAAGTGGCGTGGT 
AGCTACAA 
pHAGE-NCK1-HA - 
NCK1 SH3-
3 W229K 
GATCTTCCTGCATTT 
CCACTTCTCTGGGTC 
ATTTTCAGGT 
ACCTGAAAATGACCC 
AGAGAAGTGGAAATG 
CAGGAAGATC 
pHAGE-NCK1-HA - 
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2.5.6 Site-directed mutagenesis 
Site-directed mutagenesis by overlap extension PCR was used to generate point 
mutations in the coding sequence of NCK1. Primer sequences spanning the target region 
and incorporating the desired sequence changes in both forward and reverse 
orientations were generated (see Table 2.5.5). These, along with primers that would 
anneal at the 5' and 3' ends of the full-length NCK1 coding sequence (‘NCK1 forward 
primer’ and ‘NCK1 reverse primer’, respectively) were used to amplify two fragments of 
NCK1, each incorporating the point mutation, from the pHAGE-NCK1-HA template 
plasmid generated as described in section 2.5.5. Fragments were purified using the 
QIAquick Gel Extraction Kit (QIAGEN, as described in 2.4.3), and assembled into a full-
length mutant NCK1 coding sequence by a second round of PCR using only the ‘NCK1 
forward primer’, ‘NCK1 reverse primer’ and both NCK1 fragments as a template in the 
same reaction. The product was then purified using the QIAquick Gel Extraction Kit 
(QIAGEN, as described in 2.4.3) and subcloned into the gateway system as described 
above.  
To generate a truncation mutant of UL25, a single round of PCR was performed 
using a forward primer designed to recognize the 5’ end of the gene, and a reverse primer 
designed to recognise the 3’ end of the gene (bases 1856-1875, truncating the amino acid 
sequence at residue 625). In addition to the gene specific sequence, the reverse primer 
also contained the six base-pair linker region ‘AGCGCT’, followed by the coding sequence 
for the V5 tag and a stop codon. Both primers were flanked by four guanine residues, 
followed by Gateway attB1 (forward) or attB2 (reverse) sequences (see Figure 2.5.6). 
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UL25 coding sequence 3’: 5’- ATGTCGTCGCGGCGTCGCAG-3’ 
UL25 coding sequence 5’ (reverse complement): 5‘-GGATCGGCAGATTTGTTCGG-3’ 
 
attB1: 5’-ACAAGTTTGTACAAAAAAGCAGGCT-3’ 
Reverse complement of attB2: 5’- ACCACTTTGTACAAGAAAGCTGGGT-3’  
 
Linker: 5’-AGCGCT-3’ 
V5 tag: 5’-GGTAAGCCAATCCCTAACCCGCTCCTAGGTCTTGATTCTACGTAA-3’ 
Stop codon: 5’-TAA-3’ 
 
Reverse complement of Linker + V5 tag + Stop codon: 
5'-TTATTACGTAGAATCAAGACCTAGGAGCGGGTTAGGGATTGGCTTACCAGCGCT-3' 
 
UL25 N625 Primer forward: 
5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTATGATCCTGTGGTCCCCG-3’ 
 
UL25 N625 V5 Primer reverse:  
5’-GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTACGTAGAATCAAGACCTAGGAGC 
GGGTTAGGGATTGGCTTACCAGCGCTGGATCGGCAGATTTGTTCGG-3’ 
 
Figure 2.5.6 | Diagram of primer design for UL25 N-terminal truncation at residue 625 
 
2.5.7 Construct sequencing 
Sequencing of all genes was conducted in the pDONR223 vector using ‘M13 fwd’, 
‘M13 rev’ (see Table 2.5.1) and gene-specific primers as necessary to obtain a complete 
sequencing coverage. All pHAGE-pSFFV vectors underwent sequencing of the first ~700 
bases from the 3’ end of the SFFV promoter, using a primer that recognises the 3’ end of 
the SFFV promoter (‘SFFVp seq’, Table 2.5.1), to verify that the viral construct had 
correctly recombined. 
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2.6. RT-QPCR 
2.6.1 Cellular RNA Extraction 
Total RNA from a subset of stable cell lines expressing viral transgenes was 
extracted using an RNeasy Mini Kit (QIAGEN). For each cell line, 3x105 HFFF-TERT 
cells/well were seeded into a 6-well plate. The following day, cells were washed with PBS 
then disrupted with 350 μL RLT buffer/1 M DTT. The lysate was scraped, transferred into 
a 1.5 mL tube and homogenised by vortexing. An equal volume of 70 % (v/v) ethanol was 
added to the lysate, mixed by pipetting and transferred into an RNeasy spin column 
placed in a collection tube. The column was centrifuged at 8,000 x g, RT for 30 sec. The 
flow-through was discarded and 700 µl Buffer RW1 was added to the RNeasy spin 
column, followed by centrifugation at 8,000 x g, RT for 30 sec. After discarding the flow-
through, the spin column was washed twice with 500 µl Buffer RPE, with centrifugation 
at 8,000 x g, RT for 30 sec after the first wash, then 2 min after the second wash. The spin 
column was placed in a new 1.5 mL collection tube and 50 µl RNase-free water was added 
directly to the spin column membrane. RNA was eluted by centrifugation at 8,000 x g, for 
1 min. 
 
2.6.2 DNase treatment 
To remove residual contaminating DNA from RNA extraction samples, 1 µg total 
RNA was treated with 2 enzyme units (U) of Turbo DNase (Thermo Fisher Scientific) in 
the manufacturer’s buffer for 30 min at 37 °C, for a 10 µL reaction. The reaction was 
quenched with 1 µL of manufacturer’s DNase inactivation reagent for 5 min at RT, then 
centrifuged at 10.000 x g for 1.5 min and transferred to a new tube. 
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2.6.3 Reverse-transcription reaction 
Synthesis of cDNA was performed using the GoScript Reverse Transcription 
system (Promega). In a 1.5 mL tube, 2 µL of the DNase-treated RNA template was 
incubated with 1 µL Oligo (dT)15 primers and 2 µL Nuclease-free water for 5 min at 70 °C, 
then for 5 min on ice-cold water. A 15 µL aliquot of the reverse transcription reaction mix 
containing 1 µL GoScript Reverse Transcriptase, 2 µL 25 mM MgCl2, 1 µL dNTPs (final 
concentration 0.5 mM each dNTP), 0.5 µL 40 U/µL RNase inhibitor, 4 µL 5X GoScript 
Reaction Buffer and 6.5 µL Nuclease-free water was then added to the tube containing 
the primers and template. The reaction was then incubated for 5 min at 25 °C to allow 
primer annealing to the RNA template, then 1 h at 42 °C for extension. The reverse 
transcriptase was inactivated by 15 min incubation at 70 °C. 
 
2.6.4. qPCR 
Quantitative PCR was used to verify viral bait expression in HFFF-TERT cell lines 
where these could not be detected by immunoblotting or mass spectrometry. All assays 
employed the Fast SYBR Green Master Mix (Applied Biosystems) and 7500 Fast & 7500 
Real-Time PCR Systems (Applied Biosystems). Primers targeting HCMV genes or GAPDH 
(as an internal control) are shown in the Table 2.6.4. Templates prepared as described in 
6.3 were diluted 1:10 with nuclease-free water and 2 µL loaded onto a MicroAmp Optical 
96-well reaction plate (Applied Biosystems). An 18 µL aliquot of reaction mix containing 
10 µL 2X Fast SYBR Green Master Mix, 1 µL of each primer (10 µM) and 6 µL nuclease-
free water was added to each well. All samples were assayed in duplicate and RNA from 
each cell line as well as nuclease-free water were used as negative controls. The plate was 
sealed with MicroAmp Optical Adhesive film (Applied Biosystems) and then centrifuged 
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at 400 x g for 2 min, 10 °C. The PCR program followed the Applied Biosystems default 
settings, starting with activation at 95 °C for 2 min, followed by 40 cycles of denaturation 
at 95 °C for 5 s and annealing/extension at 60 °C for 30 s. The amplification products were 
then separated by agarose gel electrophoresis, purified from gel slices and sequenced to 
confirm viral bait expression. For UL136, UL146 and UL148D, this procedure failed to 
generate sequencing-quality amplicons and therefore generation of whole gene 
amplicons (primers listed in Table 2.6.4) by PCR (as described in 4.1) was attempted 
instead.  
 
Table 2.6.4 | Primers used for validation of transgene expression 
Gene name Short amplicon / qPCR primers Extended amplicon / PCR primers 
US13 
FWD: GACCGTGTTCCATCATCAGC 
REV: CCTACGTAGATCAGCAGCGA 
- 
US18 
FWD: CTGATCAACACCGGCATCAC  
REV: GCCAATCCCGATGACTTTCC 
- 
US33A 
FWD: GGGTTACGAGAAACTGGGATAC  
REV: AACGGAAAAGTGAACGGCAA 
- 
UL1 
FWD: CACTCACGTTGGTTGGACAG   
REV: TGTGTGGTTGACGTTGTTTCT 
- 
UL2 
FWD: GAAGATGACGACGCATATCCG  
REV: CGTCTCGAAGCAGCTTGAG 
- 
UL6 
FWD: GTTCCTCGAGCGGTTCAAAG  
REV: CAAACGCGCTGGAATTTGTC 
- 
UL9 
FWD: TGAAGCACAACACGACACTG  
REV: CGCTGTATCGGTATTGTGTGA 
- 
UL11 
FWD: CAACCACCACGAGAACAACC  
REV: GGCTTGGTTGTAACGGTGTT 
- 
UL21A 
FWD: GTCGGTGAGGGAGATGAAGA 
REV: GAGCAAAACCGGGTACATGG 
- 
UL30 
FWD: CCGGGGCATGATGGACTAT 
REV: GGCAACACAAGACAGGGAAA 
- 
UL33 
FWD: TACTCGAGCTGCACAGTAGG 
REV: CATGGAAAAGATCAGCCCGG 
- 
UL48A 
FWD: GACCGAGATCTCAGAGGCC 
REV: CTATCATGCGCAACAGGTCC 
- 
UL91 
FWD: CTTTGTCGACCGCCTCTTTC  
REV: CAGGTGTTGCTTGTCTCCAC 
- 
UL136 
FWD: TGCGGCTGTCATTATCCTGA  
REV: CCATTTCCACCGTGTCGAAG 
FWD: ATGTCAGTCAAGGGCGTGGAGAT 
REV: TAGCGGGAGATACGGCGTTC  
UL148D 
FWD: GTCAAGACCAAGGAGCAGC 
REV: GCGTAAAGTACATCAGGGCC 
FWD: ATGACGGCGCCCAAGTGTG 
REV: AACGGGAGCGGCAGCGGC 
UL146 
FWD: CGCTGCAAATGTCTTGATGG  
REV: GGTGATGGGGCGATAAACAT 
FWD: ATGCGATTAATTTTTGGTGCGTT 
REV: TTCCTTCAGACCTACTAGGGTTA  
RL6 
FWD: CTAAAAGCGACGACTGGGAG 
REV: TATGACCACAGCTCGACACA 
- 
RL9A 
FWD: ATGTCTCTAGATGCCGCCAGCC 
REV: TTAGAGAAACAGCACGTAGGTCA 
- 
RL12 
FWD: CACCCCACTATGTCCCAGAT 
REV: GTAAGAGCCCATGTAGTGCG 
- 
GAPDH 
FWD: AGGGCTGCTTTTAACTCTGG 
REV: CCCCACTTGATTTTGGAGGGA 
- 
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2.7. Immunoblotting 
2.7.1 Preparation of cell lysates 
To generate lysates for immunoblotting, a confluent monolayer of HFFF-TERT 
cells in a 175 cm2 tissue culture flask was washed with PBS, followed by incubation with 
6mL trypsin-EDTA solution for 5 min at 37 °C, 5 % CO2. Once the cells were in suspension, 
4 mL of complete medium was added and 2.5 mL of this mixture was centrifuged at 400 
x g for 5 min, RT. The cell pellet was washed with PBS and centrifuged once more at 400 
x g for 5 min, RT. After discarding the supernatant, the pellet was re-suspended in 100 µL 
of RIPA 1X buffer (CST) containing Roche protease inhibitor cocktail (1 tablet/10 mL) 
and incubated on ice for 5 min. The lysate was then mixed for 30 s using a vortex 
homogeniser, followed by centrifugation at 16,100 x g for 10 min, 4 °C. The supernatant 
was then transferred to a new tube and stored at -20 °C until necessary.  
 
2.7.2 Estimation of protein concentration 
Protein quantification was performed using the Pierce BCA Protein Assay kit 
(Thermo Fisher Scientific). Samples were diluted both 1:5 and 1:10 in PBS and 25 µL were 
loaded onto a well of a flat-bottom 96-well clear plate (Greiner). Using a multi-channel 
pipette (Gilson), 200 µL of the BCA working reagent were added to each well. The plate 
was sealed with PlateMax AxySeal adhesive film (Axygen) and incubated at 37 °C for 30 
min. The absorbance at 562 nm was then measured using a Spark Microplate Reader 
(Tecan). Serial dilutions of a 2 mg/mL Bovine Serum Albumin solution (Thermo Fisher 
Scientific) with PBS were assayed in parallel to generate a standard curve by linear 
regression analysis that allowed estimation of protein concentration.   
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2.7.3 Immunoblotting  
Approximately 20 to 50 µg of protein for each sample was reduced with 6X Protein 
Loading Dye (Tris 375 mM pH 6.8, 12 % (w/v) SDS, 30 % (v/v) glycerol, 0.6 M DTT, 0.06 
% (w/v/) bromophenol blue) for 5 min at 95 °C. Equal amounts of each protein sample 
were then separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using 4-12 
% Bis-Tris Precast Protein Gels (Invitrogen) in an XCell SureLock Mini-Cell 
Electrophoresis System (Invitrogen), for 105 min at 130 V. Pre-stained protein molecular 
weight standards were run in parallel. 
Proteins were then transferred to a PVDF membrane by semi-dry transfer using 
the Trans-Blot SD Semi-Dry Transfer Cell (Bio-rad). Gel blotting paper (Whatman) was 
immersed in transfer buffer (described in 2.1), then three sheets of blotting paper were 
layered on the negative electrode of the transfer cell. The PVDF membrane was soaked in 
methanol, then immersed in transfer buffer and placed on top of the blotting paper. The 
polyacrylamide gel was removed from the electrophoresis system, immersed in transfer 
buffer and layered onto the PVDF membrane, followed by three sheets of pre-soaked 
blotting paper. The transfer stack was then gently pressed in a rolling motion to ensure 
any air bubbles in its midst were removed. The transfer cell was then assembled and 
protein transfer onto the membrane was performed at 20 V for 45 min.  
Following transfer, the membrane was removed from the transfer cell and 
incubated with blocking solution (5 % (w/v) milk in PBST) for 1 h, RT. An appropriate 
amount of primary antibody was added to the blocking solution to achieve the dilution 
recommended by the suppliers and incubated O/N at 4 °C with agitation. The following 
day the blot was washed three times for 5 min with PBST and then incubated for 2 h with 
5 % (w/v) milk in PBST containing an appropriate dilution of secondary antibody. The 
blot was then washed three times for 5 min with PBST, followed by digital image 
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acquisition using the Odyssey CLx (LI-COR). Digital images were processed using Image 
Studio Lite (LI-COR). Information on primary and secondary antibodies used, as well as 
their dilutions can be found in Table 2.7.3. 
 
Table 2.7.3 | Antibodies  
Antibody Dilution Isotype Company Clone Application 
Primary Antibodies 
α-V5 1:2000 Mouse IgG1 Thermo Fisher E10/V4RR IB 
α-HA 1:1000 Rabbit IgG CST C29F4 IB 
α-Calnexin 1:10000 Rabbit IgG 
Lifespan 
BioSciences 
 IB 
α-GAPDH 1:10000 Mouse IgG1 R&D Systems 686613 IB 
α-CNOT7 1:1000 Mouse IgG Abcam EPR18722 IB 
α-CNOT2 1:1000 Rabbit IgG Novus  IB 
α-NEDD4 1:1000 Mouse IgG2B R&D Systems 683211 IB 
α-IE1 1:1000 Mouse IgG2A Merck 8B1.2 FACS 
APC α-HLA-A, B, C 1:1000 Mouse IgG2A Biolegend W6/32 FACS 
Secondary Antibodies 
IRDye 680RD  
α-mouse 
1:10000 Goat IgG LI-COR  IB 
IRDye 680RD  
α-rabbit 
1:10000 Goat IgG LI-COR  IB 
IRDye 800CW  
α-mouse 
1:10000 Goat IgG LI-COR  IB 
IRDye 800CW  
α-rabbit 
1:10000 Goat IgG LI-COR  IB 
AlexaFluor 488 
α-mouse 
1:1000 
Goat F(ab’)2  
Fragment 
CST  FACS 
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2.8 Flow Cytometry 
At the appropriate time-point of infection, cells were washed in PBS and brought 
into suspension with Trypsin-EDTA. The cell suspension was then centrifuged at 400 x g, 
RT for 5 min. Supernatant was discarded and cells were fixed by incubating with 200 µL 
of 4 % Paraformaldehyde, for 10 min at RT. The fixing solution was removed by 
centrifugation at 800 x g, RT for 5 min. 
For cells infected with a viral strain containing a GFP-tagged gene, cells were re-
suspended in 200 µL PBS and analysed by flow cytometry.  
For cells infected with a viral strain lacking a GFP-tagged gene, cells were re-
suspended in 200 µL ice-cold Methanol and incubated for 5 min at 4 °C, for 
permeabilisation of cell membranes. Cells were washed with PBS/0.2 % (v/v) FBS and 
pelleted by centrifugation at 800 x g, 4 °C for 5 min. After discarding the supernatant, the 
pellet was re-suspended in 25 µL Fc receptor blocking solution Human TruStain FcX 
(BioLegend) and incubated for 1 h at 4 °C. Cells were incubated with 25 µL mouse α-IE1 
primary antibody in PBS (see Table 2.7.3) for 1 h at 4 °C. After washing in ice-cold PBS 
and centrifuging at 800 x g, 4 °C for 5 min, cells were re-suspended in 50 µL goat α-mouse 
IgG Alexa Fluor (see Table 2.7.3) secondary antibody in PBS for 1 h at 4 °C. The staining 
solution was removed by centrifugation at 800 x g, 4 °C for 5 min and cells were re-
suspended in 200 µL PBS for flow cytometry analysis.  
Flow cytometry was carried with a FACSCalibur Cell Analyser (BD Biosciences) 
with CellQuest PRO software (BD Biosciences). Cell populations were selected by forward 
scatter and side scatter gating before analysis with the appropriate laser excitation. Data 
analysis was performed with FlowJo software (BD Biosciences). 
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2.9. Immunoprecipitation 
 
2.9.1 Affinity-purification mass spectrometry 
 
2.9.1.1 Viral infection 
HFFF-TERT stable cell lines expressing different viral baits were infected in 
batches of eight, in duplicate. For each cell line, 6x106 cells were plated in complete 
medium in each of two 150 cm2 dishes. The following day, media was replaced with 
serum-free DMEM containing 4 μg/ml Dexamethasone and incubated for 24 h, 37 °C, 5 % 
CO2, as this approach has been shown to improve infection efficiency [198]. After 24 h, 
cells were infected in 10 mL serum-free DMEM containing requisite volume of HCMV 
Merlin strain stock to achieve MOI 2. Cells were gently rocked for 2 h, then the infection 
inoculum was replaced with complete medium and cells were incubated for a further 58 
h. Infection of all cell lines was performed using aliquots of the same pool of virus. 
 
2.9.1.2 Cell lysis 
In order to preserve protein-proteins interactions, lysates were collected in one of 
two lysis buffers, according to the solubility of each overexpressed transgene. For soluble 
and single-pass transmembrane (TM) baits, cells were lysed on ice in 1.2 mL MCLB buffer 
(50 mM Tris pH 7.5, 300 mM NaCl, 0.5 % (v/v) NP-40, 1 M DTT and Roche protease 
inhibitor cocktail (1 tablet/10 mL)). Baits with more than one TM domain were 
solubilized on ice in 1 % (w/v) Digitonin (Merck Millipore) in TBS (Sigma) with Roche 
protease inhibitor cocktail (1 tablet/10 mL). Prediction of TM domains was taken from 
Uniprot (www.uniprot.org) for canonical HCMV proteins, and generated using TMHMM 
for the two uncharacterised ORFs [199]. Lysis buffers were pre-chilled before use. 
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Lysates were scraped on ice and transferred into a 2 mL tube. Samples were tumbled for 
15 min at 4 °C, then centrifuged at 16,100 x g for 15 min at 4 °C. Lysates were clarified by 
filtration with a 0.7 µm filter.  
For MCLB buffer, all samples were lysed using aliquots of the same batch of lysis 
buffer. 
 
2.9.1.3 Anti-V5 Immunoprecipitation 
Prior to incubation with samples, immobilised mouse monoclonal anti-V5 agarose 
resin (Sigma-Aldrich) was washed three times with 1 mL lysis buffer with intermediate 
centrifugation steps at 2,000 x g, 4 °C for 2 min. Each lysate was incubated for 3 h with 30 
µl anti-V5 agarose resin, at 4 °C in a rotating mixer (Stuart). Duplicate samples were 
combined for resin washes. Washes were performed in Pierce Spin Columns (Thermo 
Fisher Scientific) placed in a Vac-Man Laboratory Vacuum Manifold (Promega), allowing 
for the flow-through waste to be directly collected into the manifold chamber. Samples 
lysed in NP-40-containing buffer were washed seven times with 700 µl lysis buffer, 
followed by seven 700 µl ice-cold PBS pH 7.4 washes. Samples lysed in Digitonin-
containing buffer were washed once with 700 µl lysis buffer, twice with 700 µl 0.2 % 
(w/v) Digitonin in TBS and then once with 700 µl TBS. Proteins bound to the resin were 
incubated with 200 µl of 250 μg/ml V5 peptide (Alpha Diagnostic International) in PBS, 
at 37 °C for 30 min with agitation and eluted into a 1.5 mL tube by centrifugation at 4,000 
rpm for 1 min. Incubation with elution buffer and centrifugation steps were repeated 
once more.  
For MCLB buffer, all samples were washed with aliquots from the same batch of 
buffer. Several batches of the anti-V5 agarose resin used for immunoprecipitation were 
pooled and this pool was used for all samples. 
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2.9.1.4 Protein precipitation 
Eluted proteins were precipitated with 80 µl 20 % (v/v) Trichloroacetic acid 
(TCA) by incubation at 4 °C for 45 min. Samples were centrifuged at 16,100 x g, 4 °C for 
30 min and the majority of the supernatant was discarded. The protein pellet was washed 
once with 1 mL 10 % (v/v) TCA, mixed by inversion and centrifuged at 16,100 x g, 4 °C 
for 20 min. After removing the supernatant, samples were washed three times with 1 mL 
cold acetone with intermediate centrifugation steps at 16,100 x g, 4 °C for 20 min, always 
discarding the supernatant. Protein pellet was dried to completion using a centrifugal 
evaporator.  
 
2.9.1.5 Trypsin digest  
Proteins were re-suspended in 20 µL digestion buffer (50 mM Tris pH 8.5, 10 % 
(v/v) AcN, 1 mM DTT, 10 µg/mL Trypsin) and incubated O/N at 37 °C with agitation. The 
digestion reaction was quenched with 50 µL 50 % (v/v) formic acid (FA). To minimise 
variability in sample preparation, all protein digests were performed with aliquots from 
the same stock of digestion buffer. 
 
2.9.1.6 StageTip  
Peptide samples were subjected to C18 solid-phase extraction on a StageTip 
placed on a 2 mL collection tube. Prior to sample loading, the C18 solid-phase was washed 
with 50 µL Methanol and centrifuged for 1 min at 3,000 rpm. The solid-phase was washed 
with 50 µL 70 % (v/v) AcN/ 1 % (v/v) FA, followed by centrifugation for 1 min at 3,000 
rpm. The StageTip was then equilibrated with 50 µL 1 % (v/v) FA, followed by 
centrifugation for 1 min at 3,000 rpm. Peptide samples were then loaded onto the tip, 
centrifuged for 1 min at 3,000 rpm. C18-bound peptide was washed with 100 µL 1 % 
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(v/v) FA, followed by centrifugation for 1 min at 3,000 rpm. The collection tube was 
replaced by a new 1.5 mL tube and bound peptide was eluted with 50 µL 70 % (v/v) AcN/ 
1 % (v/v) FA by centrifugation for 1 min at 3,000 rpm. Samples were vacuum-centrifuged 
to complete dryness, followed by reconstitution in 10 µL 4 % (v/v) AcN / 5 % (v/v) FA. 
Samples were divided into two technical duplicates of 5 µL in glass vials, prior to LC-
MS/MS on the Orbitrap Lumos. 
 
2.9.1.7 LC-MS/MS 
Peptide samples derived from each cell line were analysed in technical duplicate. 
The LC-MS/MS queue order was reversed between batches of technical replicates, to 
avoid peptide carry-over. Additionally, two washes on the liquid-chromatography (LC) 
system were used between each sample to further minimise carry-over. Individual 
batches included 16 - 22 samples. To ensure consistent performance by the mass 
spectrometer between batches, an identical aliquot of a control IP of uninfected cells 
stably expressing the viral UL123 gene with a C-terminal V5 tag was included at the 
beginning of each batch. The total number of peptides were very similar between each 
batch (Table 5.1, page 136). 
Mass spectrometry data was acquired using an Orbitrap Lumos. An Ultimate 3000 
RSLC nano UHPLC equipped with a 300 µm ID x 5 mm Acclaim PepMap µ-Precolumn 
(Thermo Fisher Scientific) and a 75 µm ID x 50 cm 2.1 µm particle Acclaim PepMap RSLC 
analytical column was used. 
Loading solvent was 0.1 % (v/v) FA, while the analytical solvents were A: 0.1 % 
(v/v) FA and B: 80 % AcN + 0.1 % (v/v) FA. All separations were carried out at 55 °C. 
Samples were loaded at 5 µl/min for 5 min in loading solvent before beginning the 
analytical gradient. The following gradient was used: 3-7 % B over 3 min, then 7-37 % B 
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over 54 min followed by a 4 min wash in 95 % B and equilibration in 3 % B for 15 min. 
The following settings were used: MS1: 350-1500 Thompsons (Th), 120,000 resolution, 
2x105 automatic gain control (AGC) target, 50 ms maximum injection time. MS2: 
Quadrupole isolation at an isolation width of m/z 0.7, higher-energy collisional 
dissociation (HCD) fragmentation (normalised collision energy (NCE) 34) with fragment 
ions scanning in the ion trap from m/z 120, 1x104 AGC target, 250 ms maximum injection 
time, with ions accumulated for all parallelisable time. The method excluded 
undetermined and very high charge states (≥25+). Dynamic exclusion was set to +/- 10 
ppm for 25 s. MS2 fragmentation was trigged on precursors 5x103 counts and above. Two 
45 min washes were included between every affinity-purification mass spectrometry 
(AP-MS) analysis, to minimise carry-over between samples. 
 
2.9.2 Immunoprecipitation for immunoblotting 
HEK293T cells transiently transfected with lentiviral constructs expressing an 
HCMV gene and its human binding partner were plated in complete medium as described 
in 2.2.7. Alternatively, 6x106 HFFF-TERT cells from a stable cell line expressing a viral 
gene were plated in a 150 cm2 dish. The following day, cell lysates were prepared as 
described in 2.9.1.2. 
Immunoprecipitation was performed as described in 2.9.1.3 with the following 
modifications: (a) samples were washed three times with lysis buffer, followed by two 
PBS pH 7.4 washes; (b) proteins bound to the anti-V5 resin were eluted once by adding 
40 µl of 2.5 mg/ml V5 peptide (Alpha Diagnostic International) in PBS at 37 °C for 30 min 
with agitation. 
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The eluates were reduced with 6X Protein Loading Dye (Tris 375 mM pH 6.8, 12 % 
(v/v) SDS, 30 % (v/v) glycerol, 0.6 M DTT, 0.06 % (w/v) bromophenol blue) for 5 min at 
95 °C. Approximately 50 µg of protein for each sample was separated by PAGE using 4-
15 % TGX Precast Protein Gels (Bio-rad), then transferred to PVDF membranes using 
Trans-Blot Systems (Bio-rad), as described in 2.7.  
 
2.10 Proteomic analysis of whole-cell lysates  
Proteomic analysis of whole-cell lysates was performed to compare the relative 
abundance of ORFL147C protein in cells infected with WT (RCMV 2582) or ΔORFL147C 
virus (RMCV 2697), to confirm that the deletion mutant did not express ORFL147C 
protein.  
 
2.10.1 Viral infection 
1.5x105 HFFF-TERT cells were seeded per well of a 12-well plate. The following 
day, media was replaced with serum-free DMEM containing 4 μg/ml Dexamethasone and 
incubated for 24 h, 37 °C, 5 % CO2. Cells were then infected with mock (serum-free 
DMEM), WT (RCMV 2582) or ΔORFL147C virus (RMCV 2697) in duplicates, at MOI 2 for 
48 h, as described in 2.3.4. The following day, one set of samples (mock, WT and 
ΔORFL147C) were processed for flow cytometry (as described in section 2.8) using GFP 
as a marker to determine percentage of infection. The other set of samples was processed 
for whole-cell lysate proteomics to compare ORFL147C expression. 
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2.10.2 Cell lysis 
For whole-cell lysate proteomics cells were washed twice with PBS. After 
removing any residual PBS, lysates were collected from one set of duplicates using 150 
µL 6 M Guanidine / 50 mM HEPES pH 8.5 lysis buffer. Lysates were homogenised by 
vortex for 30 sec and centrifuged at 13,000 x g for 10 min. After transferring the 
supernatant to a new tube, the spin and transfer steps were repeated once more.  
 
2.10.3 Reduction and alkylation of disulphide bonds 
Then, 7.5 µL of 100 mM DTT were added to the lysate, the mixture was 
homogenised by vortex and incubated for 20 min, RT. The samples were then alkylated 
by adding 4.2 µL of 500 mM Iodoacetamide. The mixture was again homogenised by 
vortex and incubated for 20 min, RT, in the dark. Alkylation was quenched by adding 7.5 
µL of 100 mM DTT, homogenisation by vortex and incubation for 15 min, RT.  
 
2.10.4 Protein digestion with LysC and Trypsin 
The lysate was then diluted to a final concentration of 1.5 M Guanidine 
Hydrochloride by adding 450 µL 200 mM HEPES pH 8.5. Samples were incubated with 3 
µL LysC for 3 h at RT, followed by a further dilution with 1.05 mL 200 mM HEPES pH 8.5. 
Lysates were then incubated at 37 °C O/N with 150 µL of 3.33 ng/µL Trypsin. The next 
day, samples were acidified by adding 100 µL of 50 % Formic acid (FA), homogenised by 
vortex, centrifuged for 10 min at 21,000 x g and transferred to a new tube. 
 
87 
 
2.10.5 Protein isolation with SepPak 
Peptides were then purified using a SepPak column (Waters) placed on a vacuum 
manifold. The SepPack column was washed with 2 mL of 100 % Acetonitrile (AcN), 
followed by 1 mL of 70 % (v/v) AcN/ 1 % (v/v) FA and then 3 mL of 1 % (v/v) FA. After 
loading the sample, the column was washed with 3 mL 1 % (v/v) FA. Peptides were eluted 
with 350 µL 70 % (v/v) AcN/ 1 % (v/v) FA and dried to completion using a centrifugal 
evaporator. 
Peptides were then resuspended in 150 µL 200 mM HEPES pH 8.5 and the 
concentration in each sample was estimated using a Pierce BCA Protein Assay kit 
(Thermo Fisher Scientific) as described in section 2.7.2.  
 
2.10.6 Peptide labelling with Tandem Mass Tags 
Samples were then labelled with Tandem Mass Tags (TMT): mock - 126; wild-type 
– 127N; ΔORFL147C – 128N. Firstly, 16 µL of peptide (15 µg) were added to 6 µL AcN, 
homogenised by vortex and briefly spun down to collect the sample at the bottom of the 
tube. Approximately 93 µg of each TMT label was then added to each sample, followed by 
homogenisation by vortex and brief spin. The labelling reaction was incubated for 1 h at 
RT. TMT labelling was quenched by adding 5 µL of 5 % (v/v) Hydroxylamine and 
incubating for 15 min. Samples labelled with different tags were combined 1:1:1, and 
acidified by adding 5 µL 50 % (v/v) FA per number of samples combined. The sample was 
vacuum-centrifuged to near dryness and subjected to C18 SPE (Sep-Pak, Waters).  
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2.10.7 Offline high pH reversed phase fractionation 
Six fractions were then generated using high pH reversed phase fractionation to 
increase the overall number of peptides quantified. TMT-labelled tryptic peptides were 
subjected to high pH reversed phase fractionation using an Ultimate 3000 RSLC UHPLC 
system (Thermo Fisher Scientific) equipped with a 2.1 mm internal diameter (ID) x 25 cm 
long, 1.7 μm particle Kinetix Evo C18 column (Phenomenex). Mobile phase consisted of 
A: 3 % acetonitrile (MeCN), B: MeCN and C: 200 mM ammonium formate pH 10. Isocratic 
conditions were 90 % A/10 % C, and C was maintained at 10 % throughout the gradient 
elution. Separations were conducted at 45 °C. Samples were loaded at 200 μl/min for 
5 min. The flow rate was then increased to 400 μl/min over 5 min, after which the 
gradient elution proceed as follows: 0-19 % B over 10 min, 19-34 % B over 14.25 min, 
34-50 % B over 8.75 min, followed by a 10 min wash at 90 % B. UV absorbance was 
monitored at 280 nm and 15 s fractions were collected into 96-well microplates using the 
integrated fraction collector. Wells were excluded prior to the start or after the cessation 
of elution of peptide-rich fractions, as identified from the UV trace. Fractions from 
adjacent columns were combined pairwise (e.g. 1+2, 3+4, 5+6) to yield 6 combined 
fractions, which were dried in a centrifugal evaporator and subsequently re-suspended 
in 10 µL of 5 % FA/ 4 % AcN prior to LC-MS3. 
 
2.10.8 LC-MS3 
Mass spectrometry data was acquired using an Orbitrap Lumos. An Ultimate 3000 
RSLC nano UHPLC equipped with a 300 µm ID x 5 mm Acclaim PepMap µ-Precolumn 
(Thermo Fisher Scientific) and a 75 µm ID x 50 cm 2.1 µm particle Acclaim PepMap RSLC 
analytical column was used. Loading solvent was 0.1 % FA, analytical solvent A: 0.1 % FA 
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and B: 80 % AcN + 0.1 % FA. All separations were carried out at 55 °C. Samples were 
loaded at 5 µL/min for 5 min in loading solvent before beginning the analytical gradient. 
The following gradient was used: 3-7 % B over 3 min, 7-37 % B over 173 min, followed 
by a 4 min wash at 95 % B and equilibration at 3 % B for 15 min. Each analysis used a 
MultiNotch MS3-based TMT method [200]. The following settings were used: MS1: 380-
1500 Th, 120,000 Resolution, 2x105 AGC target, 50 ms maximum injection time. MS2: 
Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation (NCE 35) with 
ion trap scanning in turbo mode from m/z 120, 1.5x104 AGC target, 120 ms maximum 
injection time. MS3: In Synchronous Precursor Selection mode the top 6 MS2 ions were 
selected for HCD fragmentation (NCE 65) and scanned in the Orbitrap at 60,000 
resolution with an AGC target of 1x105 and a maximum accumulation time of 150 ms. Ions 
were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target 
time of 3 s. Dynamic exclusion was set to +/- 10 ppm for 70 s. MS2 fragmentation was 
trigged on precursors 5x103 counts and above. Data analysis is described in section 2.11. 
 
2.11 Data analysis 
 
2.11.1 Database and search parameters for protein identification 
Mass spectra were processed using a Sequest-based software pipeline for 
quantitative proteomics, “MassPike”, through a collaborative arrangement with 
Professor Steven Gygi’s laboratory (Department of Cell Biology, Harvard Medical School). 
Mass spectra were converted to mzXML using an extractor built upon Thermo Fisher’s 
RAW File Reader library (version 4.0.26). This software is a component of the MassPike 
software platform and is licensed by Harvard Medical School. 
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A combined database was constructed from (a) the human Uniprot database (26th 
January, 2017), (b) the HCMV strain Merlin Uniprot database, (c) all additional non-
canonical human cytomegalovirus ORFs described by Stern-Ginossar et al [67], (d) a six-
frame translation of HCMV strain Merlin filtered to include all potential ORFs of ≥8 
residues (delimited by stop-stop rather than requiring ATG-stop) and (e) common 
contaminants such as porcine trypsin and endoproteinase LysC. ORFs from the six-frame 
translation (6FT-ORFs) were named as follows: 6FT_Frame_ORFnumber_length, where 
Frame is numbered 1-6, and length is the length in amino acids. The combined database 
was concatenated with a reverse database composed of all protein sequences in reversed 
order. Searches were performed using a 20 ppm precursor ion tolerance [201]. Product 
ion tolerance was set to 0.03 Th. Oxidation of methionine residues (15.99492Da) was set 
as a variable modification. 
To control the fraction of erroneous protein identifications, a target-decoy 
strategy was employed [202, 203]. Peptide spectral matches (PSMs) were filtered to an 
initial peptide-level false discovery rate (FDR) of 1 % with subsequent filtering to attain 
a final protein-level FDR of 1 % [204, 205]. PSM filtering was performed using a linear 
discriminant analysis, as described [206]. This distinguishes correct from incorrect 
peptide IDs in a manner analogous to the widely used Percolator algorithm [207], though 
employing a distinct machine learning algorithm. The following parameters were 
considered: XCorr, ΔCn, missed cleavages, peptide length, charge state, and precursor 
mass accuracy. 
For MS3-based TMT analysis, TMT tags on lysine residues and peptide N termini 
(229.162932 Da) and carbamidomethylation of cysteine residues (57.02146 Da) were 
included as static modifications. Proteins were quantified by summing TMT reporter ion 
counts across all matching peptide-spectral matches using ”MassPike”. A 0.003 Th 
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window around the theoretical m/z of each reporter ion (126, 127n, 128n) was scanned 
for ions, and the maximum intensity nearest to the theoretical m/z was used. An isolation 
specificity filter with a cut-off of 50 % was employed to minimise peptide co-isolation 
[200]. Peptide-spectral matches with poor quality MS3 spectra (more than 3 TMT 
channels missing and/or a combined S:N ratio of less than 100 across all TMT reporter 
ions) or no MS3 spectra at all were excluded from quantitation. Peptides meeting the 
stated criteria for reliable quantitation were then summed by parent protein, in effect 
weighting the contributions of individual peptides to the total protein signal based on 
their individual TMT reporter ion yields. Protein quantitation values were exported for 
further analysis in Excel. For protein quantitation, reverse and contaminant proteins 
were removed, then each reporter ion channel was summed across all quantified proteins 
and normalised assuming equal protein loading across all channels. Fractional TMT 
signals were used (i.e. reporting the fraction of maximal signal observed for each protein 
in each TMT channel, rather than the absolute normalized signal intensity). This 
effectively corrected for differences in the numbers of peptides observed per protein. 
 
2.11.2 Interactor identification with CompPASS 
Data from the technical replicate from each viral bait was combined to attain a 
summary of proteins identified in both runs. Peptides within replicates were 
reassembled into proteins following the principles of parsimony [206]. Where all PSMs 
from a given HCMV protein could be explained either by a canonical gene or non-
canonical ORF, the canonical gene was picked in preference. In four cases 
(UL24/ORFL71C_(UL24), UL31/ORFL87W_(UL31), UL150A/ORFL321W, 
UL44/ORFL112C_(UL44)), PSMs assigned to a non-canonical ORF were a mixture of 
peptides from the canonical protein and the ORF. This occurred where the ORF was a 5’-
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terminal extension of the canonical protein (thus meaning that the smallest set of 
proteins necessary to account for all observed peptides included the ORFs alone). In these 
cases, the peptides corresponding to the canonical protein were separated from those 
unique to the ORF, generating two separate entries. 
For human and canonical HCMV proteins, Uniprot protein IDs were mapped to 
Entrez Gene IDs. Downstream interactor and network analysis was carried out at the 
level of Gene IDs to minimise confusion due to protein isoforms. CompPASS scoring was 
performed as described previously [189], in two analyses that were subsequently 
combined, one for NP40-based IPs and the other for Digitonin IPs. Data reported for each 
protein in every IP in the dataset included: (a) the number of peptide spectrum matches 
(PSMs), averaged between technical replicates; (b) a log(2)-based Shannon entropy 
score, comparing numbers of spectral counts observed for a protein in two technical 
replicates to eliminate proteins that were not detected consistently (see Figure 2.11.2.1). 
(c) a z-score, calculated in comparison to the average and standard deviation of PSMs 
observed across all IPs. (d) an NWD score, calculated as described in [208] using the 
fraction of runs in which a protein was observed, the observed number of PSMs, the 
average and standard deviation of PSMs observed for that protein across all IPs, and the 
number of replicates (1 or 2) containing the protein of interest. NWD scores were 
normalized so that the top 2 % earned scores were equal to or greater than 1.0. For NP40-
based IPs, the top 2 % of z-scores were greater than 6.676, and for Digitonin-based IPs 
greater than 4.329. Equations for NWD and Z scores are provided in Figure 2.11.2.2. 
As the set of Digitonin-based IPs was necessarily smaller than NP40-based IPs (18 
compared to 153 viral genes examined respectively), additional control IPs were 
included. Biological duplicates of cells transduced with empty vector controls (‘No bait’), 
and biological duplicates of cells transduced with the pHAGE-SFFV vector encoding GFP 
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were included in the Digitonin set. A single replicate of the ‘No bait’ control was included 
in the NP40 set. These controls had the effect of increasing the number of IPs that 
identified non-specific interacting proteins, thus decreasing NWD and z-scores for these 
proteins. Mass spectrometry RAW files from control UL123 IPs included to ensure batch-
to-batch consistency were not included in the final data analysis to avoid modification of 
NWD and z-scores for the infected UL123-expressing sample. 
Following CompPASS analysis, a series of filters were applied to remove 
inconsistent and low-confidence protein identifications across all IPs and minimize both 
false protein identifications and associations. These included: (a) a minimum PSM score 
of 1.5 (i.e. a minimum of 3 peptides per protein across both replicates); (b) a minimum 
entropy score of 0.75; (c) a top 2 % NWD or z-score. Previous studies have estimated a 
5% false discovery rate when employing a similar strategy with a top 2 % NWD score 
[195]. As found in prior human interactome investigations, certain known interactions 
fell just below the stringent top 2 % NWD or z-score cut-offs. Proteins were therefore also 
included with top 5 % NWD or z-scores (>0.434 and >3.688 respectively), if they were 
reported to interact with the bait in a prior study [209]. For protein UL133 (2 TM 
regions), an initial Digitonin-based AP-MS analysis failed to generate any interactors after 
filtering. This IP was repeated using the NP40-based lysis buffer. Protein-protein 
interaction visualisation and diagram generation was performed using Cytoscape ver 
3.7.1 [210].  
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Figure 2.11.2.1 | Equations for the CompPass parameter Entropy (adapted from Huttlin et 
al, 2015). This parameter is particularly useful for detection of LC-carry-over and inconsistent 
proteins, requiring technical replicates for each IP, and inverse ordering of the second replicates, 
as shown in the table for prey Z. Rows correspond to different AP-MS experiments (Baits I to X); 
PSMs quantified in each replicate for baits I to X are listed in middle columns for prey Z. Although 
prey Z was mostly observed in bait V IP, decreasing levels were seen in subsequent runs. Because 
run order was reversed for replicate B, carry-over can be distinguished based on substantial PSM 
differences between replicates, and can be quantified with an entropy score [211]. To enable 
calculation when 0 PSMs are observed, a pseudo-count of 0.5 is added to each replicate. In Huttlin 
et al, (2015) an analysis of the distribution of entropy values identified that a cut-off of 0.75 
removes irreproducible proteins (red) while leaving consistently-detected proteins (green). 
However, in the present study, two washes were included between each sample run (as opposed 
to the Huttlin study where, due to the much larger interactome size, no washes could be included). 
The degree of carry-over would therefore be expected to be considerably lower. Adapted from 
Huttlin et al, 2015. 
  
Prey Z PSMs across Runs
Bait Replicate A Replicate B Entropy
I 0 5 0.41
II 0 3 0.54
III 0 7 0.34
IV 0 17 0.18
V 508 353 0.98
VI 107 1 0.1
VII 24 0 0.14
VIII 14 0 0.21
IX 5 0 0.41
X 4 0 0.47
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Figure removed for copyright reasons. Copyright holder is Elsevier Inc. 
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Figure 2.11.2.2 | Equations for the CompPass parameters Z and NWD 
CompPass generates an interaction matrix in which the rows are the proteins identified from all 
AP-MS experiments and the columns represent each bait used for these experiments. Each cell in 
the matrix contains the Total Spectral Count (TSC) for a specific interacting protein from a 
particular bait's AP-MS experiment. The TSC for a protein provides a good estimation of that 
protein's abundance in the AP-MS experiment. Scores are then calculated for each interactor, for 
each bait. After identifying peptides and proteins, given that each bait was run twice, the 
duplicates are combined into a single "merged" run for that bait. When merging, the TSC for an 
interactor is the average TSC observed from the duplicate runs. The Z-score determines the 
number of standard deviations away from the mean (Eq. 1) at which a measurement lies (Eq. 2). 
The NWD score is calculated as shown in Eq. 5 and incorporates the frequency of the observed 
interactor, its abundance, the mean and standard deviation of TSCs observed for that protein 
across all IPs, and the reproducibility of that interaction. In Eq. 4, f is a term which is 0 or 1 
depending on whether or not the interacting protein was immunoprecipitated by a given bait. 
Placed in the summation across all baits, it is a counting term and therefore, ‘k/∑f’ represents the 
frequency (λ) of an interactor across all baits. The smaller f, the larger the frequency becomes, 
up-weighting interactors that are rare. The weight factor, ωi (Eq. 3), is added as a multiplicative 
factor to the frequency term in order to offset this low value for interactors that are found 
frequently across baits but will only be >1 if the conditions in Eq. 5 are met. In this way, only if a 
frequent interactor displays the observed characteristics of a true interactor will its score 
increase due to the weight factor. The power term r takes into account the reproducibility of the 
interaction and allows for discrimination between a true ‘one hit wonder’ (a protein found with 
1 peptide in a single run, not in the duplicate) which is likely a false positive versus a true 
interactor with low TSC (even 1) that is found in both duplicate runs. The term Xb,i is the TSC for 
interactor i from bait b and therefore multiplying by this value scales the score with increasing 
interactor TSC. This provides a higher score to interactors having high TSC and are therefore 
more abundant and less likely to be stochastically sampled. Adapted from Sowa et al, 2009. 
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2.11.3 Interaction database comparisons 
Lists of physical interactions between viral proteins and human proteins were 
downloaded in October 2018 from: BioGRID [212], IntAct [213], Uniprot 
(www.uniprot.org), MINT [214], and Virus Mentha [215]. Entries were then compiled 
into a single file with duplicate entries removed. Search terms for each database were as 
follows: 
- BioGRID: “Human Herpesvirus 5” 
- IntAct: “Human cytomegalovirus (strain AD169) (HHV-5)” 
- Uniprot: “Human cytomegalovirus (HHV-5) (Human herpesvirus 5) [10359]” 
- MINT: “Human cytomegalovirus” & “Human cytomegalovirus (strain AD169) 
(HHV-5)” 
- Virus Mentha: “Human herpesvirus 5” & “Human herpesvirus 5 strain AD169” & 
“Human herpesvirus 5 strain Merlin” & “Human herpesvirus 5 strain Towne” 
 
2.11.4 Functional enrichment analysis 
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) 
version 6.8 was used to determine functional term enrichment [216]. All human HCIPs 
for all viral baits were searched against a background of all human proteins, using default 
settings provided by this bioinformatics tool. 
 
2.11.5 Domain association analysis 
Domain associations were generated by mapping Pfam domains [217] provided 
by Uniprot onto all proteins in the dataset. Then the total number of interactions for each 
domain as well as the number of interactions involving pairs of domains from interacting 
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proteins were counted, and the significance of the association between domains was 
calculated using Fisher’s Exact Test [189]. p-values were corrected for multiple 
hypothesis testing [218]. Domains were considered significantly associated if their 
adjusted p-value was less than 0.01.  
 
2.11.6 ORFL147C DNA and amino acid sequence alignment analysis 
 Basic local alignment search tool (BLAST, National Center for Biotechnology 
Information) [219] was used to search for homologues of ORFL147C in other human 
herpesvirus. The nucleotide and amino acid sequences of ORFL147C were searched 
against a database of ‘Nucleotide collection (nr/nt)’ or ‘Non-redundant protein sequences 
(nr)’, specifying the following organisms HSV-1 (taxid: 10298), HSV-2 (taxid: 10310), VZV 
(taxid: 10335), EBV (taxid: 10376), HHV-6 (taxid: 10368), HHV-7 (taxid: 10372) and 
KSHV (taxid: 37296). 
 To identify a degree of conservation for the amino acid sequence of ORFL147C 
between HCMV strains, the DNA sequences for this ORF in strains Merlin (NC_006273), 
Towne (FJ616285), Toledo (GU937742) and AD169 (FJ527563) were translated using 
the ExPASy Translate tool (Swiss Institute of Bioinformatics) [220] and aligned using the 
Clustal Omega (EMBL-EBI) [221] with default settings.  
Alignment of the amino acid sequence of ORFL147C with cy89 protein (Uniprot: 
G8H195) from Cynomolgus macaque cytomegalovirus (CyCMV) strain Ottawa, Cy89 
protein (Uniprot: A0A0K1H0A6) from CyCMV strain Mauritius and Rh91.1 (Uniprot: 
Q2FAM5) from Rhesus cytomegalovirus (RhCMV) was also performed using the Clustal 
Omega (EMBL-EBI) multiple sequence alignment tool with default settings. 
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3 | Generating resources for AP-MS 
 
Normalised IBAQ quantification was performed by Dr. Michael Weekes (Department 
of Medicine, University of Cambridge). Codon optimisation of UL74, US14 and US17 was 
performed by Dr. James Davies and Dr. Sepehr Seirafian (School of Medicine, Cardiff 
University). Parts of the work presented in this chapter have been published in a similar 
form in eLife (Nobre et al., 2019). 
 
Affinity-purification mass-spectometry allows identification of isolated protein 
complexes bound to a specific protein bait. Systematic analysis of these datasets in 
tandem generates a network map of protein interactions, designated as an interactome, 
providing valuable insights into gene function. 
To enable the identification of interactors for each HCMV protein (HCMV 
interactome), three types of resources were necessary: (a) expression vectors with the 
coding sequences of each viral protein followed by a tag for affinity-purification; (b) cell 
lines that would constitutively express the tagged viral proteins individually; (c) an 
homogeneous stock of HCMV, sufficient to infect all cell lines to a similar MOI. 
 
3.1 Generation of the expression construct library 
Expression vectors for each viral bait were generated by cloning the coding 
sequences for 171 canonical protein-coding genes from HCMV strain Merlin and 2 
uncharacterised viral ORFs (see Figure 3.1) into the pHAGE-SFFV lentiviral vector. The 
expression vector contained a spleen focus-forming virus (SFFV) promoter replacing the 
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CMV promoter in the parental pHAGE-pCMV, to prevent promoter inactivation during 
HCMV infection by the UL122 gene product IE86 [222, 223].  
 
Coding sequence for ORFL147C 
ATGTCTCTGGCCGGCGCCAGACCGGACGACAGCGTCTCGTACGTGAGCGAGTCGAGTCATGGAGATGAATTTGTT
ACAGAAACTATGCGTAGTGTGTTCGAAATGCAACGAATACGCCATGGAGCTGGAGTGTCTAAAGTACTGCGATCC
GAACGTGTTACTGGCGGAGTCCACGCCGTTCAAGAGAAACGCGGCGGCTATAGTGTATCTGTACCGGAAGATCTA
CCCGGAGGTGGTGGCGCAGAATCGTACGCAGAGTTCGCTGCTGACTCTCTATCTGGAGATGCTGCTGAAGGCGCT
GCACGAGGATACGGCTTTGCTGGATCGGGCGCTGATGGCCTACTCGCGCCAGCCGGACCGGGCGGCCTTCTACCG
TACCGTCCTCCGTTTGGATCGCTGCGATCGCCATCACACCGTGGAGCTCCAGTTTACGGACAACGTCCGTTTCAG
CGTCAGTCTGGCCACACTCAACGACATCGAGCGCTTCCTGTGCAAAATGAACTACGTGTACGGGATCCTGGCGCC
GGAGGCCGGCCTGGAGGTCTGCGCGCAGCTGCTGGAGCTCCTCCGTCGCCTATGCGGCATCTCGCCGGTGGCGCG
TCAGGAAGTGTACGTCGAAGGGACGACATGCGCCCAATGCTACGAGGAGCTGACCATCATCCCGAATCAGGGCCG
CTCGCTGAACAAGCGGCTGCAGGGCTTGCTGTGCAACCATATAGCGGTCCACCGTCCGTCAAGCCAGTCCGATGT
GAATATCCAGACGGTGGAGCAGGACCTGCTGGACCTGACAACGCGCATCCCCCACTTGGCTGGAGTCCTTTCGGC
CCTCAAAAGCCTATTCTCTTCTTCATCGGCCTACCACAGCTACATCCAGGAGGCGGAGGAGGCGCTGAGGGAGTA
CAACCTGTTTACGGATATACCGGAACGAATATATTCCTTGTCGGATTTTACCTACTGGTCCCGTACCTCGGAGGT
TATCGTCAAGCGGGTGGGCATCACCATCCAGCAGCTAAATGTGTATCACCAGCTGTGCCGGGCGCTCATGAACGG
CATCAGTCGCCATCTGTACGGGGAGGACGTGGAGGACATCTTCGTGCTCGGGGAAAAGGCGTTGGACGGGGAGGA
GCGCATGTTCGTGGGGTCGGTCTTTGCCGCCCCCAACAGGATCATCGACCTCATCACATCCCTCAGCATTCAAGC
TTTCGAGGACAACCCGGTGTTCAACAAGCTCCACGAAAGCAACGAGATGTACACCAAAATCAAGCATATTCTCGA
GGAGATTCGACGTCCGCTGCCCGATGGCACGGGGGGCGACGGCCCCGAGGGCGAGGTTATTCACCTGCGTGGACG
GGAGGCGATGTCGGGGACGGGTACGACTTTGATGACGGCCAGCAACAGCAGCAACAGCAGTACTCACAGTCAGAG
GAA 
 
Amino-acid sequence for ORFL147C 
MSLAGARPDDSVSYVSESSHGDEFVTETMRSVFEMQRIRHGAGVSKVLRSERVTGGVHAVQEKRGGYSVSVPEDL
PGGGGAESYAEFAADSLSGDAAEGAARGYGFAGSGADGLLAPAGPGGLLPYRPPFGSLRSPSHRGAPVYGQRPFQ
RQSGHTQRHRALPVQNELRVRDPGAGGRPGGLRAAAGAPPSPMRHLAGGASGSVRRRDDMRPMLRGADHHPESGP
LAEQAAAGLAVQPYSGPPSVKPVRCEYPDGGAGPAGPDNAHPPLGWSPFGPQKPILFFIGLPQLHPGGGGGAEGV
QPVYGYTGTNIFLVGFYLLVPYLGGYRQAGGHHHPAAKCVSPAVPGAHERHQSPSVRGGRGGHLRARGKGVGRGG
AHVRGVGLCRPQQDHRPHHIPQHSSFRGQPGVQQAPRKQRDVHQNQAYSRGDSTSAARWHGGRRPRGRGYSPAWT
GGDVGDGYDFDDGQQQQQQQYSQSEE 
 
Coding sequence for ORFS343C 
ATGAAGCGGCCGTGGTGGCCGTGCTGGGCTGGGTGCATCGCTTCGAGGTTGTCGTCCGAATCGCCGGCTTGCTCC
TCTTCCAAATCTCCACGGCGGTGGCCGTCTTGGGTAGCTTCTCTCTGGTCTTCCCTACAGCGACTCTCAAGTCGC
GTCCGGGCTTTCCTTGTCACGTTGTCTGGGCGCCCGAGGTGCTCCTCCTGGTGCCTGTGGCCTCCGCGCTCTTCG
TGTATTTCCGCTATGAGCGACCGGTTCTCGCTCAGCGAAACCGGCACCCGCGCTGCCGTCGTCCGTTCCGACAGC
TGGTGCTATTACTCGCCGGCCTCCTGGCGCACATCCCGGCGC 
 
Amino-acid sequence for ORFS343C 
MKRPWWPCWAGCIASRLSSESPACSSSKSPRRWPSWVASLWSSLQRLSSRVRAFLVTLSGRPRCSSWCLWPPRSS
CISAMSDRFSLSETGTRAAVVRSDSWCYYSPASWRTSRR 
 
Figure 3.1 | Coding and amino-acid sequences for the non-canonical uncharacterised 
HCMV ORFs, ORFL147C and ORFS343C 
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Bait sequences for five proteins were modified from canonical annotation in the 
GenBank entry AY446894.2. Adaptation to fibroblasts leads to mutations in RL13 and 
UL128 genes, as a consequence, the coding sequence for UL128 in the AY446894.2 entry 
contains a single nucleotide substitution that causes premature truncation by 
introducing an in-frame termination codon into the third exon [69]. The mutation was 
absent from the clinical sample (designated ‘742’) from which Merlin was derived and 
thus Uniprot entry V9LLX6 does not contain the premature truncation. To clone UL128, 
the coding sequence from HCMV strain 6397 (EBI AFR54607.1) was used as its 
translation matches the protein sequence for Merlin UL128 annotated in Uniprot. 
Attempts to generate a stable cell line expressing the large tegument protein deneddylase 
UL48 failed, likely due to the length of the transgene exceeding the packaging limit of the 
vector. UL48 contains a predicted α-helix from residues 540-1500, but no predicted 
secondary structure between residues 1501-1509 (see Appendix A). The gene was thus 
divided into two segments, one of 4.5 kbp (1-1504 aa) terminating in a stop codon (UL48-
H1), and one of 2.2 kbp (1505-2241 aa), with an additional start codon (UL48-H2), with 
both segments transduced in separate cell lines. Protein sequences for UL74, US14 and 
US17 were codon optimised by Dr. James Davies and Dr. Sepehr Seirafian (School of 
Medicine, Cardiff University), as the expression of annotated canonical sequences could 
not be detected (see Appendix B).  
Reagents for detection of individual HCMV proteins are limited to a small subset 
of genes. To enable isolation of protein complexes bound to viral baits using AP-MS, a two 
amino acid linker sequence followed by a V5 epitope tag (GKPIPNPLLGLDST) was added 
to the C-terminus of each viral coding sequence. This 14 aa epitope was chosen as it 
should have minimal impact on transgene protein folding and function [224]. By using 
the same tag for all baits, variability among the datasets is decreased, given that the pool 
102 
 
of non-specific interactors that bind the epitope should be the same and thus more easily 
identifiable and removed from analysis.  
In addition to the viral constructs, two controls were included in the interactome 
to promote the identification of non-specific interactors. One control was generated using 
the same cloning strategy for the viral baits, containing a two amino acid linker sequence 
followed by the V5 tag, but coding for the A. victoria GFP instead of a viral gene. The 
second control, referred to as ‘no-bait’ from here on, contained neither the linker 
sequence nor the V5 tag, consisting only of a 42 bp sequence devoid of start codons in the 
place of the gateway recombination cassette.   
Coding sequences of all expression constructs were sequenced and compared to 
the Merlin strain genome, to ensure no mutations had been acquired during cloning.  
 
3.2 Detecting the expression of recombinant constructs 
Lentiviral expression constructs were stably transduced into HFFF-TERT cells and 
the expression of all baits was validated either by immunoblotting, mass spectrometry or 
PCR-based methods. Initially, lysates for all cell lines were collected as described in 2.7.1, 
and analysed by immunoblotting using an anti-V5 antibody. Blots were also incubated 
with an anti-Calnexin antibody to control for equal protein loading among samples. Bands 
were detected for 130 viral baits, validating transgene expression in 75 % of cell lines 
(see Figure 3.2.1-3.2.2). For a subset of baits, multiple bands or a band with a molecular 
size differing from theoretical (see Table 3.2.1) were observed.  
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Figure 3.2.1 | Expression of V5-tagged HCMV proteins in stable cell lines 
PVDF membranes were incubated with anti-V5 antibody to detect expression of viral transgenes 
and anti-calnexin as a control for equal protein loading among samples. Expression of proteins 
highlighted in red could not be confirmed by immunoblot and thus expression of these constructs 
was assessed using mass spectrometry. 
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Figure 3.2.2 | Expression of V5-tagged HCMV proteins in stable cell lines 
PVDF membranes were incubated with anti-V5 antibody to detect expression of viral transgenes 
and anti-calnexin as a control for equal protein loading among samples. Expression of proteins 
highlighted in red could not be confirmed by immunoblot and thus expression of these constructs 
was assessed using mass spectrometry. 
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   Table 3.2.1 | Predicted molecular sizes for HCMV proteins 
Gene Size Gene Size Gene Size Gene Size Gene Size 
US1 18 UL5 19 UL42 14 UL85 35 UL133 28 
US2 23 UL6 31 UL43 48 UL86 154 UL135 33 
US3 22 UL7 24 UL44 46 UL87 105 UL136 27 
US6 21 UL8 36 UL45 102 UL88 48 UL138 19 
US7 26 UL9 27 UL46 33 UL89 77 UL139 14 
US8 27 UL10 29 UL47 110 UL91 12 UL140 21 
US9 28 UL11 31 UL48-H1 170 UL92 23 UL141 39 
US10 21 UL13 54 UL48-H2 84 UL93 69 UL142 35 
US11 25 UL14 37 UL48A 8 UL94 38 UL144 20 
US12 32 UL15A 11 UL49 64 UL95 57 UL145 15 
US13 29 UL16 26 UL50 43 UL96 14 UL146 14 
US14 34 UL17 13 UL51 17 UL97 78 UL147 19 
US15 29 UL18 42 UL52 74 UL98 65 UL147A 8 
US16 35 UL19 11 UL53 42 UL99 21 UL148 37 
US17 32 UL20 38 UL54 137 UL100 43 UL148A 9 
US18 30 UL21A 14 UL55 102 UL102 94 UL148B 9 
US19 26 UL22A 11 UL56 96 UL103 29 UL148C 9 
US20 29 UL23 33 UL57 134 UL104 79 UL148D 7 
US21 27 UL24 40 UL69 82 UL105 107 UL150 70 
US22 65 UL25 74 UL70 108 UL111A 20 UL150A 29 
US23 69 UL26 25 UL71 40 UL112 70 TRS1 84 
US24 58 UL27 69 UL72 43 UL114 28 RL1 35 
US26 70 UL29 79 UL73 14 UL115 31 RL5A 11 
US27 42 UL30 14 UL74 55 UL116 34 RL6 12 
US28 41 UL30A 9 UL74A 8 UL117 46 RL8A 10 
US29 51 UL31 66 UL75 84 UL119 39 RL9A 5 
US30 39 UL32 113 UL76 36 UL120 23 RL10 19 
US31 19 UL33 46 UL77 71 UL121 20 RL11 27 
US32 22 UL34 45 UL78 47 UL122 63 RL12 47 
US33A 7 UL35 73 UL79 34 UL123 55 RL13 33 
US34 17 UL36 55 UL80 74 UL124 16 IRS1 91 
US34A 8 UL37 56 UL80.5 38 UL128 20 ORFL147C 50 
UL1 25 UL38 37 UL82 62 UL130 25 ORFS343C 13 
UL2 7 UL40 24 UL83 63 UL131A 15   
UL4 17 UL41A 9 UL84 65 UL132 30   
Predicted molecular sizes (in kDa) for UL48-H1, UL48-H2, ORFL147C and ORFS343C were 
calculated with the ProtParam tool (Swiss Institute of Bioinformatics) [225]. Molecular sizes 
for all other HCMV proteins were obtained from their Uniprot entries for HCMV Merlin. 
 
Affinity-purification mass-spectrometry was performed on 43 stable cell lines for 
which the detection of V5 tagged bait was unsuccessful by immunoblotting, enabling the 
validation of another 24 lines (see Table 3.2.2). iBAQ quantification values from previous 
proteomics datasets in HCMV infected cells [162, 194],  show that over half of the baits 
which were not validated using AP-MS were also not quantified in those datasets, 
suggesting that even in the context of infection, the abundance of these proteins may be 
particularly low (see Table 3.2.2). The iBAQ quantification for these datasets incorporates 
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maximum MS1 precursor intensity for each peptide quantified for these proteins across 
24, 48 and 72 hr or 24, 48, 72 and 96 hr of HCMV infection, while the cell lines used in the 
AP-MS detection method expressed the bait protein constitutively. Thus, it is unlikely that 
these proteins were detected due to the analysis of an inappropriate time point of 
expression. A possible explanation for the inability to detect expression of these baits in 
the stably-overexpressing cell lines is that these viral proteins may require co-expression 
of viral binding partners for stabilisation. Alternatively, constitutive expression outside 
the context of infection may lead to degradation of these baits by host factors that could 
be antagonised by other viral proteins in a time-dependent manner. 
Expression of the 19 remaining baits was tested by PCR-based methods. For this 
approach, total mRNA was extracted from each cell line and reverse-transcribed into 
cDNA, as described in section 2.6. Quantitative PCR was then performed on the template 
cDNA using custom-made primers, as a generic programme to generate small amplicons 
ranging from 150-200 bp. Products from the PCR reaction were then run on an agarose 
gel, isolated from gel bands and sequenced to verify homology to the bait’s coding 
sequence. Alignment of sequenced PCR products and amplicon sequence are shown in 
Table 3.2.3, where sequence identity is highlighted in blue. Short amplicons for UL136, 
UL146 and UL148D yielded low-quality sequencing that could not be aligned to the 
coding sequence, thus primers were designed to amplify full-length PCR products. While 
it was possible to obtain sequences for the PCR products with a high percentage of 
identity relative to the coding sequence of UL146 and UL148D, this was unsuccessful for 
UL136, and thus this bait was removed from any further analysis. Altogether, PCR-based 
validation verified the expression of viral transgenes in 18 cell lines. 
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Table 3.2.2 | Mass spectrometry quantification of viral protein baits 
Bait Bait peptides 
Normalised IBAQ 
experiment WCL3 
(Weekes et al, Cell 
2014) 
Normalised IBAQ 
experiment 3 
(Fielding et al, eLife 
2017) 
Average 
normalised 
IBAQ 
US2 15 2.49E-04 1.23E-04 1.86E-04 
US12 45 1.77E-05 4.94E-04 2.56E-04 
US13 NQ - - - 
US14 15 - 1.93E-04 1.93E-04 
US15 21 3.43E-05 4.56E-05 4.00E-05 
US16 1 - - - 
US17 5 - - - 
US18 NQ 5.30E-05 7.06E-06 3.00E-05 
US27 1 1.99E-03 1.21E-03 1.60E-03 
US33A NQ - - - 
UL1 NQ - - - 
UL2 NQ - - - 
UL6 NQ - 1.09E-04 1.09E-04 
UL9 NQ 1.34E-04 1.21E-04 1.27E-04 
UL10 71 - - - 
UL11 NQ 8.52E-05 4.18E-06 4.47E-05 
UL13 16 2.04E-04 9.33E-04 5.69E-04 
UL21A NQ - - - 
UL22A 10 7.43E-03 6.74E-04 4.05E-03 
UL30 NQ 1.28E-04 8.86E-06 6.84E-05 
UL30A 11 - - - 
UL32 292 7.14E-03 1.96E-02 1.34E-02 
UL33 NQ 5.15E-04 4.71E-04 4.93E-04 
UL48-H2 6 1.37E-03 5.97E-03 3.67E-03 
UL48A NQ - - - 
UL51 11 5.89E-03 1.99E-03 3.94E-03 
UL80 68 1.39E-02 9.43E-03 1.17E-02 
UL84 139 1.20E-02 1.96E-02 1.58E-02 
UL86 61 2.48E-02 8.84E-02 5.66E-02 
UL91 NQ - - - 
UL92 3 - 9.75E-06 9.75E-06 
UL96 23 5.81E-04 1.06E-04 3.44E-04 
UL120 1 - - - 
UL135 21 5.35E-03 8.54E-03 6.95E-03 
UL136 NQ 3.83E-04 1.22E-04 2.52E-04 
UL146 NQ 1.52E-02 4.91E-03 1.01E-02 
UL147 9 6.06E-04 2.09E-04 4.08E-04 
UL148D NQ - - - 
RL5A 1 - - - 
RL6 NQ - - - 
RL8A 12 - - - 
RL9A NQ - - - 
RL12 NQ 6.00E-03 6.30E-03 6.15E-03 
     Note: NQ – Not quantified 
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Table 3.2.3 | Homology between sequenced PCR products and target amplicon  
Bait Forward primer sequencing (5’ > 3’) Reverse primer sequencing (5’ > 3’) 
US13 
GACCGTGTTCCATCATCAGCGTATTCTACTC
TACGGCTACGGCGCCATCGTCTTCCTTATGA
TGACCGTGACTTTCTACGGCACGCGTTACAT
CCGCGACGAACTGCCGGCTGCTCAGACGTTA
CGCGGCTCGCTGCTGATCTACGTAGG 
GACCGTGTTCCATCATCAGCGTATTCTACTC
TACGGCTACGGCGCCATCGTCTTCCTTATGA
TGACCGTGACTTTCTACGGCACGCGTTACAT
CCGCGACGAACTGCCGGCTGCTCAGACGTTA
CGCGGCTCGCTGCTGATCTACGTAGG 
US18 
CTGATCAACACCGGCATCACCGTGTGCACGG
GCTTTTGCGGAGAAAGGCGCGTCATCGGTCT
GTCGTTTGCCCTGGTGATGGTCTTTTTCGTT
CTCTGCAGCGGTCTCACCTACCTGGCCGGCA
ACAATCCCACGCGCTGGAAAGTCATCGGGAT
TGGC 
CTGATCAACACCGGCATCACCGTGTGCACGG
GCTTTTGCGGAGAAAGGCGCGTCATCGGTCT
GTCGTTTGCCCTGGTGATGGTCTTTTTCGTT
CTCTGCAGCGGTCTCACCTACCTGGCCGGCA
ACAATCCCACGCGCTGGAAAGTCATCGGGAT
TGGC 
US33A Low-quality sequencing 
GGGTTACGAGAAACTGGGATACCGCCCGCAT
GCCAAACGCGTGTGGGTGCATGACCCGTTGG
GATTGACGCGGTTTATCATGAGGCAACTCAT
GATGTACCCGCTGGTGTTGCCGTTCACTTTT
CCGTT 
UL1 
CACTCACGTTGGTTGGACAGCCACCGTGGTG
ATAATTATCTGCGTTTTAACTTACGTTAACG
TTACAACAACCCTGAAGCACAGACTACGAAC
TAGAAACAACGTCAACCACACA 
CACTCACGTTGGTTGGACAGCCACCGTGGTG
ATAATTATCTGCGTTTTAACTTACGTTAACG
TTACAACAACCCTGAAGCACAGACTACGAAC
TAGAAACAACGTCAACCACACA 
UL2 
GAAGATGACGACGCATATCCGTCGTTCGGCA
GCCTACCCGCCTCGCACGCTCAGTACGGCTT
TCGACTGCTACGCAGCATATTTTTGATCATG
CTTGTCATTTGGACCGCAGTGTGGCTCAAGC
TGCTTCGAGACG 
GAAGATGACGACGCATATCCGTCGTTCGGCA
GCCTACCCGCCTCGCACGCTCAGTACGGCTT
TCGACTGCTACGCAGCATATTTTTGATCATG
CTTGTCATTTGGACCGCAGTGTGGCTCAAGC
TGCTTCGAGACG 
UL6 Low-quality sequencing 
GTTCCTCGAGCGGTTCAAAGCACAACCACCG
TAATGACACCCACGCTGGTTACAAACTCCAC
ATTCAGTGTGTCACTTGTTGCGTTGAGACTG
ACGACAAATTCCAGCGCGTTTG 
UL9 
TGAAGCACAACACGACACTGCCACTTCACAT
ACAATGTGGATCATACCCCTAGTTATCGTTA
TAACAATCATCGTTTTAATTTGTTTCAAGTT
CCCCCAAAAAGCTTGGAATAAATTCACACAA
TACCGATACAGCG 
TGAAGCACAACACGACACTGCCACTTCACAT
ACAATGTGGATCATACCCCTAGTTATCGTTA
TAACAATCATCGTTTTAATTTGTTTCAAGTT
CCCCCAAAAAGCTTGGAATAAATTCACACAA
TACCGATACAGCG 
UL11 
CAACCACCACGAGAACAACCACCACCGCCAA
GAAGACGACGATAAGCACTACCCATCATAAA
CACCCCAGTCCCAAAAAATCCACCACCCCTA
ACAGTCACGTAGAACATCACGTTGGTTTTGA
AGCCACAGCAGCGGAAACACCGTTACAACCA
AGCC 
CAACCACCACGAGAACAACCACCACCGCCAA
GAAGACGACGATAAGCACTACCCATCATAAA
CACCCCAGTCCCAAAAAATCCACCACCCCTA
ACAGTCACGTAGAACATCACGTTGGTTTTGA
AGCCACAGCAGCGGAAACACCGTTACAACCA
AGCC 
UL21A 
GTCGGTGAGGGAGATGAAGAGATGTTGCCGG
ATCTGCCGATGGAGATCGACATCGTCATCGA
CCGACCTCCGCAGCAACCCCTACCCAATCCG
CTGGTGCTACTGCTGGACGATGTTCCCCCCC
ATGTACCCGGTTTTGCTC 
GTCGGTGAGGGAGATGAAGAGATGTTGCCGG
ATCTGCCGATGGAGATCGACATCGTCATCGA
CCGACCTCCGCAGCAACCCCTACCCAATCCG
CTGGTGCTACTGCTGGACGATGTTCCCCCCC
ATGTACCCGGTTTTGCTC 
UL30 
CCGGGGCATGATGGACTATCACGACGGGCTC
TCGCGCCGTCAACAGCGTGCCTTTTGCCGCG
CGGGTCGCGTGTTGACGGACCCGGAGCCCAT
CCAGAGCGAGACGGAGGGGGAGAATAAACAG
TTTACGGAGCACACACACAAAGTAGTCTCGT
TTTTTATTAAAAGTGTCTTTGTATTTCCCTG
TCTTGTGTTGCC 
CCGGGGCATGATGGACTATCACGACGGGCTC
TCGCGCCGTCAACAGCGTGCCTTTTGCCGCG
CGGGTCGCGTGTTGACGGACCCGGAGCCCAT
CCAGAGCGAGACGGAGGGGGAGAATAAACAG
TTTACGGAGCACACACACAAAGTAGTCTCGT
TTTTTATTAAAAGTGTCTTTGTATTTCCCTG
TCTTGTGTTGCC 
UL33 
TACTCGAGCTGCACAGTAGGCTTTGCCACCG
TAGCCCTGATCGCCGCCGACCGATACCGCGT
TCTTCATAAGCGTACCTACGCGCGGCAGTCG
TACCGCTCCACCTATATAATTTTGCTATTGA
CCTGGTTTGCCGGGCTGATCTTTTCCATG 
Low-quality sequencing 
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UL48A 
GACCGAGATCTCAGAGGCCACCCACCCGGTG
CTGGCCACCATGCTGAGCAAGTATACGCGCA
TGTCCAGTCTGTTTAACGACAAGTGCGCCTT
TAAGCTGGACCTGTTGCGCATGATAG 
GACCGAGATCTCAGAGGCCACCCACCCGGTG
CTGGCCACCATGCTGAGCAAGTATACGCGCA
TGTCCAGTCTGTTTAACGACAAGTGCGCCTT
TAAGCTGGACCTGTTGCGCATGATAG 
UL91 
CTTTGTCGACCGCCTCTTTCAACACTTTTCC
TTCCTTTTCCAGGCCGAGGAGTCAGGCCCGC
GCCGCTTGGAACTGGTCGCGTCCGTGTTCGA
GCACCTGACGGTGGAGTGCGTCAACGACATC
CTGGACGCCTGCAGCCACCCGGACGTGAACG
TCGTGGAGACAAGCAACACCTG 
CTTTGTCGACCGCCTCTTTCAACACTTTTCC
TTCCTTTTCCAGGCCGAGGAGTCAGGCCCGC
GCCGCTTGGAACTGGTCGCGTCCGTGTTCGA
GCACCTGACGGTGGAGTGCGTCAACGACATC
CTGGACGCCTGCAGCCACCCGGACGTGAACG
TCGTGGAGACAAGCAACACCTG 
UL136 Low-quality sequencing Low-quality sequencing 
UL146 
ATGCGATTAATTTTTGGTGCGTTGATTATTT
CTTTAACGTATATGTATTATTATGAAGTGCA
TGGAACGGAATTACGCTGCAAATGTCTTGAT
GGTAAAAAACTGCCGCCCAAAACAATTATGT
TGGGTAATTTTTGGTTTCATCGCGAATCTGG
TGGTCCCAGATGCAATAACAATGAATATTTC
TTGTATCTAGGCGGAGGAAAAAAACATGGAC
CTGGAGTATGTTTATCGCCCCATCACCCTTT
TTCAAAATGGCTAGACAAACGCAACGATAAC
AGGTGGTATAATGTTAATGTAACAAGACAAC
CGGAACGAGGGCCGGGAAAAATAACTGTAAC
CCTAGTAGGTCTGAAGGAA 
ATGCGATTAATTTTTGGTGCGTTGATTATTT
CTTTAACGTATATGTATTATTATGAAGTGCA
TGGAACGGAATTACGCTGCAAATGTCTTGAT
GGTAAAAAACTGCCGCCCAAAACAATTATGT
TGGGTAATTTTTGGTTTCATCGCGAATCTGG
TGGTCCCAGATGCAATAACAATGAATATTTC
TTGTATCTAGGCGGAGGAAAAAAACATGGAC
CTGGAGTATGTTTATCGCCCCATCACCCTTT
TTCAAAATGGCTAGACAAACGCAACGATAAC
AGGTGGTATAATGTTAATGTAACAAGACAAC
CGGAACGAGGGCCGGGAAAAATAACTGTAAC
CCTAGTAGGTCTGAAGGAA 
UL148D 
ATGACGGCGCCCAAGTGTGTCACCACCACGA
CCTATCTGGTCAAGACCAAGGAGCAGCCCTG
GTGGCCCGACAACGCCATCAGGAGATGGTGG
ATCAGCGTTGCCATCGTCATCTTCATCGGAG
TCTGTCTGGTGGCCCTGATGTACTTTACGCA
GCAGCAGGCACGCAACGGGAGCGGCAGCGGC 
ATGACGGCGCCCAAGTGTGTCACCACCACGA
CCTATCTGGTCAAGACCAAGGAGCAGCCCTG
GTGGCCCGACAACGCCATCAGGAGATGGTGG
ATCAGCGTTGCCATCGTCATCTTCATCGGAG
TCTGTCTGGTGGCCCTGATGTACTTTACGCA
GCAGCAGGCACGCAACGGGAGCGGCAGCGGC 
RL6 
CTAAAAGCGACGACTGGGAGTAATTTTACCA
TTACGCATAGGAAAGATCCGTTGACAACTAA
GTGGAAAACCGTTTTTGGTAACAATGGTGAT
CAGTGGTTGTGCAACGTTACGGGTATAGGTA
ATGCTACTGTGAATGGTAACGCAACTATTTG
TGTGTCGAGCTGTGGTCATA 
CTAAAAGCGACGACTGGGAGTAATTTTACCA
TTACGCATAGGAAAGATCCGTTGACAACTAA
GTGGAAAACCGTTTTTGGTAACAATGGTGAT
CAGTGGTTGTGCAACGTTACGGGTATAGGTA
ATGCTACTGTGAATGGTAACGCAACTATTTG
TGTGTCGAGCTGTGGTCATA 
RL9A 
ATGTCTCTAGATGCCGCCAGCCACCAACCGG
CGGCACGGCGGCTCTTGGATTCGGCATTGGT
GCGCCGCGTCTTGGCCTGCATGATCATCGTC
ATCATGATCGCCATTAGCATCTGGATCCTGA
CCTACGTGCTGTTTCTCTAA 
ATGTCTCTAGATGCCGCCAGCCACCAACCGG
CGGCACGGCGGCTCTTGGATTCGGCATTGGT
GCGCCGCGTCTTGGCCTGCATGATCATCGTC
ATCATGATCGCCATTAGCATCTGGATCCTGA
CCTACGTGCTGTTTCTCTAA 
RL12 
CACCCCACTATGTCCCAGATACGTAGGAACA
CAATCAGAAGAAGACGAAGACGACGATTATA
CACTAAGCACTATCACAAATAATAACATGCG
CAAAACAAGTCACCGTGACATCTCACATGGC
ACGCGCACTACATGGGCTCTTAC 
CACCCCACTATGTCCCAGATACGTAGGAACA
CAATCAGAAGAAGACGAAGACGACGATTATA
CACTAAGCACTATCACAAATAATAACATGCG
CAAAACAAGTCACCGTGACATCTCACATGGC
ACGCGCACTACATGGGCTCTTAC 
Note: homology between sequenced PCR product and amplicon was determined by Basic local alignment 
search tool [219] and is displayed in blue.  
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3.3 Generation of HCMV stock 
In order to minimise variability, for the interactome all stable cell lines were 
infected with the same stock of HCMV strain Merlin. To generate the required amount of 
virus, aliquots of 17 supernatant harvests from 7 independent viral propagation 
experiments were pooled immediately prior to infection. To titrate the combined virus 
pool, IE1 (UL123) expression of cells infected for 24 h with serial dilutions of the stock 
was estimated by flow cytometry (see Figure 3.3.1). For the 1:64 dilution, a high degree 
of cell death was observed compared to other dilutions and thus this data was omitted 
from the calculation of the stock titre, to avoid an underestimation of the titre. The 
percentage of infected cells in the 1:16384 dilution (single sample) was below 1 %, and 
thus too small to reflect an accurate titre. Using an average of the three remaining serial 
dilutions (in duplicate), the combined stock was estimated to be 4.8x107 IE1-forming 
units/ mL. 
 
Figure 3.3.1 | Titration of the interactome virus stock using IE1 expression 
HFFF-TERT cells were infected with serial dilutions (in duplicate) of the combined HCMV virus 
stock and IE1 expression was analysed by flow cytometry at 24 h post-infection. An average titre 
for the stock was estimated using values from the 1:256, 1:1024 and 1:4096 dilutions. 
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3.4 Infection conditions 
Single AP-MS experiments can yield lists of hundreds to thousands of putative 
interactors, making it difficult to distinguish between contaminants and true interactors. 
Overlap of individual lists of putative interactors enables the identification of common 
contaminants, which can be enhanced by increasing sample size. Using similar 
experimental conditions, such as a single time-point post-infection to harvest all samples, 
inherently makes the interactor lists more comparable. 
Expression of HCMV proteins occurs with different temporal profiles, according to 
the roles they play in the viral life cycle. Proteins from all temporal classes are expressed 
to some extent at 60 h post-infection (see Figure 3.4.1), thus harvest of lysates from 
infected cells was performed at this time-point. 
 
 
Figure 3.4.1 | Temporal classes of HCMV protein expression (Adapted from Weekes et al, 
2014). Example profiles of protein abundance throughout the course of HCMV infection for 
temporal classes Tp1 to Tp5. At 60 h post-infection (grey dotted line), peptides from 139/139 
quantified canonical HCMV proteins and 14/14 quantified non-canonical ORFs were detected. 
 
Dexamethasone is a glucocorticoid that has been shown to enhance HCMV 
replication, increasing synthesis of immediate early proteins and HCMV DNA [198]. 
Additionally, serum starvation by pre-incubation with serum-free media similarly 
increases the percentage of cells infected by inducing cell cycle synchronisation.  
In order to maximise the percentage of infection that could be obtained with our 
viral stock, HFFF-TERT cells were pre-treated with 4 µg/mL dexamethasone in serum-
free media for 24 h, prior to infection with HCMV for 60 h. For MOI 0.5, and according to 
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the Poisson distribution that is applied to calculate the probability that a cell will absorb 
a number of virus particles when inoculated at a specific MOI, it would be expected that 
approximately 39 % of cells would be infected. However, in this experiment, 66 % of cells 
were IE1-positive. This observation may be explained by the effect of serum-starvation 
in enhancing viral infection, or alternatively by an underestimation of the titre of the viral 
stock. 
 Incubation with Dexamethasone resulted in a considerable increase in 
percentage infection, from 66 to 92 % (see Figure 3.4.2), thus dexamethasone pre-
treatment was performed prior to infection of the interactome stable cell lines.  
 
 
Figure 3.4.2 | Dexamethasone treatment augments viral infection in HFFF-TERT cells. 
HFFF-TERT cells were incubated O/N in serum-free DMEM containing 4 μg/ml Dexamethasone, 
24 h after seeding. Cells were then mock or HCMV infected (MOI 0.5) for 24 h and collected for 
IE1 expression analysis by flow-cytometry.  
 
Finally, an estimation of the percentage infection obtained using the exact volume 
of viral stock for each cell line was determined by flow cytometry. Using cell-surface 
downregulation of MHC Class I molecules as well as IE1 expression in cells pre-treated 
with dexamethasone, followed by infection with the combined virus stock for 60 h, 
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showed  that approximately 76 % cells were infected in these conditions (see Figure 
3.4.3). 
 
Figure 3.4.3 | IE1 expression and cell surface downregulation of MHC-1 as indicators of 
percentage infection in a cell population. HFFF-TERT cells were incubated O/N in serum-free 
DMEM containing 4 μg/ml Dexamethasone, 24 h after seeding. Cells were then mock or HCMV 
infected for 60 h and collected for analysis of expression of IE1 and MHC Class I molecules by 
flow-cytometry.  
 
3.5 Discussion 
To generate an HCMV interactome in the context of viral infection, two approaches 
could be employed: (a) infecting a multitude of cell lines individually expressing each 
tagged viral protein with one strain of HCMV; (b) infecting one cell line with multiple 
HCMV recombinants separately, with each recombinant virus containing a tag at the 
extremity of a different viral gene. The latter strategy may add variability to each AP-MS 
dataset, as HCMV canonical protein-coding genes, in addition to uncharacterised ORFs, 
overlap in their coding sequences. Thus, the addition of tags to the viral genome could 
disrupt different genes in each dataset, resulting in changes in viral protein expression, 
and a possible inability to identify a subset of viral protein-protein interactions. 
Combining tandem AP-MS datasets enabled the identification of common contaminants 
by comparing and scoring putative interactors among each dataset, while also increasing 
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confidence in the identification of true binding partners. This scoring is less effective if 
non-specific interactors vary in an inconsistent manner throughout the datasets, 
resulting in lower confidence/lower scores for true-positive interactions. 
Even though expression of all viral baits was driven under the same promoter, the 
level of each transgene expression was quite variable (see Figure 3.2.1-3.2.2). Part of this 
variability could be attributed to differential protein turnover, the balance between 
protein synthesis and degradation. Difficulty in detecting bait expression in uninfected 
lysates may be due to a requirement for other viral factors for their stabilisation.  
Detection of most members of the US12-21 family was only possible using mass 
spectrometry, suggesting that these highly hydrophobic multi-transmembrane spanning 
proteins may have been expressed at low level, or poorly solubilised. 
The molecular weight of many constructs differed from the theoretical value. 
These differences can be due to post-translational editing. While modifications such as 
glycosylation (for example UL7 has an expected molecular weight of 24 kDa based on its 
amino acid sequence, yet it has been reported to be highly glycosylated and was observed 
approximately 55 kDa) can explain a higher molecular weight, protein cleavage into 
multiple forms can explain the observation of several bands of a lower weight. 
Expression of 23 V5-tagged transgenes was detected by MS but not by 
immunoblot. Detection by immunoblot is solely dependent on the binding of an antibody 
to an epitope, while quantification by MS is achieved orthogonally by identification of any 
peptide derived from tryptic digest, which may have greater overall sensitivity. A 
particular advantage of the use of MS includes sequence-based validation of the protein 
detected, since all baits that were detected only by MS were quantified by unique peptides 
or peptides that were redundant among viral ORFs and thus could not have derived from 
a cellular protein.  
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Detection of 18 V5-tagged transgenes was only possible by PCR-based methods. 
Previously published proteomics data show that over half of these baits weren’t 
quantified by MS in HCMV infected HFFF-TERT cells either, which could be due to a very 
low abundance, or small size which would mean that few tryptic peptides were available 
for analysis. It has been found that certain baits are co-degraded with host proteins they 
target (for example, UL138 [159] and UL145 [163]), which would further limit bait 
expression. 
 UL136 is expressed as five protein isoforms, yet transgene expression was not 
validated by any of the methods employed. iBAQ quantification in previous proteomics 
datasets (see Table 3.2.2) showed that although these gene products were not highly 
abundant, they were within the limits of detection. Codon optimisation of the canonical 
sequence might increase the translation efficiency of this gene. Nevertheless, the inability 
to validate UL136-V5 expression by any of the methods employed led to its exclusion 
from the interactome. 
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4 | Optimising the immunoprecipitation protocol 
 
Optimization of the liquid chromatography gradient and injection of samples in the 
Orbitrap Fusion Lumos Tribrid Mass spectrometer was performed by Dr. Robin Antrobus 
(Cambridge Institute for Medical Research, University of Cambridge). The starting protocol 
for immunoprecipitation used for optimisation throughout this chapter was developed by 
Professor Steven Gygi’s laboratory (Department of Cell Biology, Harvard Medical School). 
 
The immunoprecipitation protocol used by Huttlin et al (2015) for the human 
interactome project was adapted for a smaller scale throughput [189]. The adapted 
protocol was then optimised to ensure a robust peptide quantification.  
Cell lines expressing viral proteins were chosen for use in optimisation of the 
protocol based on (a) transgene solubility (absence of transmembrane domains), (b) 
length and abundance (>15 kDa to avoid excessively small proteins, and proteins easily 
detected by immunoblot), and (c) having interactors reported in the literature, which 
could be used as positive controls. UL27, UL54 and UL123 fitted these criteria. Multiple 
steps of the protocol (see Figure 4) were then optimised, and optimal conditions were 
determined based on the number of bait, positive control and overall peptides as well as 
the number of protein identifications (IDs) quantified in each sample. None of the 
experiments discussed in this chapter were performed in the context of HCMV infection 
to simplify the experimental workflow. 
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Figure 4 | Overview of sample processing for affinity-purification mass-spectrometry  
 
4.1 Anti-V5 agarose beads 
In the original protocol from Huttlin et al (2015), 60 µL of a 50 % slurry of 
immobilized mouse monoclonal anti-HA agarose resin (Sigma-Aldrich), that was pre-
washed in lysis buffer (without protease inhibitor), was added to each lysate (comprised 
of five confluent 10 cm2 dishes) [189]. Given that the majority of baits for the HCMV 
interactome were cloned from recombinant adenoviral vectors containing the viral 
coding sequences followed by a V5 tag, this similarly small epitope was chosen for this 
interactome instead of the HA tag. Thus, it was necessary to select an anti-V5 agarose 
resin for affinity purification. 
Agarose beads conjugated to anti-V5 antibody from two different suppliers, 
Sigma-Aldrich and Abcam, were tested for optimal isolation of the V5-tagged bait. Resin 
from the Sigma-Aldrich product was conjugated to approximately 2 mg of mouse 
monoclonal (clone V5-10) per mL of bead volume. The Abcam product contained a goat 
polyclonal anti-V5 antibody attached to the agarose at a ratio of 500 µg of antibody per 
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mL of bead. According to the manufacturer’s instructions, both antibodies were coupled 
to the agarose using cyanogen bromide and supplied as a 50 % slurry. 
In this optimisation experiment the most important measurement was the 
number of bait peptides as this provided a measurement of affinity between the anti-V5 
agarose beads and the V5-tagged bait, reflecting an enrichment in the protein of interest.  
The UL54-expressing cell line was chosen for this purpose given that the catalytic subunit 
of the DNA polymerase is a large protein, capable of yielding relatively abundant peptides. 
Lysates from two confluent 15 cm2 dishes were incubated with 60 µL of anti-V5 agarose 
from either supplier and processed for affinity purification as described in section 2.9.1. 
Two confluent 15 cm2 dishes were used instead of five 10 cm2 dishes as this provided an 
equivalent surface area and cell density and facilitate sample handling. 
Immunoprecipitation with anti-V5 beads from Sigma-Aldrich yielded more bait 
peptides, suggesting that the overall sensitivity to detect specific interactions would also 
increase (see Figure 4.1). The total number of peptides and proteins was considered at 
best a secondary measure of performance, since this also included known and possible 
contaminants. The difference in overall sensitivity may be partly due to the ratio of anti-
V5 antibody conjugated to the resin. Yet, given the difference in volume of slurry provided 
and cost, Sigma-Aldrich’s anti-V5 agarose proved to be more cost-effective for this 
purpose and hence was used for all consecutive experiments.  
To reduce variability in sample preparation, ten vials of the same batch of anti-V5 
resin were combined and the same pool (a total of 20 mL) was used for all interactome 
samples. 
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Figure 4.1 | Comparing Sigma-Aldrich and Abcam’s anti-V5 agarose binding capacity  
Numbers of UL54-V5 peptides (A), overall quantified peptides (B) and protein IDs (C) obtained 
from immunoprecipitation with anti-V5 resins from either Sigma-Aldrich (Sigma) or Abcam. This 
figure is representative of n= 1 experiment. 
 
4.2 Bead volume per sample 
Upon selection of the Sigma-Aldrich anti-V5 resin for affinity purification, a 
titration of the agarose slurry was performed to determine the optimal bead volume per 
IP. In the original protocol 60 µL of immobilized agarose resin were added to each lysate. 
For this titration, three different volumes of anti-V5 conjugated agarose used per sample 
(30, 60 or 120 µL) were compared. As in 4.1, each sample comprised lysates from two 
confluent 15cm2 dishes. Samples were processed for affinity purification as described in 
section 2.9.1. 
The cell line expressing UL27 was chosen for this experiment, as the human 
interactors that have been described in the literature for this protein could provide an 
additional measure of sensitivity in addition to the number of bait peptides. UL27 
promotes cell cycle arrest in G0/G1 by targeting the host histone acetyltransferase 
Tip60/KAT5 to the proteasome for degradation. Previous AP-MS data in primary human 
foreskin fibroblasts infected with a recombinant HCMV encoding UL27-FLAG, has 
suggested that UL27 interacts with members of the Tip60 acetyltransferase complex, 26S 
proteasome subunits, proteins involved in ubiquitin E3 ligase complexes, among others 
[226]. Table 4.2 shows 27 suggested putative interactors of UL27 from this AP-MS dataset 
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that were quantified by at least 2 peptides, and Tip60 which was identified as an 
interactor using co-IP with an antibody to the endogenous protein in cells infected with 
the recombinant HCMV (AD169 background) encoding UL27-FLAG. Similarly, this study 
also validated the interactions with TRRAP, EP400 and PSME3 using the same co-IP 
experimental setup. However, these interactions have not been reported in any further 
studies. 
 
Table 4.2 | UL27-interacting proteins identified in Reitsma et al (2011) [226] 
UL27 Interactors 
TRRAP ACTL6A PSMC4 PSMD3 UBR5 RAN NUDT21 
EP400 STAT3 PSMD14 PSMA3 DDB1 HNRNPH3 TMEM43 
RUVBL1 Tip60/KAT5 PSMD2 PSMB6 WDR26 CBR1 RAB1A 
RUVBL2 PSME3 PSMC6 PSMB4 ACLY FKBP10 PDIA4 
 
Increasing the volume of resin did not lead to an increase in peptide numbers or 
protein IDs, suggesting that 30 µl of beads provided an excess of V5 binding sites (see 
Figure 4.2). Furthermore, the total number of peptides from known UL27 interactors also 
did not increase.   
The number of peptides per known interactor of UL27 was quite variable, 
although this pattern was evened out by assessing the total number of peptides from all 
known interactors. In fact, only 10/27 known interactors of UL27 were detected in this 
experiment, with just PSMD2, RAN, EP400 and PSME3 being co-purified in all samples. 
This may reflect differences in the experimental conditions such as cell type and affinity-
purification in the context infection instead of transgene bait overexpression. 
Given that there was no substantial gain in using more than 30 µl per sample, all 
immunoprecipitation experiments onwards were performed using this volume of resin.  
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Figure 4.2 | Titration of Anti-V5 resin 
Numbers of UL27-V5 peptides (A), overall quantified peptides (B) and protein IDs (C) obtained 
from immunoprecipitation with three different amounts (30, 60 or 120 µl per lysate) of anti-V5 
resin. D) Numbers of peptides from known UL27 interactors quantified for each condition. This 
figure is representative of n= 1 experiment. 
 
4.3 Input material per immunoprecipitation reaction 
In the previous optimisation steps, two confluent 15 cm2 dishes were used per 
immunoprecipitation reaction to provide an equivalent surface area and cell density to 
the original protocol.  
The next optimisation step aimed to determine the optimal amount of protein 
added to each immunoprecipitation reaction. For this purpose, lysates from one, two or 
four confluent 15 cm2 tissue culture dishes of UL27 or UL54-V5 expressing stable cell 
lines were compared. As determined in 4.2, 30 µl of anti-V5 agarose was used per lysate. 
Consequently, 30 µl, 60 µl or 120 µl were used for the lysates of one, two or four confluent 
15 cm2 tissue culture dishes, respectively. Samples were processed for affinity 
purification as described in section 2.9.1. 
UL27 Interactor 30µL 60µL 120µL
RAB1A 0 1 0
KAT5 0 0 1
DDB1 0 1 0
TRRAP 0 0 1
ACLY 1 8 3
PSMD3 1 2 0
PSMD2 1 2 1
RAN 3 1 1
EP400 5 1 13
PSME3 15 7 11
Interactor peptide total 26 23 31
Positive controls identified 6 8 7
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The number of bait peptides, overall peptides and protein IDs increased two-fold 
between lysates from one and two dishes. However, this direct proportionality was not 
observed when using lysates from four dishes, (see Figure 4.3 A-C). A second experiment, 
comparing the protein contents of one, two and three confluent 15 cm2 tissue culture 
dishes yielded similar results (see Figure 4.3.D-F), which were supported by the 
quantification of known interactors of UL27 (see Figure 4.3.G-H). 
Similarly to the results in 4.2, the number of peptides per known interactor of 
UL27 was quite variable, with a substantial number of these interactors being detected 
inconsistently across the AP-MS samples. In this experiment, PSMD2, RAN and EP400 
were detected in 4/5 IP reactions and PSME3 was the only known interactor of UL27 
being co-purified in all samples.  
Increasing the amount of input material beyond two 15 cm2 dishes did not result 
in an increase of bait peptide or positive interactors suggesting that maximum resin 
binding capacity might have been achieved. Using both a higher volume of beads and 
more lysate could improve quantification, however this would hinder the throughput of 
the project as it would have increased the number of dishes necessary per cell line and 
reduce the number of cell lines that could be infected in parallel. Most importantly, it 
would have substantially increased the amount of virus required to infect these cells. 
Therefore, lysates from two confluent 15 cm2 tissue culture dishes were used in all 
immunoprecipitations from here onwards. 
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Figure 4.3 | Assessing immunoprecipitation input material  
Two stable cell lines overexpressing UL27-V5 and UL54-V5 were used in two independent 
experiments with different amounts of input material (1, 2, 3, 4x confluent 15 cm2 dishes per 
reaction). Numbers of peptides (A, D), overall quantified peptides (B, E), protein ID’s (C, F) and 
UL27 known interactors (G, H) obtained for these conditions are shown. This figure is 
representative of n= 2 experiments. 
 
 
 
 
UL27 Interactor 1 dish 2 dishes 4 dishes
PSMC4 0 1 0
FKBP10 0 4 4
PSMA3 0 1 1
HNRNPH3 0 6 7
EP400 0 4 9
ACLY 0 5 9
RAN 0 4 4
PSMD2 0 2 2
PSMB6 0 1 0
ACTL6A 0 1 4
DDB1 0 1 1
PSME3 2 7 8
Interactor peptide total 2 37 49
Positive controls identified 1 12 10
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UL27 Interactor 1 dish 2 dishes 3 dishes
PSMC4 0 2 0
DDB1 0 3 1
RAN 0 0 1
PSMB6 0 1 0
CBR1 1 0 1
PSMC6 1 2 0
PSMA3 1 0 1
RAB1A 1 2 0
PSMD2 1 2 1
ACTL6A 1 3 5
RUVBL1 2 0 0
RUVBL2 2 0 0
NUDT21 2 0 3
PSMB4 2 0 0
PDIA4 2 1 0
FKBP10 4 7 5
HNRNPH3 6 10 8
EP400 7 9 17
ACLY 8 7 4
PSME3 9 19 20
Interactor peptide total 50 68 67
Positive controls identified 16 13 12
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4.4 Peptide and protein yields of V5 elutions  
The original protocol from Huttlin et al (2015) employed two elutions with 200 
µL of 250 µg/mL HA peptide in PBS at 37 °C with agitation for 30 min, to elute protein 
complexes [189]. Both elutions were then combined before protein precipitation with 
Trichloroacetic acid. For the HCMV interactome, the concentration of eluting peptide (in 
this case V5) and elution conditions were kept the same.  
In order to test whether both elutions with V5 peptide provided comparable 
peptide and protein yields, lysates from UL27 and UL54-V5 expressing cell lines were 
used to compare the first (EL1) and second (EL2) elution of protein complexes from the 
anti-V5 resin. For each lysate, instead of combining both elutions as per the initial 
protocol, these were processed separately (as described in 2.9.1) and analysed on the 
mass spectrometer as two separate samples. 
 This experiment showed that a variable amount of protein complexes were eluted 
with EL2 across the two baits, ranging from approximately ¼ to ½ of the number of 
peptides compared to the total sum of both elutions (see Figure 4.4A, B and D). 
Furthermore, the number of proteins IDs that were unique to each elution also varied 
between the two baits. In the case of UL54-V5, there were no unique protein IDs in the 
second elution. For UL27-V5, approximately half of the protein IDs in elution 1 and 2 were 
unique, while the other half comprised proteins that were present in both elutions (see 
Figure 4.4C and D). Thus, similarly to the initial protocol by Huttlin et al, two elutions 
were used and combined for all interactome samples.  
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Figure 4.4 | Assessing efficiency of V5 elutions 
Numbers of UL27-V5 and UL54-V5 bait peptides (A) and overall quantified peptides (B). Total 
protein IDs and the fraction of unique protein IDs for each elution are shown in (C). Percentages 
of total and bait peptides as well as unique protein IDs obtained with the first (EL1) and second 
(EL2) V5 elutions for each viral bait (D). This figure is representative of n= 1 experiment. 
 
4.5 Peptide solubilising agents  
After elution, protein samples were precipitated with TCA to remove the PBS salt 
that derived from the elution buffer, as high monovalent salt concentrations may 
interfere with trypsin activity. Proteins were then re-suspended directly into the 
digestion buffer which contained 10% acetonitrile for the purposes of solubilising dried-
down protein.  
The last optimisation step aimed to determine whether replacing 10 % 
acetonitrile by 10 % guanidine hydrochloride (GuHCl) would increase protein solubility, 
which can be measured by an increase in the number of quantified. Using two sets of V5 
immunoprecipitation lysates from both UL54 and UL123-V5 expressing cell lines, 
samples were processed as described in 2.9.1, but for protein digest samples were 
resuspended either in digestion buffer containing 10 % acetonitrile or 10 % GuHCl. As 
depicted in Figure 4.5, acetonitrile-containing buffer led to the greatest number of bait 
and overall peptides, and was therefore used.  
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To reduce variability in sample preparation for the interactome samples, a batch 
of digestion buffer containing acetonitrile was prepared and aliquoted, so that all samples 
could be processed as similarly as possible. After digestion peptide samples were loaded 
onto a StageTip. This is a pipette tip containing a fixed C18 silica-based medium, used in 
proteomics for single-step desalting, enrichment and purification of protein/peptide 
samples. It can be seen as a buffer-exchange step that placed samples in injection buffer 
for liquid chromatography tandem mass spectrometry. 
 
Figure 4.5 | Efficacy of solubilising agents in trypsin digestion buffer 
Numbers of bait peptides (A), overall quantified peptides (B) and protein IDs (C) obtained by 
solubilising proteins for trypsin digestion using guanidine hydrochloride or acetonitrile. This 
figure is representative of n= 1 experiment. 
 
4.6 Discussion 
Optimisation of the immunoprecipitation protocol was necessary to yield a robust 
quantification of interacting proteins while guaranteeing an efficient use of resources. 
The number of bait peptides and quantified positive control interactors were the most 
specific measurements used to assess the optimisation procedure, as the number of total 
peptides and protein IDs include common AP-MS contaminants, and non-specific 
interacting proteins.  
Identification of UL27-interacting proteins was inconsistent among experiments, 
with only one of the 28 known interactors, PSME3, being quantified in all datasets. Almost 
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a third of UL27-interacting proteins were not quantified in any of the optimisation 
experiments. This could be due to differences in experimental conditions between 
different studies. Potential reasons could include differences in most parts of the 
immunoprecipitation protocol. For example, different tags were used for affinity 
purification, presence of virus and time-point of harvest post-infection, different lysis 
buffer composition including distinct detergents, as well as cell type were not the same 
as described in Reitsma et al (2011) [226]. Furthermore, a subset of the interactors 
seemed to vary with the amount of input material, alluding to their relative abundance.  
In fact, despite its relative low molecular weight (29.5 kDa), PSME3 was quantified by the 
greatest number of peptides in all experiments, which may indicate that it is particularly 
likely to be a specific UL27 interactor. Other possible reasons for this observation may 
include relative protein abundance or UL27 binding affinity. 
Both the organic solvent acetonitrile and the chaotropic agent GuHCl solubilise 
proteins through denaturation [227]. In a direct comparison with either 10 % acetonitrile 
or 10 % GuHCl in the digestion buffer, the acetonitrile-containing buffer yielded a greater 
number of quantified bait and total peptides. GuHCl has been shown to increase 
identification of hydrophobic peptides [228] whereas hydrophobic proteins have 
generally low solubility in acetonitrile/aqueous solutions [229]. The observed effect may 
however not solely reflect an effect on solubility, with another possible explanation of 
this data including improved protein digestion in the presence of acetonitrile. 
One step that was not optimised was a comparison between elution of interacting 
proteins using excess V5 peptide followed by in-solution digest and elution by boiling the 
resin with SDS sample buffer, running the sample on a gel followed by in-gel band digest. 
However, the latter approach has a few caveats: (a) elution by boiling includes 
nonspecific interactions of proteins that bind to the resin but not the bait; (b) 
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hydrophobic peptides may prove difficult to isolate from gel bands; (c) each gel lane is 
typically separated into multiple slices that require individual MS analysis. 
In order to increase detection of weaker interactions, two other common 
strategies that could have been trialled as modifications to the starting 
immunoprecipitation protocol from Huttlin et al, are the use of cross-linking agents and 
cryogenic cell lysis. Cross-linking agents stabilise transient and weak interactions, while 
cryogenic lysis helps preserving protein complexes by immediately freezing and then 
mechanically grinding the sample. However, both of these may also increase detection of 
non-specific interactions [230]. 
Mass spectrometry is a powerful technique that has increasingly become the 
preferred method for analysis of complex protein samples. Viral interactome studies 
commonly employ yeast two-hybrid (Y2H) screens or AP-MS. Y2H allows identification 
of direct interactions between a pair of proteins, but has a relatively high false-positive 
rate resulting from non‐physiological expression of baits in a different organism. Y2H 
may also give false negative results, missing relevant interactions since pathogen 
proteins are expressed outside the context of infection, and may not fold properly in yeast 
[230]. AP-MS can identify members of stable protein complexes in the context of 
infection, however does not provide information on whether all the isolated proteins 
directly interact with each other. 
Sample labelling with tandem-mass tags (TMT) or SILAC has been used in the 
generation of small sample-size viral interactomes, as for example HSV-1 UL37 and the 
NS1 and NS2 proteins of Human respiratory syncytial virus [177, 181]. However, label-
free quantitation (LFQ) remains the most common method for relative quantitative 
analysis. SILAC quantitation has a maximum sample number of three (in tandem), with 
an additional requirement that cells be cultured in labelling medium for two to three 
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weeks prior to analysis [231]. A recent study comparing TMT and LFQ quantitative 
coverage, has shown that the former is more sensitive due to fewer missing values [232]. 
However, for the interactome dataset, there were two caveats of using TMT labelling: (a) 
the current number of samples that can be analysed in tandem is eleven; (b) given that 
substantially different levels of bait expression were observed, each IP would yield 
disparate amounts of protein resulting in very unequal protein content between 
channels. If mixing resultant samples 1:1:1:1:1:1:1:1:1:1:1, quantitation of proteins in 
channels with low-abundant baits would suffer, as the majority of ions would derive from 
other channels. The benefits of LFQ include unlimited sample number, no additional 
labelling steps, and most importantly, slight differences in bait abundance between 
samples are tolerated [231].  
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5 | HCMV-host protein interactions 
 
CompPass filtering was performed in collaboration with Dr. Edward Huttlin 
(Department of Cell Biology, Harvard Medical School). DAVID functional enrichment 
analysis was performed by Dr. Michael Weekes (Department of Medicine, University of 
Cambridge). PFAM domain association analysis was performed by Dr. Edward Huttlin and 
Dr. Michael Weekes. Validation of the interactions between RL1-CUL4A, UL71-TRIM22 and 
Ul25-NCK1 was performed by Dr. Katie Nightingale (Department of Medicine, University of 
Cambridge). Parts of the work presented in this chapter have been published in a similar 
form in eLife (Nobre et al., 2019). 
 
To generate the HCMV interactome, stable cell lines were made from HFFF-TERT 
cells, each expressing a C-terminally V5-tagged HCMV ORF to enable affinity-purification. 
The immunoprecipitation baits included 170 canonical ORFs and two non-canonical 
ORFs, ORFL147C and ORFS343C. These were included as they ranked close to both ends 
of HCMV protein relative abundance detected in previous proteomics studies (see Figure 
1.4) [162, 194]. Expression of all tagged ‘baits’ but UL136 was validated by IB, MS or RT-
qPCR (see Figure 5.0.1) before AP-MS. 
To enable detection of virus-virus interactions, the affinity-purification was 
performed on lysates of the stable cell lines, which were harvested after 60 h of infection 
with HCMV Merlin at an MOI of 2. As detailed in 1.2.6, this strain was cloned into a BAC 
to minimise genetic instability and prevent loss of gene function. It contains a full-length 
genome which expresses all HCMV genes apart from UL128 and RL13. Lysates were 
collected at 60 h post-infection as all detectable proteins have been shown to be 
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expressed at this point with this strain [162] (see Figure 3.4.1). HCMV ORFs were divided 
into two sets of baits according to their solubility: proteins with zero or one TM region 
(n=153), were solubilized using an NP40-based lysis buffer; proteins with 2-8 TM 
regions, were solubilized using a digitonin-based buffer. Digitonin was chosen to 
solubilize multi-pass membrane baits as mild detergent extraction has been shown to 
improve identifications of interacting proteins (‘prey’) with hydrophobic membrane 
proteins [233, 234]. A schematic of the AP-MS strategy is shown in Figure 5.0.2. 
 
Figure 5.0.1 | Percentage of HCMV interactome baits validate by IB, MS or RT-qPCR 
Prior to AP-MS in the context of infection, uninfected lysates were used to validate bait expression 
by IB, MS or RT-qPCR (as detailed in 3.2). Expression of 78 % of baits was further validated in the 
interactome itself, including 9/18 baits which had only been detected by RT-qPCR. In this figure, 
these nine baits were included in the ‘validated by Mass spectrometry’ class. From the remaining 
baits which were only detected by RT-qPCR, four were small proteins of 47-111 aa, with 1-4 
theoretically observable peptides, and none were detected in two previous proteomic analyses of 
HCMV infection [162, 163]. Another 4/9 viral proteins in the ‘validated by RT-qPCR’ class were 
only detected by a median of 0-2 peptides in these two previous proteomic analysis, with two 
containing multiple transmembrane domains. This suggested that detection may have been 
limited by protein abundance or hydrophobicity. Known interactions for these nine viral baits 
were detected in the AP-MS data (for example the interaction between UL48A and UL86 [235], 
and US18 and the natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1) [194]) and thus 
data for baits in the ‘validated by RT-qPCR’ class was included in this interactome. UL136 was 
excluded from further analysis as its expression could not be validated by any method. 
 
 
Immunoblot
RT-qPCR
Mass
spectrometry
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Figure 5.0.2 | Schematic of the AP-MS strategy. 
Lentiviral constructs were generated, each containing the coding sequence for one of 172 HCMV 
ORFs, followed by a C-terminal V5 tag to facilitate immunoprecipitation (IP). Stable cell lines were 
then generated from HFFF-TERT cells, and the expression of each construct was validated by 
either immunoblot, mass spectrometry or RT-qPCR. Cells were infected with Merlin strain HCMV 
at an MOI of 2 for 60 h. IP samples were generated and analysed in technical duplicate, using the 
method originally described in Huttlin et al (2015) and detailed in 2.9.1 [189, 236]. The 
CompPASS algorithm was used to assign scores for all quantified interactors for each bait. Then, 
stringent filters were applied to remove inconsistent and low-confidence protein identifications 
across all IPs [189, 195]. Interactions passing these criteria were designated ‘high confidence 
interacting proteins’ (HCIPs), and were used in the analyses shown in Chapters 5 and 6.  
 
AP-MS experiments can yield lists of hundreds to thousands of interactors. Data 
filtering thus becomes a crucial tool for the distinction between true interactors and 
common background between experiments. This chapter will focus on the strategies 
(controls, combined database for protein identification, filtering criteria) used for the 
identification of ‘high-confidence interacting proteins’ (HCIPs) and the subsequent 
bioinformatic analysis of the filtered dataset, while showcasing experimental validation 
for a subset of interactions. 
  
Generate 172 stable cell lines in 
HFFF-TERTs and validate
Generate lentiviral constructs 
expressing 172 HCMV genes with 
C-terminal V5 tags
Infect for 60h with HCMV
Lysis, V5 IP and LC-MSMS
High confidence interacting 
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5.1 Controls and correlation between replicate samples 
In this interactome, the biological replicates were pooled and samples were 
analysed in technical duplicate, as described in Huttlin et al., 2015. This approach was 
chosen in order to address potential carry-over of peptides between consecutive samples 
with different baits. Furthermore, two ‘wash’ injections were queued in between AP-MS 
samples, with the overall run order of replicate batches being reversed. This guaranteed 
that carry-over for each sample in either batch was different (i.e. Batch A1: Sample 1, 
wash x2, Sample 2, wash x2, Sample 3; Batch A2 (replicate of A1): Sample 3, wash x2, 
Sample 2, wash x2, Sample 3). Then, a score incorporated within CompPass was used to 
filter out carry-over contaminants. This score, designated ‘entropy’, compared the 
number of peptide-spectrum matches (PSM) between technical replicate injections and 
eliminated prey that were not detected consistently (detailed further in 2.11.2, Figure 
2.11.2.1 and 5.3).  
It was therefore important that replicate injection material was as similar as possible to 
ensure this filter was effective. 
Using technical replicates also aimed to address sufficiency of the amount of 
injected material, ensuring that enough material was present for MS analysis after all 
sample preparation steps had been completed. Using biological replicates would have 
required the use of additional technical replicates for each for compatibility with the 
entropy score. This would have doubled the required MS instrument time and reagents 
such as the amount of virus to infect interactome samples. 
In order to assess the impact of biological variability in HCIP identification, six AP-
MS experiments were re-run with biological replicates instead of technical replicates. In 
this independent analysis, depicted in Figure 5.1.1, a very good correlation between the 
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numbers of PSM from each identified HCIP between biological replicates was observed, 
adding confidence that HCIP identified by CompPass are likely to be genuine interactors. 
 
Figure 5.1.1 | Reproducibility of biological replicate AP-MS samples 
For the HCMV interactome samples were analysed as technical replicates. To assess the 
reproducibility between biological replicate samples, six AP-MS experiments were repeated with 
independent analysis of each biological replicate. PSM are shown for HCIPs predicted by the 
interactome for each of the baits.  
 
A control to assess instrument performance was included at the start of the queue 
of samples to run on the mass spectrometer, in order to prevent samples being analysed 
in suboptimal conditions. The control sample was generated by harvesting 30 confluent 
15 cm2 dishes of uninfected UL123-V5 expressing HFFF-TERT cells, and processing those 
lysates in the same way as the samples that constituted the HCMV interactome. Peptides 
from these lysates were pooled and aliquoted to generate 30 identical control samples 
(technical replicates).  Three uninfected UL123 controls were run using the same settings 
as the interactome samples, and averages of summary search statistics (generated by the 
software pipeline for quantitative proteomics) were calculated to produce a standard for 
comparison (see ‘Benchmark’, Table 5.1). Summary statistics for all subsequent 
uninfected UL123 control samples were compared against the standard to assess 
instrument performance (see Table 5.1). Data from these controls was not included in the 
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final data analysis, to avoid modification of NWD and z-scores for the infected UL123-
expressing sample. 
 
Table 5.1 | Summary statistics of UL123 control samples 
Control Sensitivity 
Success 
rate 
xCorr 
Total 
peptides 
Unique 
peptides 
Total 
peptides  
ratio to 
benchmark 
Unique 
peptides  
ratio to 
benchmark 
Benchmark 94.5 30.7 2.8 11228 7264 1 1 
UL123 A1 91.7 38.89 2.80 18662 10918 1.7 1.5 
UL123 A2 95.3 29.67 2.77 13575 7932 1.2 1.1 
UL123 A3 93.4 35.16 2.86 12435 7222 1.1 1.0 
UL123 A4 96.8 31.63 2.88 10990 7036 1.0 1.0 
UL123 A5 94.4 31.28 2.85 10083 6446 0.9 0.9 
UL123 A6 93.2 28.40 2.76 10674 5940 1.0 0.8 
UL123 A7 93.8 26.07 2.77 8338 5465 0.7 0.8 
UL123 A8 97.7 27.64 2.66 6570 4651 0.6 0.6 
UL123 A9 94.1 28.85 2.70 11892 7962 1.1 1.1 
UL123 A10 94.9 30.64 2.62 11064 7572 1.0 1.0 
UL123 A11 96.6 29.57 2.62 10751 7255 1.0 1.0 
UL123 A12 95.8 30.75 2.63 10090 6672 0.9 0.9 
UL123 A13 94.7 30.06 2.58 10417 7185 0.9 1.0 
UL123 A14 93.0 33.72 2.65 11849 8660 1.1 1.2 
UL123 A15 92.9 33.87 2.48 10133 7499 0.9 1.0 
UL123 A16 93.1 28.53 2.63 9418 6447 0.8 0.9 
UL123 A17 95.2 32.62 2.63 9902 7017 0.9 1.0 
UL123 A18 91.5 28.15 2.65 10739 6656 1.0 0.9 
UL123 A19 92.8 30.76 2.59 11511 7902 1.0 1.1 
UL123 A20 93.9 33.81 2.87 11434 7307 1.0 1.0 
UL123 A21 93.2 32.17 2.82 11552 8283 1.0 1.1 
UL123 A22 92.9 35.05 2.82 11373 7428 1.0 1.0 
UL123 A23 92.9 32.05 2.84 11390 7387 1.0 1.0 
 
Each batch of samples was run in a specific order to prevent baits with similar 
function or virion location from running consecutively. As an additional quality control, 
replicate samples were compared in terms of summary search statistics and LC 
chromatogram, to ensure instrument performance had not decreased throughout the 
batch. A high level of correlation in peptide quantification between technical replicates 
was observed (see Figure 5.1.2). 
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Figure 5.1.2 | Correlation of the number of total, unique and bait peptides for proteins 
identified in technical replicates 1 and 2 of the HCMV interactome. ‘Total peptides’ refers to 
the sum of all peptides identified in each sample. ‘Unique peptides’ refers to peptides that can 
only be matched to the tryptic profile of the sequence of one protein from proteomes in the 
combined database (in this case, human and HCMV Merlin). ‘Bait peptides’ refers to peptides 
derived from the bait protein for each IP (i.e. from US1 in the US1 IP). This metric is independent 
of the V5 epitope sequence, as the sequences of the baits featured in the database do not feature 
the linker region nor the tag. Additionally, contrary to the ‘total peptides’ and ‘unique peptides’, 
‘bait peptides’ is not provided by the summary search statistics function within ‘MassPike’. All 
data for this figure are also shown in (Appendix C, C1). 
 
5.2 Data filtering with CompPass 
 The raw data was searched against a combined database containing human and 
HCMV strain Merlin Uniprot entries (detailed in section 2.11.1), to assign mass spectra 
to peptide sequences which were then assembled into proteins. The full list of interacting 
proteins quantified in all AP-MS experiments was then processed using CompPass, which 
calculated scoring metrics for each interactor (as detailed in 2.11.2). Each of the two 
buffers used for lysis and IP yielded a distinct background of non-specific interactors. 
Thus for CompPass filtering, samples were segregated into two datasets according to lysis 
buffer, and the datasets were scored independently to better account for detergent-
specific variation in the AP-MS background [189, 195]. 
For each prey protein in every IP, CompPass calculated: (a) an average of the 
number of peptide spectral matches (PSMs) between the two replicates; (b) an entropy 
score, aiming to eliminate proteins inconsistently detected proteins by comparing the 
number of PSMs between replicates of the same IP; (c) a z-score, calculated by comparing 
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the average and standard deviation of PSMs observed across all IPs; and (d) a normalized 
WD (NWD) score, which incorporated each protein’s frequency of detection across all IPs, 
as well as their reproducibility among replicates. The NWD score was calculated as 
described in 2.11.2 (see Figure 2.11.2.2) using an equation that incorporated the fraction 
of runs in which a protein was detected, the number of PSMs as well as their average and 
standard deviation from the mean of PSMs observed for that protein across all samples, 
and the number of replicates (1 or 2) where it was identified [208]. NWD scores were 
normalized so that the top 2 % earned scores of ≥1.0. 
HCIPs were identified using the following criteria: (a) a PSM score ≥1.5 (i.e. a 
minimum of 3 peptides per protein across both replicates); (b) an entropy score ≥0.75; 
(c) a top 2 % NWD or Z-score. A similar filtering strategy has been applied by a previous 
study, estimating a 5 % false discovery rate within the top 2 % NWD score [195].  
Setting the thresholds for HCIP identification affects the interactor lists for all baits 
simultaneously. Applying the same cut-offs across the whole dataset disregards factors 
such as the total number of interactors quantified in the AP-MS data for each bait. This 
may result in the identification of a high number of HCIPs for a subset of baits (for 
example through binding to protein complexes with several subunits or co-
immunoprecipitation of secondary interactors to directly-interacting proteins) while no 
HCIPs are identified for another subset. Thus, threshold setting is a critical and non-trivial 
task that aims to balance identification of known interaction partners while avoiding loss 
of stringency and consequently, a compromise had to be made. 
As reported in prior interactome studies, certain known interactions scored below 
these stringent NWD or Z-score criteria. For example, the interaction between the DNA 
polymerase subunits UL54 and UL44 had an NWD score below 1 with either protein as a 
bait, but met all other filtering criteria. Thus, proteins scoring within the top 5 % NWD or 
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Z-scores (>0.434 and >3.688 respectively) were also included, if they were reported to 
interact with the bait in a prior study [209]. In order to use an unbiased collection of 
reported interactions, HCMV protein interaction data from a combination of online 
databases was used.  This was comprised by entries from BioGRID, IntAct, Uniprot, MINT 
and Virus Mentha (search terms provided in section 2.11.3). 
After CompPass filtering, 132 baits were themselves identified as self-interacting 
proteins. There are examples of known oligomeric or multimeric viral proteins (e.g. 
UL104 assembles as a dodecamer, UL86 forms homomultimeric pentons and hexons, 
among others), however from this interactome, it was not possible to make a distinction 
between peptides who derive from the V5-tagged transgene or the virally-expressed 
protein. Thus, these HCIPs resulting from bait-enrichment were removed from the 
filtered dataset. 
 
5.3 High-confidence interacting proteins 
An initial Digitonin-based AP-MS analysis failed to generate any interactors for 
protein UL133 (2 TM regions) after filtering. This IP was repeated using the NP40-based 
lysis buffer which identified 13 HCIPs.  
No interacting proteins passed the stringent filters employed for UL120 and 
UL142. For seven further proteins (US2, US11, UL93, UL96, UL119, UL146 and RL13), 
only the bait itself passed filtering, leaving 162 viral baits with ≥1 HCIP (see Figure 5.3.1). 
A total of 3440 HCIPs (excluding self-HCIP identification) were quantified across all 162 
baits (see Figure 5.3.2 – 5.3.19), with a range of 1-174 and median of 9 interactions per 
bait, similar to what had been previously observed in the Bioplex 2.0 human interactome 
[189]. 
140 
 
 
 
Figure 5.3.1 | High-confidence interacting proteins quantified in the HCMV interactome 
Numbers of human (green) and viral (purple) HCIPs per bait, excluding bait-self interactions.   
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Figure 5.3.2 | Interaction diagrams for US10, UL11, UL16, UL18, UL40, UL111A, UL121, 
UL135, UL138, UL140 and UL144. Straight lines connect the viral baits (light blue) to their 
human interactors (light pink) and viral interactors (light purple).  
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Figure 5.3.3 | Interaction diagrams for UL5, UL6, UL7, UL17, UL21A, UL27, UL29, UL34, 
UL36, UL37, UL38, UL41A, UL52, UL72 and UL140. Straight lines connect the viral baits (light 
blue) to their human interactors (light pink) and viral interactors (light purple).  
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Figure 5.3.4 | Interaction diagrams for UL9, UL30, UL30A, UL31, UL46, UL48A, UL74A, 
UL77, UL80, UL80.5, UL85, UL86 and UL98. Straight lines connect the viral baits (light blue) to 
their human interactors (light pink) and viral interactors (light purple).  
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Figure 5.3.5 | Interaction diagrams for US22, US23, UL22A, UL23, UL24, UL69, UL76, UL88, 
UL124, UL133 and UL147. Straight lines connect the viral baits (light blue) to their human 
interactors (light pink) and viral interactors (light purple).  
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Figure 5.3.6 | Interaction diagrams for UL14, UL50, UL53, UL71, UL94, UL99, UL71, UL94, 
UL99 and UL103. Straight lines connect the viral baits (light blue) to their human interactors 
(light pink) and viral interactors (light purple).  
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Figure 5.3.7 | Interaction diagrams for IRS1, TRS1, RL1, US24, UL2, UL42, UL49, UL79, UL84, 
UL87, UL91, UL92, UL95, UL97, UL112, UL117, UL122, UL123 and UL139. Straight lines 
connect the viral baits (light blue) to their human interactors (light pink) and viral interactors 
(light purple).  
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Figure 5.3.8 | Interaction diagrams for UL8, UL44, UL54, UL57, UL70, UL102, UL105, UL114 
and UL147A. Straight lines connect the viral baits (light blue) to their human interactors (light 
pink) and viral interactors (light purple).  
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Figure 5.3.9 | Interaction diagrams for UL51, UL56, UL89 and UL104. Straight lines connect 
the viral baits (light blue) to their human interactors (light pink) and viral interactors (light 
purple).  
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Figure 5.3.10 | Interaction diagrams for UL19, UL20 and US30. Straight lines connect the viral 
baits (light blue) to their human interactors (light pink) and viral interactors (light purple).  
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Figure 5.3.11 | Interaction diagrams for US26, US29, US32, US33A, US34, US34A, UL10, 
UL13, UL15A, UL150 and UL150A. Straight lines connect the viral baits (light blue) to their 
human interactors (light pink) and viral interactors (light purple).  
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Figure 5.3.12 | Interaction diagrams for US3, US8, US27, US28, UL1, UL33 and UL78. Straight 
lines connect the viral baits (light blue) to their human interactors (light pink) and viral 
interactors (light purple).  
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Figure 5.3.13 | Interaction diagrams for US9, UL4 and UL132. Straight lines connect the viral 
baits (light blue) to their human interactors (light pink) and viral interactors (light purple).  
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Figure 5.3.14 | Interaction diagrams for UL25, UL26, UL32, UL35, UL43, UL45, UL47, UL48, 
UL82 and UL83. Straight lines connect the viral baits (light blue) to their human interactors (light 
pink) and viral interactors (light purple).  
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Figure 5.3.15 | Interaction diagrams for US12, US13, US14, US15, US16, US17, US18, US19, 
US20 and US21. Straight lines connect the viral baits (light blue) to their human interactors (light 
pink) and viral interactors (light purple).  
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Figure 5.3.16 | Interaction diagrams for UL55, UL73, UL74, UL75, UL100, UL115, UL116, 
UL128, UL130 and UL131A. Straight lines connect the viral baits (light blue) to their human 
interactors (light pink) and viral interactors (light purple).  
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Figure 5.3.17 | Interaction diagrams for RL5A, RL6, RL8A, RL9A, RL10, RL11 and RL12. 
Straight lines connect the viral baits (light blue) to their human interactors (light pink) and viral 
interactors (light purple).  
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Figure 5.3.18 | Interaction diagrams for UL148, UL148A, UL148B, UL148C and UL148D. 
Straight lines connect the viral baits (light blue) to their human interactors (light pink) and viral 
interactors (light purple).  
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Figure 5.3.19 | Interaction diagrams for US1, US6, US7, ORFL147C and ORFS343C. Straight 
lines connect the viral baits (light blue) to their human interactors (light pink) and viral 
interactors (light purple).  
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A comparison of the list of HCIPs with the previously reported interactions from 
the combined database validated 59 HCIPs identified in this interactome (see Figure 
5.3.20A).  
 
 
Figure 5.3.20 | Comparing HCMV interactome HCIPs with curated protein interaction data 
(A) HCMV protein interaction data annotated on Uniprot, Virus Mentha, BioGRID, IntAct and 
MINT was compiled into a combined database (167 interactions, red circle). Of these, 127 were 
identified in the unfiltered dataset from the HCMV interactome, with 59 (blue circle) meeting the 
stringent filtering criteria. (B) Overlap between the combined database and the unfiltered 
interactome data. 
 
In the overlap with the filtered data, there were 26 interactions between viral 
proteins (see Figure 5.3.21), with 16 being reciprocal (i.e. A was identified as an HCIP of 
bait B, and B was identified as an HCIP of bait A).  These included structurally relevant 
interactions for the virion such as binding between the major capsid (UL86) and small 
capsomere-interacting protein (UL48A) [235], large (UL48) and inner (UL47) tegument 
proteins [237], in addition to the envelope glycoproteins gM (UL100) and gN (UL73) [38]; 
gB (UL55), gH (UL75), gL (UL115) and gO (UL74) [39, 238, 239]. Viral-viral protein 
interactions relevant to the viral lifecycle and identified by this dataset included the 
binding between the tripartite terminase subunits TRM1 (UL56), TRM2 (UL51) and 
TRM3 (UL89) [20, 240], the nuclear egress proteins NEC1 (UL53) and NEC2 (UL50) [28], 
as well as the cytoplasmic envelopment proteins CEP2 (UL94) and CEP3 (UL99) [241]. 
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The remaining viral-viral interaction positive controls were part of the DNA replication 
machinery and included binding between the lytic DNA synthesis trans-acting factors 
UL84 and IE2 (UL122) [242, 243]; the complex formed by the viral helicase (UL105), 
primase (UL70) and the helicase-primase associated factor (UL102) [244]; the viral DNA 
polymerase catalytic subunit (UL54), its processivity factor (UL44) and the uracyl-DNA 
glycosylase (UL114) [245-247]. 
 
 
Figure 5.3.21 | Positive controls highlighted from overlap of HCMV interactome with 
curated databases. Representation of known interactions between HCMV (light blue) and host 
(orange) proteins. Reciprocal interactions are shown as two lines (one straight, one curved) 
connecting the protein names. 
 
 
Interactions between viral and human proteins provided additional positive 
controls, many relating to subversion of the host immune system. For example, binding 
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between pp65 (UL83) and the innate immune viral DNA sensor IFI16 or pp71 (UL82) and 
hDaxx, a component of the viral genome silencing complex Promyelocytic leukemia 
protein nuclear bodies (PML-NBs) [165, 248]. Binding of IE1 to STAT2 disrupts 
interferon signalling, while interaction between UL135 and the WAVE2 complex member 
ABI1 triggers remodelling of the actin cytoskeleton in order to reduce efficiency of 
immune synapse formation [249, 250]. Other synergistic interactions that result in 
override of host defence mechanisms are the interaction of UL141 with PVR, causing 
retention in the ER for this ligand of activating NK-cell receptors, as well as the interaction 
of UL16 with the NK-cell activating KLRK1/NKG2D receptor ligands ULBP2, ULBP5 and 
MICB [251-254]. 
Other viral-human protein interactions related to the hijacking of cellular 
machinery in order to facilitate viral replication, as for example the interaction of several 
subunits of RNA polymerase II with UL87, a component of a viral protein complex 
required for the transcription of true late genes [187]. 
Of the remaining 108 protein interactions featured in the combined database list, 
42 were not detected in the interactome, as the prey was not quantified, and 66 did not 
pass the stringent scoring thresholds employed. A larger degree of overlap 
(approximately 75%) was observed when comparing the combined database with the 
unfiltered interactome data (see Figure 5.3.20B). Full data regarding the overlap with the 
combined database is shown in Appendix D. 
 
5.4 Functional enrichment analysis 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
[216] is a bioinformatics platform that provides a comprehensive set of functional 
annotation tools to enable understanding of biological meaning behind large lists of genes 
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by identifying enriched biological themes such as ‘Gene Ontology’ terms, protein domains 
and cellular pathways, among others. Thus, to gain an overview on the pathways targeted 
by all proteins during infection, DAVID functional annotation clustering was used to 
determine which cellular and molecular terms were enriched amongst the 3416 human 
proteins that interact with viral baits.  
 
Figure 5.4.1 | Functional enrichment analysis of HCMV interactome data  
DAVID software with default settings [216] was applied to determine which pathways were 
enriched amongst all interactome HCIPs, using the human proteome as a ‘background’. 
Benjamini-Hochberg adjusted p-values are shown as blue surrounds to each pathway enriched at 
p<0.05. Viral baits are linked to enriched pathways where >33 % of human interacting proteins 
belonged to a given pathway, and examples are shown around the outside of the figure. For 
example, 6/9 (67 %) human HCIPs for UL43 were part of the 14-3-3 protein. These examples are 
indicated in the central part of the figure by purple shading. Viral baits are shown as large 
turquoise circles, and interacting viral proteins as smaller turquoise circles. Members of enriched 
pathways are shown in orange or yellow (for NuRD complex and histone deacetylation, protein 
membership of both pathways is indicated by half-orange, half-yellow circles). Solid lines indicate 
interactions identified in the HCMV interactome, and dashed lines indicated interactions drawn 
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from the human interactome (Bioplex 2.0) and subsequent unpublished data 
(http://bioplex.hms.harvard.edu/downloadInteractions.php).  
 
 
Components of the Nucleosome Remodelling and Deacetylase (NuRD) complex 
were significantly enriched among HCMV-interacting proteins. The NuRD complex (see 
Figure 5.4.2A) is one of the major chromatin remodeling complexes in mammalian cells, 
and is known to be co-opted by HCMV UL29 and UL38 to enhance expression of 
immediate-early genes [174, 255]. The interactome confirmed that UL29 and UL38 
interact in a complex with all components of the NuRD complex, in addition to p53 [255]. 
UL29 was also found to interact with several human proteins that function in histone 
deacetylation. Five of these proteins (NCOR1, NCOR2, TBL1X, TBL1XR1 and HDAC3) 
interacted with UL29, but not UL38, and are in fact components of the Nuclear receptor 
corepressor (NCoR) complex (see Figure 5.4.2B) [256-258]. Another component of the 
NCoR complex, GPS2 was also identified in the interactome as an HCIP of UL29. These 
interactions had not been previously reported.  
 
 
Figure 5.4.2 | Diagram of the NuRD and NCoR complexes 
(A) The Nucleosome Remodeling and Deacetylase (NuRD) complex is comprised of proteins with 
chromatin remodelling and histone deacetylation activity. It consists of two subcomplexes 
containing a total of seven different proteins: the nucleosome remodelling subcomplex contains 
one chromodomain-helicase-DNA-binding protein (CHD3/CHD4/CHD5), one cyclin-dependent 
kinase 2-associated protein 1 (CDK2AP1), and one transcriptional repressor 
(GATAD2A\GATAD2B); one methyl-CpG-binding domain protein MBD2/MBD3 protein bridges 
the remodelling subcomplex to the histone deacetylase subcomplex, which consists of histone 
deacetylase core proteins HDAC1/HDAC2 proteins, two metastasis-associated proteins 
MTA1/MTA2/MTA3 proteins, and four histone-binding proteins RBBP4/7 proteins (adapted 
from Hoffmann and Spengler, 2019) [259]. (B) The Nuclear receptor Co-Repressor complex binds 
to ligand-free nuclear receptors and represses transcription, partly by deacetylating histones. The 
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complex consists of the F-box-like/WD repeat-containing proteins TBL1X and TBL1XR1, G 
protein pathway suppressor 2 (GPS2), the nuclear receptor co-repressor 1 or 2 (NCOR1/NCOR2) 
and the histone deacetylase HDAC3 (adapted from Emmett and Lazar, 2019) [260]. 
 
 HCIP analysis of the tegument protein UL43 showed an enrichment for 14-3-3 
proteins, a family of regulatory molecules that can bind a wide range of functionally 
diverse signalling proteins, including kinases, phosphatases, and transmembrane 
receptors [261]. Members of this protein family have been identified in virions from 
HCMV, HSV-1, KSHV and PRV (pseudorabies virus/suid herpesvirus 1 – does not infect 
humans), but not EBV (see Table 5.4.1). For HSV-1, 14-3-3 beta has been shown to 
interact with its tegument protein UL46 [262], while a small interfering RNA functional 
screen found that 14-3-3 zeta/delta supported viral proliferation in cell culture [263]. It 
remains to be determined whether 14-3-3 proteins can influence HCMV infection.  
 
Table 5.4.1 | 14-3-3 Proteins quantified in virions from the Herpesviridae family 
14-3-3 Family Members 
HCMV 
[56] 
HSV-1 
[264] 
KSHV 
[265] 
EBV 
[266] 
PRV 
[267] 
14-3-3 beta/alpha (YWHAB) X X - - X 
14-3-3 epsilon (YWHAE) X X - - X 
14-3-3 gamma (YWHAG) - X - - - 
14-3-3 eta (YWHAH) - - - - - 
14-3-3 theta (YWHAQ) X - - - X 
14-3-3 sigma (YWHAS) - - - - X 
14-3-3 zeta/delta (YWHAZ) X X X - - 
 
The HCMV genes UL87, UL49, UL79, UL88, UL91, UL92 and UL95 are conserved 
between beta- and gammaherpesvirus, but not alphaherpesvirus. All these genes except 
for UL88 have been shown to be necessary for transcriptional activation of viral genes 
expressed with ‘true late’ kinetics, and it has been suggested that these proteins may form 
one or more complexes that modulate the activity of RNA polymerase II [268-271]. 
Interactome data confirmed that UL87 interacted with UL79, UL49, UL91 and UL95 but 
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did not detect a high-confidence interaction with UL92. Several interactions between 
UL92 and UL91, UL87, UL95 and UL79 were detected but did not meet the filtering 
criteria. The lack of identification of any high-confidence viral-viral UL92 interactions 
may be due to UL92 being one of the two least abundantly expressed viral proteins during 
HCMV infection (see Figure 1.4). UL87 also interacted with all 12 components of the RNA 
polymerase II (RPII) complex and the associated protein RPII Associated Protein 2 
(RPAP2). The UL87-RPII interaction was anticipated by analogy to the orthologous RPII-
interacting EBV protein BcRF1, but had not previously been demonstrated. Interaction of 
UL87, UL95 and UL79 with the UL97 protein kinase was also novel. UL97 has been shown 
to phosphorylate the carboxyl-terminal domain of RPII located in the POLR2A subunit 
[272], however this interaction was not detected in the interactome potentially due to its 
transient nature. 
UL72 is regarded as the evolutionary counterpart of the deoxyuridine 5'-
triphosphate nucleotidohydrolase (dUTPase) in other herpesviruses, but lacks dUTPase 
activity [273]. UL72 interacted with all 11 components of the CCR4-NOT (carbon 
catabolite repressor 4-negative on TATA) complex (see Figure 5.4.3), which is a key 
regulator of gene expression from production of mRNAs in the nucleus to their 
degradation in the cytoplasm [274]. Additionally, UL72 also interacted with BTG3 which 
has been previously isolated by co-IP with subunits of this complex [275]. The interaction 
between UL72 and CNOT2/CNOT7 was confirmed by co-IP in transiently transfected 
HEK293T cells, and in HFFF-TERT cells stably overexpressing V5-tagged UL72 (see 
Figure 5.4.4).  
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Figure 5.4.3 | Diagram of the CCR4-NOT complex 
The carbon catabolite repression 4 (CCR4)–negative on TATA-less (NOT) complex plays a 
fundamental role in eukaryotic mRNA metabolism and has a multitude of different roles that 
impact eukaryotic gene expression. CNOT1 acts as a scaffold subunit around which the other 
members of the complex assemble, including the deadenylase subunits CNOT6/6L and CNOT7/8 
(adapted from Shirai et al, 2014) [276]. 
 
 
Figure 5.4.4 | Interaction of UL72 with members of CCR4-NOT complex CNOT2 and CNOT7 
Co-IPs validating that UL72 interacts with CNOT2 and CNOT7, conducted in HEK293T cells (A 
and B) or HFFFs (C and D). For all experiments in this figure, left panels show an IB of 1-2 % of 
input sample, and right panels show an anti-V5 co-IP. HEK293T cells were transiently transfected 
with two plasmids, one expressing the C-terminally V5-tagged viral protein and the other 
expressing the C-terminally HA-tagged cellular prey. Bait proteins were detected with anti-V5, 
and prey with antibodies against CNOT7 or CNOT2 protein. Controls included GFP and the viral 
proteins UL34 or UL52. CANX – calnexin loading control. This figure is representative of n= 1 
experiment (A); n= 2 experiments (B); n= 2 experiments (C); n= 1 experiment (D). Expected sizes: 
CNOT7: 33 kDa; CNOT2: 52 kDa; CANX: 72 kDa; UL72: 44 kDa; UL34: 45 kDa. 
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It is possible that UL72 directly binds just one subunit of the CCR4-NOT complex 
and co-IPs the whole complex via interaction with that protein. To determine if a single 
CCR4-NOT complex subunit was preferentially enriched in the UL72 AP-MS experiments, 
a ratio between the average number of PSMs (in both replicates) and the length of each 
protein was calculated (see Table 5.4.2). It is necessary to account for the effect of protein 
length, as large proteins tend to yield more peptides than small ones. This ratio is 
equivalent to a normalised spectral abundance factor, but without the normalisation by 
dividing by the sum of all PSMs/protein length for all proteins in the experiment.  This 
analysis showed a wide spread of ratios, and whereas it appears that CNOT6 was 
relatively less enriched than CNOT2, there was no clear result. Thus, preferential affinity 
for just one subunit cannot be identified from this analysis. Other complementary 
methods would be required to address this question, for example yeast two-hybrid could 
be employed to test interactions from UL72 with each subunit.  
 
Table 5.4.2 | Details of CCR4-NOT complex subunits in UL72-V5 AP-MS experiments 
CCR4-NOT  
complex subunit Uniprot 
Average 
PSMs 
Protein length  
(aa) 
Average PSMs/ 
Protein length ratio 
CNOT1 (isoform 1) A5YKK6 296.5 2,376 12.5 % 
CNOT1 (isoform 2) A5YKK6-2 4 2,371 0.2 % 
CNOT2 Q9NZN8 101 540 18.7 % 
CNOT3 O75175 51.5 753 6.8 % 
CNOT6 Q9ULM6 11.5 557 2.1 % 
CNOT6L Q96LI5 24 555 4.3 % 
CNOT7 Q9UIV1 29 285 10.2 % 
CNOT8 Q9UFF9 10 292 3.4 % 
CNOT9 Q92600-2 11 331 3.3 % 
CNOT10 Q9H9A5-6 30 804 3.7 % 
CNOT11 Q9UKZ1 21 510 4.1 % 
 
The CCR4-NOT complex is targeted for degradation during adenovirus infection 
in order to promote expression of early viral proteins and increase concentration of viral 
DNA [277]. Degradation of CCR4-NOT complex members does not seem to be induced by 
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HCMV infection [162], thus the biological function of UL72 binding to this complex 
remains to be determined. 
UL145 has recently been shown to recruit the Cullin 4 E3 ligase scaffold and 
associated adaptor proteins in order to degrade the helicase-like transcription factor 
HLTF [163]. Interactome data suggested that all human proteins interacting with UL145 
and the paralogous RL1 were part of the ubiquitin conjugation pathway, and furthermore 
that RL1 interacted with Cullin 4. Using co-immunoprecipitation in transiently 
transfected 293Ts with RL1-V5 and CUL4A-HA, Dr Katie Nightingale validated the RL1-
CUL4A interaction (see Figure 5.4.5A). Proteins that are degraded after binding 
RL1/CUL4 still require identification; it is possible that their abundance after degradation 
may have been insufficient to enable identification in this study, as for example the 
interaction between UL145 and its degraded target HLTF was not detected in the 
interactome. Multiple other HCMV proteins additionally interacted with elements of the 
ubiquitin transfer or conjugation pathways, including the DNA helicase/primase 
associated factor UL102, which interacted with the E3 ligase RNF114 and E2 conjugating 
enzyme UBE2L6. Similarly, the inhibitor of apoptosis UL36 which bound the Cullin 1 
scaffold, E3 ligase UBR5, and F-box component FBOX3.  
UL71 has been shown to play a role in the secondary envelopment. However, this 
viral protein is expressed with Tp3 kinetics, suggesting that this tegument protein may 
also play a role earlier during infection [162, 278, 279]. The interactome identified 
interactions of UL71 with multiple interferon-stimulated proteins (see Figure 5.4.5B), 
including TRIM22, a restriction factor for HIV-1, influenza A and hepatitis B and C viruses 
[280]. Using co-immunoprecipitation in transiently transfected 293Ts with UL71-V5 and 
TRIM22-HA, Dr. Katie Nightingale validated the UL71-TRIM22 interaction, suggesting 
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that investigation of a putative innate immune role for UL71 will be important (see Figure 
5.4.5C). 
 
Figure 5.4.5 | Validation of the interaction between RL1 and CUL4A, UL71 and TRIM22.  
(A) Co-IP validating the interaction between RL1 and CUL4A, conducted in HEK293T cells as 
described in Figure 5.4.4, but with detection of CUL4A using anti-HA. This figure is representative 
of n= 4 experiments. Expected sizes: CUL4A: 77 kDa; RL1: 35 kDa; UL34: 45 kDa; CANX: 72 kDa. 
(B) HCMV UL71 interacted with multiple interferon-stimulated proteins, including TRIM22. (C) 
Co-IP validating the interaction between UL71 and TRIM22, conducted as described in Figure 
5.4.4. This figure is representative of n= 3 experiments. Expected sizes: TRIM22: 56 kDa; UL71: 
40 kDa; UL34: 45 kDa; CANX: 72 kDa. 
 
Using functional enrichment analysis, an alternative approach identified enriched 
terms whose members interacted predominantly with single baits.  Figure 5.4.6 shows 
enriched terms with p<0.05 (after Benjamini-Hochberg adjustment) and for which >33 
% of the identified members of the enriched term interacted with a given viral bait. For 
example, US28 interacted with all quantified members of thick filament/muscle myosin 
complexes (myosin heavy and light chain components, a myosin binding protein and 
titin), suggesting a putative role for US28 in processes such as cytoskeletal remodeling 
[281]. Another viral GPCR, US27 interacted with multiple components of the SNARE 
complex, which mediates vesicle fusion [282]. The envelope glycoprotein UL132 
interacted with the AP-2 adaptor complex, which functions in clathrin-mediated 
endocytosis (see Figure 5.4.6) [283]. Altogether, this data suggested a putative role for 
these viral proteins in modulation of vesicular transport.  
 
A
CUL4A
-HA
G
F
P
R
L
1
-V
5
U
L
3
4
-V
5
G
F
P
R
L
1
-V
5
U
L
3
4
-V
5
IPInput
CANX
V5 
75  
75  
37  
50  
kDa
B Interferon 
stimulated genes
C
CANX
U
L
7
1
-V
5
U
L
3
4
-V
5
IPInput
75  
50  
50  
V5
TRIM22-HA
U
L
7
1
-V
5
U
L
3
4
-V
5
kDaCLIC4
FAR2
DDX60
IFIT5
TRIM22
OASL PPP2R2A
PPP2R2D
PPP2R2B
ZDHHC17
HSD17B11
SEC63
ITGA2
SLC20A2
ZC3HC1
ABHD12
AP1M1
TMCO4
HOXD10
LCLAT1
ENPP1
UL71
170 
 
Functional enrichment analysis was then used to gain insights into the temporal 
regulation of protein-protein interactions. For this, viral baits were segregated according 
to their temporal class and lists of their human HCIPs were analysed, using a list of all 
human HCIP as a background [162]. This analysis yielded an enrichment in functions 
required at different stages of the viral life-cycle (see Figure 5.4.7A). For example, HCIPs 
of Tp1 and Tp2 proteins were enriched in NuRD complex members, proteins involved in 
histone deacetylation and proteins with SANT domains (which function in chromatin 
remodelling). HCIPs of Tp3 proteins were enriched in functions required for viral DNA 
replication and immune evasion. HCIPs of Tp5 proteins were enriched in terms related 
to intracellular trafficking and secretion (see Figure 5.4.7A).  
A similar analysis was performed on viral HCIPs to assess the temporal regulation 
of viral-viral protein interactions. Two general patterns were observed from this analysis, 
viral proteins either interacted mainly with others from the same class or adjacent 
classes, or with proteins from the largest class Tp5 (see Figure 5.4.7B). For example, Tp1 
and Tp2 class proteins UL29 and UL38 interacted, as previously reported (see Figure 
5.4.1). Tp1-class tegument proteins US23 and US24 interacted. The majority of Tp5 
interactions were with other Tp5 proteins, 15/37 of which were tegument-tegument, 
capsid-capsid or tegument-capsid protein interactions (see Figure 5.4.7B). Interactions 
between proteins in different temporal classes have long been reported and include the 
interaction between the DNA polymerase subunits UL54 (Tp2) and UL44 (Tp5). This 
interactome has now identified novel interactions between other distinctly expressed 
proteins, such as the interaction between the functionally unknown membrane protein 
UL14 (Tp2) and two Tp5-class proteins, membrane protein UL121 and envelope 
glycoprotein UL4. 
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Figure 5.4.6 | Pathways enriched with p<0.05 (after Benjamini-Hochberg adjustment) and 
for which >33 % of the identified components interacted with a given viral bait. Examples 
are indicated in the central part of the figure by purple shading. All members of the thick 
filament/muscle myosin complex detected in this interactome interacted with US28 (100 %). For 
the bottom three complexes (UL74, US27 and UL132), each viral bait interacted with a total of 
52-107 proteins. For simplicity, only members of the illustrated pathway identified in this 
interactome are displayed. For example, 14 members of the SNARE complex were enriched in the 
interactome, of which 9 interacted with US27 (64 %). Green circles show members of a pathway 
that were detected in the interactome but did not interact with the bait. Viral baits are shown as 
large turquoise circles, and interacting viral proteins as smaller turquoise circles. Members of 
enriched pathways are shown in orange or yellow (membership of two pathways is indicated by 
half-orange, half-yellow circles). Solid lines indicate interactions identified by this interactome, 
and dashed lines indicated interactions derived from the human interactome (Bioplex 2.0) and 
subsequent unpublished data (http://bioplex.hms.harvard.edu/downloadInteractions.php).  
UL26
UL26
UL70
UL56
UL132
RL6
UL56
UL43
UL38
US27 UL148A
Thick
filament
Chaperonin-containing
T-complex
Muscle
myosin
complex
VCP-NPL4-UFD1 
AAA ATPase 
complex
Prefoldin
complex
SNARE
complex AP-2 adaptor complex
14-3-3 
protein
NuRD complex
Muscle
myosin
complex
Histone deacetylation
CCR4-NOT complex
Protease inhibitor
Transcription-coupled 
nucleotide-excision repair
Thick
filament
COPII vesicle coat
0.05 5x10-9p-value
VCP-NPL4-UFD1 AAA 
ATPase complex
Histone deacetylase 
complex
Prefoldin
complex
Chaperonin-containing
T-complex
Glycation
Rotamase
Endoplasmic reticulum 
quality control compartment
CTLH domain
Mitochondrial translational elongation UL44
UL94
UL29
US26
UL29
UL38
UL72
UL87
US28 US28
US30
UL74
UL29
UL70
AP-2 adaptor
complex
SNARE 
complex
Enriched 
terms
Identified member of pathway 
that does not interact with 
illustrated bait
This interactome
Huttlin et al Nature 2017
Viral protein
Member of illustrated pathway
Other human interactor
MYH1
MYH3
MYH6
MYH2 MYH4
MYH7
CCT7
GPR89A
UL53
AP2A1
AP2A2
AP2M1
EPS15
EGFR
TBC1D5
SGIP1
STX8
NAPA
STX18
SCFD1
STX12
STX6
STX7
VAMP7
VTI1A
VTI1B
NAPBSTX4
VAMP2STX16
FAF2
US29
VCP UFD1L
NPLOC4
EIF2AK3
TMED9
INTS4
YME1L1
WWP2
WWP1
TOM1L2
PTPRK
CNNM3
TCP11L1
IFNGR1
GPC1
NEDD4L
KRT87P
NEDD4
METTL13
TMED1
CHCHD2
C1QBP
TNFRSF1A
ATP9A
VPRBP
TTC13 SYNE3
SEC63
UBAC2ANKRD13A
SYNJ2BP
HECW2
CUL9
HSPD1
UL105
PFDN1UL102
TCP1
CCT3
CCT5
CCT4
CCT2
CCT6A
PFDN2
PFDN5
PFDN6
PFDN4
VBP1
CHCHD4
HSPA1B
HSPA1L
HSPA6
HSPB6
BAG3
BAG2
BAG5
FKBP5
HGH1
AK2 BABAM1
DNAJB4
DNAJC7
PDCD5
IGBP1
STUB1
CDC37
MYH7B
MYBPC2
TTN
B4GALT1
MYLPF
TTNC2
RAB6A
MPO
CPD
AK1
GYPC
AK5
ZG16B
IGHA1
IGKC
CKM
CA6C10orf54
NAGPA
CEP250
ACTN3 GNA13 FURIN
LDB3
HTN1
QSOX2
LAMTOR1
ATP6V0A2
UL70
US28
US30
UL132
US27
ER quality control 
compartment
MAN1B1
EDEM2
DERL2
RHBDD1
EDEM3
FBXO6
UGGT2
UL74
TRIM26
172 
 
 
Figure 5.4.7 | Further details of interactions according to viral protein temporal class  
(A) Functional enrichment of human HCIPs according to the temporal class of their viral bait. 
DAVID software with default settings [216] was applied using all human HCIP as a ‘background’. 
Benjamini-Hochberg adjusted p-values are shown on the x-axis. (B) Temporal analysis of viral-
viral protein interactions. This analysis was only performed on interactions for which both bait 
and prey had a defined Tp class according to Weekes et al (2014) [162]. 
 
DAVID analysis can also be applied to individual lists of genes with a considerable 
number of interactors. US22 is a tegument protein and an uncharacterised member of the 
betaherpesvirus-specific US22 family. DAVID analysis of the 61 HCIPs of US22 revealed 
an enrichment for proteins containing RNA recognition motifs (see Figure 5.4.8). Among 
the 61 US22 HCIPs, 24 were associated with the term ‘transcription’, while 14 were 
related to the term ‘repressor’ including TASOR and Periphilin-1. These two proteins, in 
addition to MPP8, form the epigenetic repressor Human Silencing Hub (HUSH) complex 
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[284]. Validation of these interactions is necessary, however DAVID analysis may provide 
an unbiased approach to determine individual gene function. 
 
Figure 5.4.8 | Functional enrichment analysis of US22 HCIPs 
DAVID software with default settings [216] was applied to determine which pathways were 
enriched amongst all US22 HCIPs, in comparison to all human proteins as background. Negative 
log base 10 for Benjamini-Hochberg adjusted p-values is shown as a measurement of enrichment. 
 
5.5 Viral proteins that degrade cellular prey 
A multiplexed approach has recently been employed to discover proteins that 
have innate immune function on the basis of their active degradation by the proteasome 
or lysosome during the early phase of HCMV infection. In Nightingale et al, 2018, three 
orthogonal proteomic/transcriptomic screens were employed to quantify protein 
degradation. The combination of the three screens included a shortlist of 133 proteins 
degraded by the proteasome or lysosome during early phase infection [163]. A final 
screen employed a panel of HCMV gene-block deletion mutants, to aid mapping of viral 
gene functions. However, this screen was unable to confidently identify the genetic region 
containing the viral effector which targeted 121/133 degraded proteins. Additionally, 
depending on the number of genes within each block, identification of which individual 
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viral genes degraded cellular targets could prove arduous. For example, identification of 
the viral factor within the UL133-UL150 block, UL145, which targeted HLTF to the 
proteasome required testing of 19 single viral gene deletion mutants [163]. 
In order to extend the findings of the study by Nightingale et al (2018), HCIP data 
from this interactome was combined electronically to identify viral factors interacting 
with the shortlist of 133 degraded host factors. This overlap identified viral interactors 
for 31 of these degraded prey (see Table 5.5). A subset of these interactions has already 
been described in the literature and are shown on Figure 5.3.3, for example the binding 
and sequestering of Signal transducer and activator of transcription 2 (STAT2) by IE1-72 
[285]. Additionally, the ubiquitin E3 ligase ITCH (Itchy E3 Ubiquitin Protein Ligase) is 
also known to be targeted for degradation by viral UL42 [286].  
Isoform A of the nuclear autoantigen Sp-100 is known to be targeted for 
degradation via proteasome and to interact directly with IE1 through the N-terminal 
dimerization domain [129]. Overlap between the interactome data and the shortlist of 
133 host degraded targets from Nightingale et al (2018) identified UL56 and the non-
canonical ORFL147C as HCIPs for the degraded isoform C of Sp-100, indicating that the 
seven isoforms of this nuclear autoantigen may be targeted by different viral proteins.   
Despite the inclusion of 14-3-3 epsilon, theta, zeta/delta and beta/alpha in HCMV 
virions, the latter is the only protein from this family in the shortlist of host factors 
degraded in all three screens.  
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Table 5.5 | Viral interactors for degraded host proteins identified in Nightingale et al, 
2018 [163] 
Uniprot Gene Symbol Description Interactome 
P52630 STAT2 
Signal transducer and activator of 
transcription 2 
UL123 
Q96J02 ITCH E3 ubiquitin-protein ligase Itchy homolog UL42, UL55 
Q96PU5 NEDD4L E3 ubiquitin-protein ligase NEDD4-like 
US30, UL20, UL42, UL55, 
UL133 
P78357 CNTNAP1 Contactin-associated protein 1 US9, US21, UL55 
P22694-2 PRKACB 
Isoform 2 of cAMP-dependent protein 
kinase catalytic subunit beta 
US9, US19, UL150A, 
ORFL147C 
P55899 FCGRT IgG receptor FcRn large subunit p51 US7, UL20 
P11908-2 PRPS2 
Isoform 2 of Ribose-phosphate 
pyrophosphokinase 2 
US12 
O75663 TIPRL TIP41-like protein US12 
P61244 MAX MYC associated factor X UL94 
Q15003 NCAPH Condensin complex subunit 2 UL9, UL19, UL132 
P56945-6 BCAR1 
Isoform 6 of Breast cancer anti-estrogen 
resistance protein 1 
UL86, UL150A, 
ORFL147C 
Q96JK2 DCAF5 DDB1- and CUL4-associated factor 5 UL80.5 
P23497-4 SP100 
Isoform Sp100-C of Nuclear autoantigen 
Sp-100 
UL56, ORFL147C 
Q99685 MGLL Monoglyceride lipase UL50, ORFL147C 
P31946 YWHAB 14-3-3 protein beta/alpha UL43 
P17302 GJA1 Gap junction alpha-1 protein 
UL42, UL100, UL148A, 
UL148C, US21 
Q86Y39 NDUFA11 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 11 
UL40 
O14730 RIOK3 Serine/threonine-protein kinase RIO3 UL40 
P16333 NCK1 
Non-catalytic region of protein tyrosine 
kinase 1 
UL25 
Q8IVD9 NUDCD3 NudC domain-containing protein 3 UL23 
P14324 FDPS Farnesyl pyrophosphate synthase UL16 
Q9NRY4 ARHGAP35 Rho GTPase-activating protein 35 UL150A 
P01008 SERPINC1 Antithrombin-III UL14, UL78, UL130 
P17612 PRKACA 
cAMP-dependent protein kinase catalytic 
subunit alpha 
UL14 
Q9Y6D5 ARFGEF2 
Brefeldin A-inhibited guanine nucleotide-
exchange protein 2 
UL132, UL75 
P04049-2 RAF1 
Isoform 2 of RAF proto-oncogene 
serine/threonine-protein kinase 
UL132 
Q13671 RIN1 Ras and Rab interactor 1 UL132 
Q13907-2 IDI1 
Isoform 2 of Isopentenyl-diphosphate 
Delta-isomerase 1 
UL13, UL27 
P61088 UBE2N Ubiquitin-conjugating enzyme E2 N RL6, UL56 
Q9UKI2 CDC42EP3 Cdc42 effector protein 3 ORFS343C 
A1A4S6 ARHGAP10 Rho GTPase-activating protein 10 IRS1 
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In addition to ITCH, UL42 interacted with Neural Precursor Cell Expressed, 
Developmentally Down-Regulated 4 (NEDD4)-family E3 ligases NEDD4 (both isoforms 1 
and 4) and NEDD4-like (NEDD4L), as well as the HECT, C2 and WW Domain Containing 
E3 Ubiquitin Protein Ligases HECW1 and 2 (see Figure 5.5.1A). Both NEDD4 and NEDD4L 
have been shown to be degraded during early HCMV infection (see Figure 5.5.1B) [163].  
 
 
Figure 5.5.1 | UL42 as a hub of E3 destruction  
(A) High-confidence cellular interactors of UL42. Interactors in orange circles exhibited ubiquitin 
protein transferase activity. (B) ITCH, NEDD4 and NEDD4L are degraded during early HCMV 
infection (data from Nightingale et al, 2018). Protein degradation was measured using three 
orthogonal tandem mass tag (TMT)-based proteomic screens. The first measured protein 
abundance throughout early infection in the presence or absence of inhibitors of the proteasome 
or lysosome. The second compared transcript and protein abundance over time to distinguish 
between degraded and transcriptionally regulated proteins. The third employed an unbiased 
global pulse-chase to compare the rates of protein degradation during HCMV infection against 
mock infection (NEDD4 and NEDD4L were not quantified in this latter screen). Benjamini-
Hochberg adjusted Significance A values were used to estimate p-values in the top panels; 
**p<0.005, ***p<0.0005. Mean and SEM are shown for transcript quantitation (n= 3) in the middle 
panels. A p-value for the difference between rates of degradation is shown in the bottom panel; 
***p<0.0005. (C) UL42 transcript is expressed contemporaneously with NEDD4 and NEDD4L 
degradation. Protein profiles from Figure 5.5.1B (red colour, data from Nightingale et al, 2018) 
are overlaid with a UL42 transcript profile (blue colour, data from Stern-Ginossar et al, 2012).  
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UL42 protein was not detected in the previous proteomic studies by Weekes et al 
(2014), Fielding et al (2017) or Nightingale et al (2018) [162, 163, 194]. UL42 transcript 
was quantified by Stern-Ginossar et al (2012) [67], with a peak of expression 72 h post-
infection, yet still detectable at earlier time points. This suggested that UL42 protein may 
be expressed coincidentally with degradation of NEDD4 and NEDD4L (see Figure 5.5.1C). 
The interactions between UL42 and NEDD4/NEDD4L were validated by co-IP in 
transiently transfected HEK293T cells using C- and N-terminally tagged UL42 (see 
Figures 5.5.2A and 5.5.3). Furthermore, stable overexpression of UL42 in HFFF-TERT 
cells was shown to be sufficient for degradation of NEDD4 (see Figure 5.5.2B).  
 
 
Figure 5.5.2 | Validation of the interaction between UL42 and NEDD4/NEDD4L 
(A) Validation of interaction between UL42 and NEDD4/NEDD4L by co-IP. HEK293T cells were 
transiently transfected with the indicated plasmids, one expressing the C-terminally V5-tagged 
viral protein and the other expressing C-terminally HA-tagged NEDD4 or NEDD4L. These proteins 
were detected with anti-V5 and anti-HA. This figure is representative of n= 2 experiments 
(NEDD4); n= 1 experiment (NEDD4L). Expected sizes: NEDD4: 104-149 kDa; NEDD4L: 96-111 
kDa; UL42: 14 kDa; UL34: 45 kDa; CANX: 72 kDa. (B) UL42 was sufficient to degrade NEDD4. 
HFFF-TERTs expressing UL42 or controls were lysed and immunoblotted as indicated. Anti-
NEDD4 was used to detect endogenous NEDD4. This figure is representative of n= 1 experiment. 
Expected sizes: NEDD4: 104-149 kDa; UL42: 14 kDa; UL34: 45 kDa; CANX: 72 kDa. 
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The route of degradation of these interactors of UL42 requires further 
characterization. As depicted in Figure 5.5.1B, MG132 and leupeptin both inhibited 
degradation of ITCH, NEDD4 and NEDD4L, although this may be explained by the known 
effects of MG132 on lysosomal cathepsins in addition to the proteasome [287], or 
conversely by effects of leupeptin on certain proteasomal proteases in addition to 
lysosomal proteases. 
 
 
Figure 5.5.3 | Further validation of the interaction between UL42 and NEDD4/NEDD4L 
Validation of interaction between UL42 and NEDD4 (left panel) and NEDD4L (right panel) by co-
IP, conducted as described in Figure 5.5.1. HEK293T cells were transiently transfected with the 
indicated plasmids, one expressing N-terminally V5-tagged UL42 and the other expressing C-
terminally HA-tagged NEDD4 or NEDD4L. These proteins were detected with anti-V5 and anti-
HA. This figure is representative of n= 1 experiments. Expected sizes: NEDD4: 104-149 kDa; 
NEDD4L: 96-111 kDa; UL42: 14 kDa; CANX: 72 kDa. 
 
The sensitivity of the HCMV interactome for detecting interactions with weakly-
expressed prey was assessed by examining the interaction between the cell surface 
adhesion molecule Leucine Rich Repeat And Fibronectin Type III Domain Containing 3 
(LRFN3) and US10.  
LRFN3 was previously quantified by 1 peptide in samples enriched for PM 
proteins only [162, 163], being rapidly downregulated from the PM and accompanied by 
upregulation of transcript over the same period. This suggested that LRFN3 is either 
degraded or retained within the infected cell (see Figure 5.5.4 A). The ER-resident 
transmembrane glycoprotein US10 was the only bait interacting with LRFN3. Using the 
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same methodology as for interactions validated in this chapter, the interaction between 
US10 and LRFN3 was validated by co-IP (see Figures 5.5.4 B-C). This suggested that US10 
may regulate LRFN3 in a manner similarly to the reported degradation for HLA-G [288]. 
 
Figure 5.5.4 | US10 interacts with HCMV degradation target LRFN3 
(A) LRFN3 was rapidly downregulated from the PM during HCMV infection, in the presence of 
upregulated transcript (mean and SEM are shown for transcript quantitation (n= 3); data are from 
(Nightingale et al., 2018)) (B) HCIPs of US10, including LRFN3. (C) Validation of the interaction 
between US10 and LRFN3 by co-IP, conducted as described in Figure 5.4.2. Prey were detected 
using anti-HA. This figure is representative of n= 2 experiments. Expected sizes: LRFN3: 66 kDa; 
US10: 21 kDa; UL34: 45 kDa; CANX: 72 kDa. 
 
5.6 Protein domain associations inferred from interaction data 
A protein domain can perform similar functions within different proteins, often 
via interactions with complementary protein domains or molecular structures. The 
function and interaction(s) of these domains can be predicted by analysing interactions 
between their parent proteins [189, 289]. Domains that are necessary for an interaction 
between two proteins tend to co-occur at higher frequency, as depicted in Figure 5.6.1. 
Certain protein domains co-occur frequently but do not necessarily interact directly, 
however these associations can still provide insights into their function. 
The Pfam database is a repository where proteins have been grouped into families 
according to characteristic domains using multiple sequence alignments and hidden 
Markov models. This database has 168 entries for HCMV strain Merlin, comprised of 96 
protein domains annotated for 115 viral proteins. By mapping Pfam domains to every 
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bait and prey protein in the interactome, it was possible to identify domain pairs that 
interact with unusual frequency (see Figure 5.6.2). 
 
Figure 5.6.1 | Schematic representation of domain association analysis 
The association of protein domains ‘a’, ‘b’ and ‘c’ with domains ‘1’, ‘2’, ‘3’, ‘4’ and ‘5’ is mapped 
onto an interaction matrix to determine unusual frequency of interaction between two domains 
(i.e. domain ‘a’ and domain ‘1’ interact more frequently with each other than with other domains). 
 
Significant associations for domains shared by at least two viral proteins were 
found for seven viral protein domains (see Table 5.6). A full list of significant domain 
associations for each viral protein, including prey proteins and interacting domains, is 
provided in Appendix E.  
 
Table 5.6 | Annotated PFAM domains in canonical HCMV proteins 
Domain name 
 Number of 
proteins 
HCMV protein members 
PFAM 
accession 
US22 13 
IRS1, TRS1, US22, US23, US24, US26, UL23, 
UL24, UL26, UL29, UL36, UL38, UL43 
PF02393 
Bax1-I 5 US12, US15, US17, US20, US21 PF01027 
CMV_US 4 US7, US8, US9, US11 PF08001 
7tm_1 3 US27, US28, UL33 PF00001 
RL11D 2 RL5A, RL6 PF11088 
Herpes_IE2_3 2 UL117, UL122 PF03361 
UL141 2 UL141, UL14 PF16758 
Herpes_pp85 2 UL25, UL35 PF04637 
Herpes_UL82_83 2 UL82, UL83 PF05784 
Cytomega_US3 2 US2, US3 PF05963 
 
a
b
a c
b a
c
1
1
2
13
3 4
1
4
1 4
3
5
Domain 1 2 3 4 5
a 5 0 2 3 0
b 2 1 0 2 0
c 2 0 3 1 1
Figure B removed for copyright reasons. Copyright holder is Elsevier Inc. 
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As depicted in Figure 5.6.2, this analysis correctly predicted that HCMV 
glycoprotein UL141 interacts with TNFR cysteine-rich domains (TNFR c6), which has 
been demonstrated for TNFRSF10B and predicted for TNFRSF10A [251]. UL141 also 
interacted with TNFRSF10D as reported in Smith et al (2013) and was found to interact 
with TNFRSF1A suggesting that these interactions may also occur via the TNFR c6 
domain [290]. 
Domain analysis also predicted an interaction between Herpes pp85 proteins and 
SH3 domains (see Figure 5.6.2). HCIP data suggested that the phosphoprotein pp85 
(UL25) interacted with SH3 domain-containing proteins NCK1 (Non-catalytic region of 
protein tyrosine kinase 1) and NCK2. UL25 also interacted with two other human 
proteins, WDR26 and RPS6KA3, in addition to the viral tegument protein UL26. The 
tegument protein UL26 had more diverse targets, including proteins with E3 ligase 
activity, ribosomal S6 kinases, COPII vesicle coat proteins, members of the CPSF and CTLH 
complexes, and NCK2 but not NCK1 (see Figure 5.6.3). 
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Figure 5.6.2 | PFAM protein domain association analysis 
Heatmap depicting significant associations between domains present in HCMV baits (top) and 
human or viral prey (side). Pfam domains were mapped onto every bait and prey protein in the 
interactome [289]. The numbers of interactions emanating from proteins containing each domain 
were tallied individually, along with the numbers of interactions linking each observed domain 
pair. Contingency tables were then populated to relate domain associations. For each pair, 
Fisher’s exact test determined the likelihood of a non-random association. p-values were adjusted 
for multiple hypothesis testing [218]. Coloured boxes identify domain pairs that associate at a 1 
% false discovery rate. Red boxes indicate domain pairs from this analysis discussed in the text. 
Domain associations are only shown for domains occurring in at least two viral proteins. 
Appendix E shows the full underlying data. 
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Figure 5.6.3 | HCIPs of UL25 and UL26 
DAVID analysis identified that members of the C-terminal to LisH (CTLH) complex and COPII 
vesicle coat proteins were enriched among UL26 HCIPs (see Figure 5.4.6). Domain association 
analysis suggested that interaction of UL26 with CTLH components may occur via interaction of 
the viral US22 domain with either cellular CLTH or LisH domains. Dashed lines represent human-
human interactions derived either from Bioplex 2.0 as described in Figure 5.4.1 or from curated 
or experimental data in the STRING database. CPSF - Cleavage and polyadenylation specificity 
factor. 
 
SH3 domains have been shown to interact with proline-rich regions [291]. Given 
that UL25 has a proline-rich C-terminus, and NCK1 has three N-terminal SH3 regions, Dr. 
Katie Nightingale designed a series of mutations on each SH3 domain of NCK1 and cloned 
a C-terminally truncated form of UL25 without the proline-rich region (see Figure 
5.6.4A). These mutations were based on previous functional studies of NCK1 function 
[292, 293]. Using transiently transfected HEK293T cells with plasmids expressing the 
NCK1-SH3 mutants, in combination with full-length or truncated UL25, Dr. Katie 
Nightingale performed a series of co-IPs which suggested that the UL25 C-terminus 
interacts with the first NCK1 SH3 domain alone, validating and extending the prediction 
from domain association analysis (see Figure 5.6.4B). 
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Figure 5.6.4 | Validation of the interaction between UL25 and NCK1 
(A) Schematic of NCK1 and UL25 protein structures, indicating the position of point mutations or 
truncation used in (B). NCK1 point mutation design was based on previous studies on the function 
of this adaptor protein [292, 293]. (B) Co-IP demonstrating that the UL25 proline-rich C-terminal 
domain associates with the first NCK1 SH3 domain, conducted as described in Figure 3. HEK293T 
cells were transiently transfected with the indicated plasmids, one expressing the C-terminally 
V5-tagged viral protein and the other expressing C-terminally HA-tagged NCK1. These proteins 
were detected with anti-V5 and anti-HA. Mutations or truncations of each gene are indicated in 
the figure. GAPDH – loading control. This figure is representative of n= 3 experiments. Expected 
sizes: NCK1: 43 kDa; UL25: 74 kDa; UL26: 21 kDa; GAPDH: 36 kDa. 
 
5.7 Discussion 
Instrument performance controls as well as monitoring sample summary 
statistics were necessary to avoid samples being run in suboptimal conditions which 
would impair overall protein quantification. Additionally, disparities in quantification 
between replicates would undermine CompPass filtering, given that parameters (for 
example ‘entropy’) looked for inconsistently detected prey.  
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The ‘no bait’ control had no V5 tag but was still able to co-purify over a thousand 
proteins. A single replicate of this control was included in the NP-40 set. Technical 
replicates of biological duplicates of cells transduced with the empty vector control, as 
well as biological duplicates of cells transduced with a vector encoding GFP were included 
in the digitonin set in order to increase the sample number for CompPass filtering. This 
was necessary to help distinguish genuine interactors from common contaminants, given 
that the latter were different between lysates containing NP-40 and digitonin, and thus 
could not be processed together. In both datasets, these controls had the effect of 
increasing the number of IPs that identified non-specific interacting proteins, thus 
decreasing NWD and z-scores for these proteins. 
Given the extensive list of proteins identified in each AP-MS dataset, a stringent 
filtering strategy was necessary to remove false positives. CompPass has been previously 
employed in large-scale protein-protein interaction studies including the human 
interactome project where similar filtering thresholds for each parameter were used 
[189, 195, 208, 209, 236].  
The PSM filter employed to identify HCIPs for this interactome guaranteed that at 
least 3 peptides had to be identified among the two replicates in order for a protein to be 
considered a genuine interactor.  
 The entropy score used probability to measure variability of PSMs from each 
protein among the replicates, attributing low scores for proteins which had very 
disparate numbers of PSMs when comparing replicate ‘A’ to ‘B’ or vice-versa. This was 
particularly useful in the case of carry-over of unusually abundant proteins which would 
result in one replicate having a high number of PSMs, whereas the other would have a 
very low number (close to or indeed zero PSMs).  
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Another CompPass parameter, the Z-score, was calculated for each prey for each 
bait, and thus the same prey had a different score depending on the bait. This parameter 
can identify bait-prey pairs where the number of PSMs differs significantly from the mean 
and was most useful when analyzing proteins that were present in multiple complexes 
but were found at much higher levels in a subset of these (thus having high standard 
deviation in these cases). However, it does not differentiate an interactor with 1 PSM from 
another with 30 PSM, resulting in a tendency to upweight unique proteins regardless of 
their abundance.  
The NWD score is a version of the z-score with higher discriminating power, as it 
takes into account the frequency of an interactor across all baits, up-weighting interactors 
that are rare. Additionally, previous studies have shown that by taking only the top 2 % 
of interactors according to NWD and Z parameters, false protein identifications should be 
limited to 5 %. In this case, it is possible that out of the 3440 HCIPs (excluding self-HCIP 
identification), approximately 172 interactors may be false positives. However, these 
false positives are likely to predominate amongst prey with low NWD or Z-scores; 
particularly high scores reflect particularly confident bait-prey interactions [189]. 
Interactomes of this type include false discoveries, however simultaneous analysis 
of AP-MS experiments decreases false discovery rate in comparison to isolated AP-MS 
experiments, given that non-specific interacting proteins can be identified and excluded 
due to their frequent identification in several IPs [195]. 
Interactomes may also fail to detect genuine interactions. Assessing false negative 
is less straightforward, and literature reporting previously identified interactions also 
suffers from false discoveries. A potential cause for missed identifications is the 
abundance of the prey protein. The HCMV interactome clearly had the ability to identify 
prey with low cellular abundance such as LRFN3, which was below the limit of detection 
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in two unbiased quantitative proteomic studies from whole cell lysates of HFFFs [193]. 
While 36 % of previously described interactions that were not identified in this 
interactome were also unquantified in whole cell lysates [193], degradation of human 
factors during HCMV infection may also decrease their abundance below the limit of 
detection by MS. Future studies aiming to validate interactions from this dataset with a 
prey protein with low cellular abundance may be more successful using co-IP of 
overexpressed prey rather than endogenous protein. 
Presence and overexpression of each viral bait prior to and throughout the course 
of infection may have induced temporal dysregulation of the expression of other viral 
proteins. Thus changing the regulation of interactions that would usually commence 
earlier or later than 60 h of infection. Yet, given that 153/153 quantified viral ORFs were 
expressed at 60 h [162], the interactions observed in this interactome should occur at 
this phase of infection, regardless of whether either bait or prey protein (or both) were 
not maximally expressed. Furthermore, the abundance of certain stably expressed 
proteins may actually have been below the level of expression usually observed during 
HCMV infection. Additionally, previous human interactome studies found no correlation 
between bait protein expression and the number of HCIPs [195].  
Alternative approaches to generate an interactome would suffer from other 
confounding issues. For example, introduction of a tag in the viral genome may generate 
a construct for AP-MS with similar abundance and temporal profile as during infection 
with unmodified virus. However, the transcription of overlapping viral ORFs during 
infection may disrupt expression of neighbouring genes [67]. 
The interactome did not identify HCIPs for nine HCMV canonical proteins. The 
only interactors identified for US2, US11 and UL93 were the baits themselves. 
Nevertheless, US2, US11 and UL93 were detected after filtering as prey for UL148C, UL18 
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and US22 respectively. The viral immunoevasins US2 and US11 are known to interact 
with the SEC61 translocon to redirect MHC I heavy chains from the endoplasmic 
reticulum to the cytosol where they are degraded by the proteasome [287, 294, 295]. 
Both these viral baits contain a single-pass transmembrane domain and were quantified 
in their own IPs. For US2, an interaction with HLA-A, HLA-C and SEC61A2 was detected 
in the unfiltered dataset but these were all quantified by 1 PSM and had low NWD and Z-
scores. Similarly, US11 immunoprecipitated HLA-A (1 PSM), HLA-B (1 PSM), HLA-C (2 
PSM) and SEC61A2 (1 PSM) but these did not meet the stringent filtering criteria. Given 
that certain US2 and US11 interactions occur via the transmembrane domain (e.g. 
interaction between US2 and TRC8, [296]; interaction between US11 and Derlin-1, [297, 
298]), and are thus inherently weak, it may not be surprising that we did not detect any 
non-bait HCIP for these proteins, particularly given that NP40 was employed as opposed 
to Digitonin. A future avenue would be to determine if additional interactors were 
detected with Digitonin as a detergent (likewise for other single-pass TM proteins). 
Additionally, US2 and US11 targets are rapidly degraded (for example MHC Class I 
molecules are degraded with a half-time of less than one minute in cells expressing US11) 
[287]. Thus, repeating these IPs in cells pre-treated with inhibitors of proteasome 
degradation may also enable detection of host targets for US2 and US11.  UL93 is a 
positional homolog for HSV-1 capsid vertex component CVC1 and is known to interact 
with the HCMV ortholog for CVC2, UL77. Both these proteins play a role in viral genome 
cleavage and packaging [22]. Although the soluble UL93 was enriched in its own IP, an 
interaction with the UL77 was not detected. Additionally, UL93 was not quantified as a 
prey for UL77. Interaction with other capsid proteins as well as proteins that have been 
reported to be present in the virion were detected but had an overall low score for most 
parameters. 
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 UL96 has been reported to interact with the UL32 gene product pp150 [299]. Both 
these bait and prey were quantified in the UL96 AP-MS samples but the interaction scored 
low for NWD and Z-scores and was quantified by a single PSM between the two replicates. 
In contrast, UL96 was not detected in the UL32 IPs. 
 UL119 encodes for a viral Fc-gamma receptor-like protein with a single-
transmembrane domain. This bait was enriched in its own IP and even though an 
interaction with IGHG1 (Immunoglobulin heavy constant gamma 1) was detected, this 
prey was quantified by 1 PSM between both replicates and scored low for NWD and Z-
scores, and therefore did not pass the final stringent filtering criteria employed. This 
example illustrates that the unfiltered data may nevertheless be useful in testing 
hypotheses – since it is likely to include false negative interactions. Identification of such 
interactions could potentially be made by lowering the PSM criteria, or adjusting this 
criteria according to the overall estimated cellular abundance of each host protein, which 
has been estimated in Nobre et al (2019) [193]. 
 UL146 encodes for a viral CXCL1 chemokine. As UL146 is a secreted protein, this 
may explain why this bait was poorly detected in its own IP. UL146 has been reported to 
interact with CXCR1 and CXCR2 receptors [300, 301], but these baits were not detected 
in the dataset in any IP. 
 The membrane protein RL13 was also enriched in its own IP. It has been shown to 
modulate viral DNA replication by interacting with Nudix Hydrolase 14 (NUDT14) [302], 
however this prey was not detected in the interactome. Additionally, an interaction with 
Fc region of Immunoglobulin G has been reported [43], and even though IGHG1 was 
detected as prey for RL13, it scored low for entropy, NWD and Z-score. 
Despite previous validation of transgene expression, neither UL120 nor UL142 
baits were quantified in their respective IPs. UL120 was also not quantified in the 
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proteomics dataset from Weekes et al (2014), indicating that this protein may have low 
abundance. In contrast, UL142 has previously been quantified using PM profiling, 
although this method relies on enrichment of sialylated PM glycoproteins and employs a 
lysis buffer with different composition (e.g contains Triton instead of NP-40) [162]. There 
are no studies showing binding partners for the single-pass membrane protein UL120, 
but ULBP3 [303] and SNAPIN [304] have previously been identified as interactors for the 
glycoprotein UL142. For both UL120 and UL142 the only prey to meet the entropy, NWD 
and Z-score filtering criteria were quantified by 1 PSM only. 
Taken altogether, the stringency of the filtering criteria may partly explain the lack 
of identification of HCIP for these nine baits. Protein abundance and interaction strength 
are additional factors. Weakening the filtering criteria would need to be undertaken with 
caution due to the increase in false positive identifications, however it could be 
undertaken with specific testable hypotheses in mind. 
Overlap with published data annotated in interaction databases was only 35 %. 
For 25 % of the annotated interactions in the combined positive control database (167 
listed interactions, see Appendix D), the prey was not detected in the AP-MS data for the 
expected bait. There are a number of possible reasons for these observations. These 
include: differences in experimental conditions employed; differences in cell type; 
whether or not HCMV infection or simply single-gene overexpression alone was 
employed; differences in the protein tag and whether this was attached to the N- or C-
terminus. Even though a 5 % cut-off for NWD and Z-score was applied to include 
previously published interactions that didn’t meet the more stringent threshold of 2 %, 
approximately 40 % of the interactions in the combined dataset still failed to meet the 
filtering criteria. This was partly caused by inconsistent detection in the interactome 
(quantification by 1 PSM or entropy score of 0) but most predominantly due to low Z and 
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NWD scores, a consequence of a high frequency of detection of these interactors across 
all baits, a low standard deviation of PSMs or a combination of these two. Nevertheless, 
lack of detection of a given ‘positive control’ does not mean that the interactome has failed 
to identify a correct interaction. There is no ‘gold standard’ for correct interactions; and 
many of the published interactions for HCMV are based on less-well controlled AP-MS 
studies, yeast two-hydrid, in vitro binding assays with purified protein or 
immunofluorescence. For example, from the list of known interactors of UL27 (see Table 
4.2 or Appendix D), only 4/27 were identified as HCIP for this bait in this interactome. 
Three of these published interactors were not quantified in the dataset, which could 
reflect a difference in protein abundance in the cell types used in both experiments. For 
the remaining 20/27 published interactors of UL27, the entropy scores were close to 1, 
yet the NWD scores were below 0.2, suggesting that although these proteins may be 
consistently detected in AP-MS experiments they are detected to a similar degree in 
several other IPs and thus may not be specific interactors of UL27. Furthermore, a 
multitude of published interactions has not yet been curated into a database, limiting the 
extent of the evaluation of the HCMV interactome data.  
DAVID analysis of all HCIPs revealed enrichment in biological terms which had 
been reported previously in the literature, such as 14-3-3 proteins which have been 
identified in HCMV virions; the association of UL29 and UL38 with the NuRD complex; as 
well as the interaction of several RNAII subunits with a complex of viral proteins required 
for the transcription of late genes. This analysis has also highlighted biological terms that 
have not been studied in the context of HCMV infection such as the CNOT and NCoR 
complex. As seen for UL72, UL43 and US22, which have an enrichment for interacting 
proteins with related functions, DAVID analysis can provide an unbiased approach to 
generate hypothesis for determining individual gene function. 
192 
 
Combination of HCIP data with the screens of protein degradation during early 
HCMV infection from Nightingale et al (2018) showed that UL42 targets multiple 
ubiquitin E3 ligases for degradation, and predicted novel interactions between viral baits 
and 29 other degraded host factors. In fact, the interactome suggested that multiple viral 
proteins interact with members of the ubiquitin conjugation pathway, with 51 viral 
proteins interacting with one at least one E3 ligase (defined in Medvar et al., 2016) [305]. 
These interactions may identify previously uncharacterised viral effectors of cellular 
protein degradation. For example, UL25 interacted with the adaptor protein WD Repeat 
Domain 26 (WDR26), which can recruit substrates to the Cullin-4 RING ubiquitin ligase 
family [306]. UL25 also interacted with UL26, which itself had HCIPS with E3 ligase 
activity, such as the members of CTLH complex [307, 308]. Additionally, UL26 also 
interacted with other ligases and scaffolds, such as Cullin 3 and SMAD Specific E3 
Ubiquitin Protein Ligase 2 (SMURF2). Future work may identify whether UL25 or UL26 
prey are degraded and via which of these degradation mechanisms.  
The HCMV interactome also highlighted UL20 as a hub of degradation. This viral 
protein was previously reported to be rapidly degraded, with the suggestion that it may 
target unidentified cellular proteins to lysosomes [309]. Several HCIPs of UL20 have 
previously been shown to be rescued from degradation by application of the lysosomal 
protease inhibitor Leupeptin, such as Interleukin 6 Signal Transducer (IL6ST), the 
neonatal Fc receptor (FCGRT), Ephrin A2 (EPHA2), and Interferon Gamma Receptor 1 
(IFNGR1) [163]. These four HCIPs were shown to be rescued upon deletion of members 
of the viral US12-US21 family [194], suggesting that there may be cooperativity between 
these proteins and UL20, potentially with UL20 acting as a common final mediator of 
degradation. 
193 
 
DAVID analysis also highlighted several viral baits that interact with proteins 
involved in ubiquitin mediated degradation. While for UL42 and US10 it was possible to 
detect interactions with degraded prey, the interactome did not identify host targets for 
baits such as RL1 or UL145. For these baits, an interaction with SLFN11 and HLTF was 
expected, respectively [163, 310]. However, for HLTF at least, prey overexpression was 
required to observe this interaction, which might have been due to low prey abundance, 
weak bait-prey interaction or both. It will therefore be important to repeat this 
interactome with cells pre-treated with lysosomal or proteasomal inhibitors prior to AP-
MS in order to prevent the degradation and increase the abundance of such targets, which 
could enable their identification. In fact, unpublished work by Fletcher-Etherington et al 
(in preparation), has employed this approach to identify an interaction between UL36 
(for which DAVID analysis determined an enrichment for Ubiquitin protein transferase 
activity) and the necroptosis mediator MLKL [311].  
Higher frequency of co-occurrence between two domains does not necessarily 
mean that these interact or that two proteins containing each of those domains bind to 
each other. For example, the interaction between UL35 and UL82 may not be due to a 
binding between the respective PFAM domains ‘Herpes pp65’ and ‘Herpes UL82 UL83’, 
given that no interaction is observed between UL35 and UL83. 
In cases where an interaction is indeed observed between proteins containing 
domains that co-occur with high frequency, PFAM domain association analysis can 
provide insight into which domains may be necessary for this interaction. The exact 
residues required for binding can be determined using single-residue mutants or 
truncations for each binding partner. For example, Dr Katie Nightingale validated the 
interaction between the viral tegument pp85 phosphoprotein UL25 and the SH3 domain-
containing protein NCK1, and using the domain association predictions determined that 
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both the C-terminus of UL25 and the first SH3 domain of NCK1 are necessary for this 
interaction. Given the multifunctional roles of NCK1 in signal transduction, including 
receptor tyrosine kinases, cytoplasmic remodelling via regulation of actin 
polymerization, apoptosis and the DNA damage response, the interaction with UL25 may 
fulfil a variety of functions [292, 293, 312]. One hypothesis includes inhibition of the 
immune synapse formation via regulation of actin polymerisation, similarly to UL135 
which has been reported to dispel association between F-actin filaments in target cells 
and the immune synapse [250].  
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6 | Characterisation of ORFL147C  
 
Functional enrichment analysis of ORFL147C HCIPs was performed by Dr. Michael 
Weekes (Department of Medicine, University of Cambridge). Generation of HCMV Merlin 
recombinants used for viral growth experiments was performed by Dr. Richard Stanton 
(School of Medicine, Cardiff University). Validation of the interactions between ORFL147C 
and MBNL1/CELF1 was performed by Dr. Katie Nightingale (Department of Medicine, 
University of Cambridge). Parts of the work presented in this chapter have been published 
in a similar form in eLife (Nobre et al., 2019). 
 
The 604 HCMV ORFs identified by ribosome profiling  remain uncharacterised and 
thus it is unclear whether they play a functional role in HCMV infection [67]. As depicted 
in Figure 1.4, the two uncharacterised ORFs included in the HCMV interactome showed a 
relative abundance within the range of canonical HCMV proteins. ORFL147C was the 
most abundant non-canonical ORF and was quantified at approximately 25x lower copy 
number than the most abundant viral protein UL83. ORFS343C was observed in the lower 
end of the abundance range, yet it was still quantified at approximately 3x higher copy 
number than the least abundant viral protein US18.  
HCIPs have now been identified for the polypeptides encoded by these two non-
canonical ORFs. This chapter will focus on a preliminary characterisation of the protein 
encoded by the ORFL147C ORF. 
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6.1 Sequence analysis and conservation 
The coding sequence of ORFL147C initiates upstream to the 5’ end (in a different 
reading frame) of UL56, which is a canonical gene encoding a subunit of the viral 
terminase, and approximately 0.5 kbp from the 3’ end of the canonical gene encoding the 
single-stranded DNA binding protein UL57 (see Figure 6.1).  
 
Figure 6.1.1 | ORFL147C coding sequence and relation to neighbouring viral genes 
The coding sequence for the uncharacterised ORFL147C starts 58bp upstream of the start codon 
for UL56. Coding sequences for both these proteins are located on the same strand but not in 
frame, thus ORFL147C is not an N-terminal extension of UL56. 
 
This region of the HCMV genome contains genes conserved across Alpha, Beta- 
and Gammaherpesvirinae (thus designated core genes), including UL56 and UL57 [69]. A 
basic local alignment search of the nucleotide and protein sequences for the 
uncharacterised ORFL147C against HSV-1, HSV-2, VZV, EBV, HHV-6, HHV-7 and KSHV 
entries found no significant similarity, thus this ORF is not conserved among other genus 
of human herpesvirus.  
In contrast, alignment of ORFL147C protein sequences for HCMV strains Merlin, 
Toledo, AD169 and Towne showed that not only do these four strains contain the coding 
sequence for this ORF, they also share 98 % residue identity, with the high-passage 
strains being slightly more dissimilar (see Figure 6.1.2). 
A basic local alignment search of the protein sequence against the ‘Non-redundant 
protein sequences (nr)’ database generated only three significant alignments with 65.4 – 
66.6% identity (see Figure 6.1.3): the cy89 protein from Cynomolgus macaque 
cytomegalovirus (CyCMV) strain Ottawa, Cy89 protein from CyCMV strain Mauritius and 
UL55 UL56 UL57
ORFL147C
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Rh91.1 from Rhesus cytomegalovirus (RhCMV). These three homologs of ORFL147C are 
similarly positioned between the homologs of UL56 (cyUL56 or Rh91/RhUL56) and UL57 
(cyUL57 or Rh92/RhUL57) [313, 314], but no function has been assigned to either of the 
homologs of this ORF. ORFL147C thus appears to be conserved in human 
cytomegalovirus strains and have homologs in other primate CMVs, but not in other 
human herpesvirus genus. 
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Towne       MSLAGARPDDSVSYVSESSHGDEFVTETMRSVFEMQRIRHGAGVSKVLRSERVTGGVHAV 60 
AD169       MSLAGARPDDSVSYVSESSHGDEFVTETMRSVFEMQRIRHGAGVSKVLRSERVTGGVHAV 60 
Merlin      MSLAGARPDDSVSYVSESSHGDEFVTETMRSVFEMQRIRHGAGVSKVLRSERVTGGVHAV 60 
Toledo      MSLAGARPDDSVSYVSESSHGDEFVTETMRSVFEMQRIRHGAGVSKVLRSERVTGGVHAV 60 
            ************************************************************ 
 
Towne       QEKRGGYSVSVPEDLPGGGGAESYAEFAADALSGDAAEGAARGYGFAGPGADGLLAPAGP 120 
AD169       QEKRGGYSVSVPEDLPGGGGAESYAEFVADALPGDAAEGAARGYGFAGSGADGLLAPAGP 120 
Merlin      QEKRGGYSVSVPEDLPGGGGAESYAEFAADSLSGDAAEGAARGYGFAGSGADGLLAPAGP 120 
Toledo      QEKRGGYSVSVPEDLPGGGGAESYAEFAADALSGDAAEGAARGYGFAGSGADGLLAPAGP 120 
            ***************************.**:* *************** *********** 
 
Towne       GGLLPYRPPFGSLRSPSHRGAPVYGQRPFQRQSGHTQRHRALPVQDELRVRDPGAGGRPG 180 
AD169       GGLLPYRPPFGSLRSPSHRGAPVYGQRPFQRQSGHTQRHRALPVQNELRVRDPGAGGRPG 180 
Merlin      GGLLPYRPPFGSLRSPSHRGAPVYGQRPFQRQSGHTQRHRALPVQNELRVRDPGAGGRPG 180 
Toledo      GGLLPYRPPFGSLRSPSHRGAPVYGQRPFQRQSGHTQRHRALPVQNELRVRDPGAGGRPG 180 
            *********************************************:************** 
 
Towne       GLRAAAGASPSPMRHLAGGASGSVRRRDDMRPMLRGADHHPESGPLVEQAAAGLAVQPYS 240 
AD169       GLRAVAGAPPSPMRHLAGGASGSVRRRDDMRPMLRGADHHPESGPLAEQAAAGLAVQPYS 240 
Merlin      GLRAAAGAPPSPMRHLAGGASGSVRRRDDMRPMLRGADHHPESGPLAEQAAAGLAVQPYS 240 
Toledo      GLRAAAGAPPSPMRHLAGGASGSVRRRDDMRPMLRGADHHPESGPLAEQAAAGLAVQPYS 240 
            ****.*** *************************************.************* 
 
Towne       GPPSVKPVRCEYPDGGAGPAGPDNAHPPLGWSPFGPQKPILFFIGLPQLHPGGGGGAEGV 300 
AD169       GPPSVKPVRCEYPDGGAGPAGPDNAHPPLGWSPFGPQKPILFFIGLPQLHPGGGGGAEGV 300 
Merlin      GPPSVKPVRCEYPDGGAGPAGPDNAHPPLGWSPFGPQKPILFFIGLPQLHPGGGGGAEGV 300 
Toledo      GPPSVKPVRCEYPDGGAGPAGPDNAHPPLGWSPFGPQKPILFFIGLPQLHPGGGGGAEGV 300 
            ************************************************************ 
 
Towne       QPVYGYTGTNIFLVGFYLLVPYLGGYRQAGGHHHPAAKCVSPAVPGAHERHQSPSVRGGR 360 
AD169       QPVYGYTGTNIFLVGFYLLVPYLGGYRQAGGHHHPAAKCVSPAVPGAHERHQSPSVRGGR 360 
Merlin      QPVYGYTGTNIFLVGFYLLVPYLGGYRQAGGHHHPAAKCVSPAVPGAHERHQSPSVRGGR 360 
Toledo      QPVYGYTGTNIFLVGFYLLVPYLGGYRQAGGHHHPAAKCVSPAVPGAHERHQSPSVRGGR 360 
            ************************************************************ 
 
Towne       GGHLRARGKGVGRGGAHVRGVGLCRPQQDHRPHHIPQHSSFRGQPGVQQAPRKQRDVHQN 420 
AD169       GGHLRARGKGVGRGGAHVRGVGLCRPQQDHRPHHIPQHSSFRGQPGVQQAPRKQRDVHQN 420 
Merlin      GGHLRARGKGVGRGGAHVRGVGLCRPQQDHRPHHIPQHSSFRGQPGVQQAPRKQRDVHQN 420 
Toledo      GGHLRARGKGVGRGGAHVRGVGLCRPQQDHRPHHIPQHSSFRGQPGVQQAPRKQRDVHQN 420 
            ************************************************************ 
 
Towne       QAYSRGDSTSAARWHGGRRPRGRGYSPAWTGGDVGDGYDFDDGQQQQQQQYSQSEE 476 
AD169       QAYSRGDSTSAARWHGGRRPRGRGYSPAWTGGDVGDGYDFDDGQQQQQQQYSQSEE 476 
Merlin      QAYSRGDSTSAARWHGGRRPRGRGYSPAWTGGDVGDGYDFDDGQQQQQQQYSQSEE 476 
Toledo      QAYSRGDSTSAARWHGGRRPRGRGYSPAWTGGDVGDGYDFDDGQQQQQQQYSQSEE 476 
            ******************************************************** 
Figure 6.1.2 | Alignment of ORFL147C amino acid sequences from different HCMV strains. 
Multiple sequence alignment was generated using Clustal Omega (EMBL-EBI) with default 
settings for protein sequences. Consensus symbols key: ‘*’ denotes positions that have a single 
and fully conserved residue; ‘:’ denotes conservation between groups of strongly similar 
properties; ‘.’ denotes conservation between groups of weakly similar properties. 
  
199 
 
ORFL147C      MSLAGARPDDSVSYVSESSHGDEFVTETMRSVFEMQRIRHGAGVSKVLRSERVTGGVHAV 60 
Rh91.1        MSLSEQITEDAVCYADEQGAGDEFVAETVRSVFQMQRIRHGTGVSKVLRSERVTGGVKSV 60 
cy89          MSLSEQITEDAVCYADEQGAGDEFVAETVRSVFQMQRIRHGTGVSKVLRSERVTGGVKSV 60 
Cy89          MSLSEQITEDAVCYADEQGAGDEFVAETVRSVFQMQRIRHGTGVSKVLRSERVTGGVKSV 60 
              ***:    :*:*.*..*.. *****:**:****:*******:***************::* 
 
ORFL147C      QEKRGGYSVSVPEDLPGGGGAESYAEFAADSLSGDAAEGAARGYGFAGSGADGLLAPAGP 120 
Rh91.1        QEERTGYRLSVPQDLPGAGAPEPYTDFAVEPVHGDDFEGSVRGYGAARPRSQGVLQEAGP 120 
cy89          QEERTGYRLSVPQDLPGAGAPEPYTDFAVESVHGDDFEGSVRGYGAARPRSQGVLQEAGP 120 
Cy89          QEERTGYRLSVPQDLPGAGAPEPYTDFAVESVHGDDFEGSVRGYGAARPRSQGVLQEAGP 120 
              **:* ** :***:****.*. * *::**.: : **  **:.**** *   ::*:*  *** 
 
ORFL147C      GGLLPYRPPFGSLRSPSHRGAPVYGQRPFQRQSGHTQRHRALPVQNELRVRDPGAGGRPG 180 
Rh91.1        GGVLPYSPSLRSVRSAPHGGAYVHGQRKVQRHASNAQRHRALPVQDELRIRDPVPGERAG 180 
cy89          GGVLPYSPSFRSVRSAPHGGAYVHGQRKVQRHASNAQRHRALPVQDELRIRDPVPGERTG 180 
Cy89          GGVLPYSPSFRSVRSAPHGGAYVHGQRKVQRHASNAQRHRALPVQDELRIRDPVPGERAG 180 
              **:*** * : *:**  * ** *:*** .**::.::*********:***:***  * * * 
 
ORFL147C      GLRAAAGAPPSPMRHLAGGASGSVRRRDDMRPMLRGADHHPESGPLAEQAAAGLAVQPYS 240 
Rh91.1        GLLATPPAAASPVRSVTGSLPRGVRGGNNVRPMLRGTDHHPQPGALAEQAPAGLALQPYC 240 
cy89          GLLATPPAAASPVRSVAGSLPRGVRGGNNVRPMLRGADHHPQPGALAEQAPAGLALQPYC 240 
Cy89          GLLATPPAAASPVRSVAGSLPRGVRGGNNVRPMLRGADHHPQPGALAEQAPAGLALQPYC 240 
              ** *:  *  **:* ::*.   .**  :::******:****: * ***** ****:***. 
 
ORFL147C      GPPSVKPVRCEYPDGGAGPAGPDNAHPPLGWSPFGPQKPILFFIGLPQLHPGGGGGAEGV 300 
Rh91.1        GPPAVEPVRCEYTNGGAGSHGADAAHPQPFWGPHGPQKPVLFFFGLPQLYPGGGGGAEGV 300 
cy89          GPPAVEPVRCEYPNGGAGPHGADAAHPQPFWGPHGPQKPVLFFFGLPQLYPGGGGGAEGV 300 
Cy89          GPPAVEPVRCEYPNGGAGPHGADAAHPQPFWGPHGPQKPVLFFFGLPQLYPGGGGGAEGV 300 
              ***:*:****** :****  * * ***   *.*.*****:***:*****:********** 
 
ORFL147C      QPVYGYTGTNIFLVGFYLLVPYLGGYRQAGGHHHPAAKCVSPAVPGAHERHQSPSVRGGR 360 
Rh91.1        QPVYGYTGTNIFLVGFYLLVPYLGGYSQAGGDKHAAAKCLSPPVQGPHERPQQVPVRGGR 360 
cy89          QPVYGYTGTNIFLVGFYLLVPYLGGYSQAGGDKHAAAKCLSSPVQGPHERPQQVPVRGGR 360 
Cy89          QPVYGYTGTNIFLVGFYLLVPYLGGYSQAGGDKHAATKCLSSPVQSPHERPQQVPVRGGR 360 
              ************************** ****.:* *:**:*  * . *** *.  ***** 
 
ORFL147C      GGHLRARGKGVGRGGAHVRGVGLCRPQQDHRPHHIPQHSSFRGQPGVQQAPRKQRDVHQN 420 
Rh91.1        GGHFRARGKAAFSRAASFRGVGLCRPQQDHRPNYIPQHSSFRGQPGFQQTPRKQRNVYQN 420 
cy89          GGHFRARGKAAFSRAASFRGVGLCRPQQDHRPNYIPQHSSFRGQPGFQQAPRKQRNVYQN 420 
Cy89          GGHFRARGKAAFPRAASFRGVGLCRPQQDHRPNYIPQHSSFRGQPGFQQAPRKQRNVYQN 420 
              ***:*****..   .* .**************::************.**:*****:*:** 
 
ORFL147C      QAYSRGDSTSAARWHGGRRPRGRGYSPAWTGGDVGDGYDFDDGQQQQQQQYSQSEE 476 
Rh91.1        QMPPGRDQASRARWGGG-G-RGGGRGHSWAGPPEYVQ------------------- 455 
cy89          QMPPGRDQAPRARWGGGGG-RGGGRGHSWAGPPEYVQ------------------- 456 
Cy89          QMPPGRDQAPRARWGGG-G-RGGGRGHSWAGPPEYVQ------------------- 455 
              *     *.:  *** **   ** * . :*:*                          
 
Figure 6.1.3 | ORFL147C amino acid sequence alignment with homologs from other 
primate CMV species. Multiple sequence alignment for ORFL147C (HCMV), Rh91.1 (Macacine 
betaherpesvirus 3/Rhesus cytomegalovirus), cy89 (Cynomolgus macaque cytomegalovirus 
strain Ottawa) and Cy89 (Cynomolgus macaque cytomegalovirus strain Mauritius) generated 
using Clustal Omega (EMBL-EBI) with default settings for protein sequences. Consensus symbols 
key: ‘*’ denotes positions that have a single and fully conserved residue; ‘:’ denotes conservation 
between groups of strongly similar properties; ‘.’ denotes conservation between groups of weakly 
similar properties. 
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6.2 ORFL147C interactors  
CompPass filtering identified 80 HCIP for this bait, with no viral interactors. 
Additionally, ORFL147C was not identified as an HCIP for any of the other viral baits. 
Functional enrichment analysis of ORFL147C HCIPs predicted functions in RNA binding, 
mRNA splicing or transcription (see Figures 6.2.1 and 6.2.2).   
 
Figure 6.2.1 | ORFL147C high-confidence interacting proteins 
Interactors of ORFL147C are shown in small circles, coloured according to functional enrichment 
(pink: RNA Pol II pre-transcription events; orange: RNA binding; yellow: mRNA splicing; dual 
membership of pathways is indicated by half-coloured circles). Solid lines indicate interactions 
identified in the HCMV interactome while dashed lines indicate interactions drawn from the 
human interactome (Bioplex 2.0) and subsequent unpublished data (Huttlin et al, 2017 and 
http://bioplex.hms.harvard.edu/downloadInteractions.php). 
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Figure 6.2.2 | Enrichment analysis of HCIPs of ORFL147C 
(A) DAVID functional enrichment analysis was performed using all human proteins as a 
‘background’. Benjamini-Hochberg adjusted p-values are shown. (B) Reactome database analysis 
[315] showing results with a minimum of 4 entities per enriched pathway. 
 
Furthermore, the interaction between ORFL147C and the Muscleblind-Like 
Splicing Regulator 1 (MBNL1) and CUG Triplet Repeat RNA-Binding Protein 1 (CELF1), 
two proteins with roles in mRNA splicing and RNA binding, was validated by Dr. Katie 
Nightingale, using co-immunoprecipitation of transiently transfected ORFL147C-V5 and 
MBNL1-HA or CELF1-HA [193].    
Similarly to HSV-1 ICP27 and HCMV UL69, ORFL147C possesses RGG box RNA-
binding motifs. HSV-1 ICP27 and its HCMV homolog UL69 bind to intronless viral RNAs 
and shuttle between the nucleus and cytoplasm, working as viral mRNA export factors 
[316, 317]. In contrast, interactome data suggested that ORFL147C does not bind any of 
the components of the mRNA nuclear export machinery employed by ICP27 and UL69, 
although it co-precipitated Exportin-7 (XPO7), a broad-spectrum bidirectional nuclear 
transporter [318]. 
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Figure 6.2.3 | Validation of interaction between ORFL147C, MBNL1 and CELF1 
HEK293T cells were transiently transfected with the indicated plasmids, one expressing the C-
terminally V5-tagged viral protein and the other expressing C-terminally HA-tagged MBNL1 or 
CELF1. These proteins were detected with anti-V5 and anti-HA. GAPDH – calnexin loading control. 
This figure is representative of n= 1 experiment. Expected sizes: MBNL1: 33-42 kDa; CELF1: 50-
55 kDa; ORFL147C: 50 kDa; UL25: 74 kDa; GAPDH: 36 kDa. 
 
6.3 Deletion of ORFL147C impairs viral growth 
To assess whether ORFL147C plays an important role in viral replication, Dr. Rich 
Stanton mutated the three most N-terminal methionine residues in ORFL147C without 
modifying the coding sequence of UL56, generating an HCMV recombinant with 
ORFL147C deletion (see Figure 6.3.1).  
 
 
Figure 6.3.1 | Construction of a viral ORFL147C deletion mutant 
The N-terminal protein sequences and coding sequences of ORFL147C and UL56 are shown, with 
point mutations signalled by black arrows, and residue mutations shown in red for the 
recombinant. The three most N-terminal methionines in ORF147C were mutated (M to Stop, or 
V) without affecting the amino acid sequences coded by UL56.  
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Absence of ORFL147C expression was verified by tandem-mass tag-base 
quantitative proteomics of HFFF-TERT cells which were mock-infected or infected with 
WT Merlin HCMV or the ORFL147C deletion mutant (see Figure 6.3.2A). Due to difficulties 
in growing and tittering the ORFL147C deletion virus, replicates to the samples analysed 
by proteomics were collected for flow cytometry and analysed for GFP expression as a 
measure of percentage of infection (see Figure 6.3.2B). The percentage of cells infected 
with WT and the ORFL147C deletion mutant was very similar (82.7 % and 82.1 % 
respectively), suggesting that differences in the abundance of ORFL147C protein 
observed in Figure 6.3.2A were not a consequence of disparities in infection.  
Growth of the ORFL147C deletion virus in HFFF-TERT cells was significantly 
impaired compared to WT Merlin, suggesting that ORFL147C plays a role in viral 
replication (see Figure 6.3.2C).  
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Figure 6.3.2 | Growth analysis of an ORFL147C-deficient recombinant 
(A) HFFF-TERT cells were incubated with 4 μg/ml Dexamethasone in serum-free DMEM O/N, 
followed by mock-infected, infected with wild-type or ORFL147C-deficient recombinant (MOI=2) 
for 48 h. Lysates were then collected and processed for tandem mass tag-based proteomics. Both 
recombinant viruses contained an immediate-early gene UL36 3’-terminally fused with enhanced 
GFP (eGFP) gene and a self-cleaving P2A peptide. This peptide released the eGFP marker 
following synthesis. Additionally, insertion of the marker did not impede UL36 function in such 
recombinants [163]. ORFL147C relative protein abundance was similar in mock and ORFL147C-
deficient recombinant infected cells. (B) Biological replicates of the samples analysed in A were 
collected for flow-cytometry analysis of GFP expression. Samples had simultaneously been 
infected for 48 h at MOI=2. (C) Cells were infected in biological duplicates at an MOI of 1, and 
supernatants harvested every two days. Viral supernatants were then titred in technical 
duplicates. Mean values are shown, and error bars represent SD. p-values for a difference 
between wild-type and ORFL147C-deficient virus or wild-type and ORFL147C-V5 overexpressing 
HFFF-TERT cells were estimated using a two-tailed Student’s t-test. *p<0.05, ***p<0.001, 
****p<0.0001.  
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6.4 Discussion 
Despite previous detection by ribosome profiling or mass spectrometry, the 
functions of non-canonical ORFs remain uncharacterised. Three ORFs previously 
identified by ribosomal profiling and two 6FT-ORFs were identified as interactors of 
canonical HCMV proteins. Additionally, seven interacting 6FT-ORFs had not previously 
been identified. This data suggests that at least a subset of uncharacterised ORFs may 
play a role in infection, warranting further characterisation. Initial predictions of these 
functions can be achieved by interaction analysis.  
ORFL147C contains RGG RNA-binding motifs similarly to other herpesvirus 
proteins that interact with host factors involved in mRNA processing. Additionally, 
interactions with proteins involved in mRNA splicing, MBNL1 and CELF1, have been 
validated [193]. Another interactor of ORFL147C, Ribonucleotide PTB-binding 1 
(RAVER1) modulates alternative splicing events. In fact, up to 100 splice junctions have 
been identified in HCMV [67, 70, 319], with several spliced transcripts identified at all 
times post infection [320]. 
Deletion of ORFL147C slowed viral replication. However, its large HCIP network 
suggests that various putative mechanisms (for example splicing or transcriptional 
effects) which could underlie this observation and thus need to be examined.  
The ORFL147C protein is the most abundant non-canonical ORF [193], yet the 
absence of homologues in other genera of human herpesvirus may explain why its role in 
viral infection has not been studied to date. 
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7 | Conclusion and future work 
 
Parts of the work presented in this chapter have been published in a similar form in eLife 
(Nobre et al., 2019). 
 
This dataset identifies virus-virus and virus-host interactions for 160/171 
canonical HCMV proteins, comprising the largest host-pathogen protein interaction 
network to date and the first interactome for a DNA virus in infected cells. Thus, this 
dataset may prove valuable in future studies of HCMV and other herpesviruses. 
Systematic analysis of this dataset has predicted functions and domain 
associations for multiple uncharacterized or partly characterized viral proteins, in 
addition to providing evidence that the non-canonical HCMV protein ORFL147C may play 
a role in viral infection. 
The combination of interactome data generated in the present study with previous 
screens of protein degradation during early HCMV infection identified viral interactors 
for degraded host factors, revealing potential viral mechanisms of cellular protein 
degradation. Functional enrichment analysis of the interactome data suggested that 
HCMV devotes multiple proteins to interactions with the ubiquitin conjugation pathway, 
with a subset of viral proteins as hubs of degradation for multiple ubiquitin E3 ligases. 
In addition to the vast protein-protein interaction dataset, the HCMV interactome 
has generated other resources which have already proven useful to other researchers in 
the field, such as the library of lentiviral expression vectors for each HCMV canonical 
gene, a collection of stable cell lines overexpressing each canonical HCMV protein as well 
as lysates from these, which allow screening of single-gene effects.  
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There are several lines of research arising from this work which could be pursued. 
One line of research would be to understand how changes in the methodology could 
better results. CompPass filtering was unable to identify HCIPs for nine canonical HCMV 
genes, thus it would be important to understand which changes to the methodology could 
address this. For example, cryogenic cell lysis or a different detergent could be trialled to 
improve identification of weak interactions. The use of an inducible expression system 
where abundance of the bait protein can be tuned, may also improve results for baits with 
low constitutive expression. 
Further research could aim to understand the biological implications of the fixed 
time-point of 60 h on the HCMV interactome. For example, the viral proteins could be 
divided in five batches according to their relative abundance temporal profile and 
immunoprecipitated at the time point for which their expression peaks. This could 
potentially reveal novel interactions which are time-point dependent but biologically 
relevant. Additionally, for HCMV proteins expressed during latency, future research could 
aim to determine how this part of the viral life cycle affects the list of binding partners. 
Several lines of research stem from chapter 5. One example would be to apply the 
methodology in this study to other ORFs identified by ribosome profiling and proteomics 
to determine whether they are functional polypeptides. Novel interactions reported in 
the HCMV interactome dataset require further validation followed by studies into their 
biological significance in viral infection. The role of UL72 binding to CCR4-NOT complex 
or UL43 binding to the 14-3-3 proteins which are involved in diverse signalling functions 
and present in the virion, are only two examples of several that could be examined.  
The dataset did not reveal every viral bait that interacts with degraded human 
prey. A possible explanation is that such proteins were degraded to below the limit of 
detection by MS. Further research could aim to repeat this interactome in the presence of 
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lysosomal and proteasomal inhibition to identify such targets. Regarding the overlap of 
this dataset with previously published degradation data, future experiments may focus 
on showing sufficiency of the identified viral genes for degradation of host factors. 
Protein domain association analysis requires experimental validation to 
determine whether the co-occurring domains are necessary for the binding between 
proteins which contain these domains. Further research may employ single-residue 
mutants and truncated protein forms to determine how changes in these domains affect 
binding to interactors. 
Another line of research, which follows from chapter 6, would be to elucidate the 
function of ORFL147C protein in HCMV infection. Preliminary analysis on this ORF raises 
the hypothesis that it could play a role in mRNA export using different cellular machinery 
from UL69/ICP27. Firstly, it could be tested whether the presence of RGG box RNA-
binding domains allow ORFL147C protein the ability to bind mRNA molecules. Secondly, 
the subcellular location of this protein should be examined to determine whether it is 
able to shuttle between nucleus and cytoplasm. Validation of interaction with its HCIP 
XPO7, which mediates nuclear export, could then be performed in a similar way to 
validation of other interactions reported in this study. Finally, it could be tested whether 
an ORFL147C mutant that is unable to bind nuclear export machinery or mRNA, results 
in a similar viral growth phenotype as observed for the ORFL147C deletion virus. 
Apart from the newly-approved Letermovir, all drugs used to treat HCMV infection 
induce significant side effects and are subject to the development of mutations which can 
confer resistance. Innovative therapeutic strategies are thus required and may arise from 
the identification of key interactions in virus-virus or virus-host protein complexes. For 
example, small molecule inhibitors may be developed to selectively target and disrupt 
these interactions, potentially restoring innate antiviral restriction through the inhibition 
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of degradation of host factors [321-323]. Factors targeted by a single viral protein 
provide a more straightforward opportunity for therapeutic interruption by small 
molecule inhibitors, such as for example the interaction of UL72 with members of the 
CCR4-NOT complex. If this interaction proves important for HCMV infection, the function 
of the CCR4-NOT complex may be disrupted, for example by employing inhibitors of the 
CNOT7 deadenylase, providing another target for antiviral therapy [324]. Furthermore, 
a combination of therapies simultaneously targeting several pathways may also be 
employed to inhibit viral replication. For example, cytotoxins may be developed based on 
ligands for the viral GPCRs, enabling targeting and killing of cells infected with HCMV 
[53]. 
More broadly, future research may compare this dataset with other published 
viral interactomes in order to identify common pathways targeted by viruses as well as 
diverging strategies of host factor modulation. 
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Appendix A | UL48 secondary structure 
prediction 
 
Secondary structure prediction was generated using the YASPIN Secondary Structure 
Prediction tool from the Centre for Integrative Bioinformatics VU (Vrije Universiteit 
Amsterdam) [197]. 
 
Ruler : .........10........20........30........40........50........60 
Sequence : MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLD 
Prediction: -EEEEEE--------------EEEEEHHHHHHHHHHH--------HHHHHHHHHHHHHHH 
Ruler : ........70........80........90........100.......110.......120 
Sequence : ARLERELQKKLPAGGRLPVYRLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCP 
Prediction: HHHHH--------------EEE-----EEEEE------------------------EEEE 
Ruler : .......130.......140.......150.......160.......170.......180 
Sequence : GIFDFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFDPHSSAECHNAAVYHCEGLHQ 
Prediction: -HHHHHH--------EEEEEEE----EEEEEE--EEEEE----------EEEEEEE-HHH 
Ruler : .......190.......200.......210.......220.......230.......240 
Sequence : VLMVLTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESAD 
Prediction: HHHHH-----------EEEEEEEEEEE-----HHHHHHHHHHH----------------- 
Ruler : .......250.......260.......270.......280.......290.......300 
Sequence : TAATTTTAAPSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGK 
Prediction: ------------------------------------------------------------ 
Ruler : .......310.......320.......330.......340.......350.......360 
Sequence : KKPPSTTSKTLATASSSPSAIAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKA 
Prediction: --------------------HHH--------------HHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .......370.......380.......390.......400.......410.......420 
Sequence : LTLPPLPANTSAWTLHAAGTESGANAATATAPSFDEAFLTDRLQQLIIHAVNQRSCLRRP 
Prediction: -------------EEEE------------------HHHHHHHHHHHHHHHHH-EEEE--- 
Ruler : .......430.......440.......450.......460.......470.......480 
Sequence : CGPQSAAQQAVRAYLGLSKKLDAFLLNWLHHGLDLQRMHDYLSHKTTKGTYSTLDRALLE 
Prediction: ---HHHHHHHHHHHHHHHHHHHHHHHHHHH-HHHHHHHHHH------HHHHHHHHHHHHH 
Ruler : .......490.......500.......510.......520.......530.......540 
Sequence : KMQVVFDPYGRQHGPALIAWVEEMLRYVESKPTNELSQRLQRFVTKRPMPVSDSFVCLRP 
Prediction: HHHHHH--HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH-----HHHHHHH-H 
Ruler : .......550.......560.......570.......580.......590.......600 
Sequence : VDFQRLTQVIEQRRRVLQRQREEYHGVYEHLAGLITSIDIHDLDASDLNRREILKALQPL 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .......610.......620.......630.......640.......650.......660 
Sequence : DDNAKQELFRLGNAKMLELQMDLDRLSTQLLTRVHNHILNGFLPVEDLKQMERVVEQVLR 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .......670.......680.......690.......700.......710.......720 
Sequence : LFYDLRDLKLCDGSYEEGFVVIREQLSYLMTGTVRDNVPLLQEILQLRHAYQQATQQNEG 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .......730.......740.......750.......760.......770.......780 
Sequence : RLTQIHDLLHVIETLVRDPGSRGSALTLALVQEQLAQLEALGGLQLPEVQQRLQNAQLAL 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .......790.......800.......810.......820.......830.......840 
Sequence : SRLYEEEEETQRFLDGLSYDDPPTEQTIKRHPQLREMLRRDEQTRLRLINAVLSMFHTLV 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .......850.......860.......870.......880.......890.......900 
Sequence : MRLARDESPRPTFFDAVSLLLQQLPPDSHEREDLRAANATYAQMVKKLEQIEKAGTGASE 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
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Ruler : .......910.......920.......930.......940.......950.......960 
Sequence : KRFQALRELVYFFRNHEYFFQHMVGRLGVGPQVTELYERYQHEMEEQHLERLEREWQEEA 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .......970.......980.......990.......1000.........1010.........1020 
Sequence : GKLTVTSVEDVQRVLARAPSHRVMHQMQQTLTTKMQDFLDKEKRKQEEQQRQLLDGYQKK 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1030.........1040.........1050.........1060.........1070.........1080 
Sequence : VQQDLQRVVDAVKGEMLSTIPHQPLEATLELLLGLDQRAQPLLDKFNQDLLSALQQLSKK 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1090.........1100.........1110.........1120.........1130.........1140 
Sequence : LDGRINECLHGVLTGDVERRCHPHREAAMQTQASLNHLDQILGPQLLIHETQQALQHAVH 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1150.........1160.........1170.........1180.........1190.........1200 
Sequence : QAQFIEKCQQGDPTTAITGSEFESDFARYRSSQQKMEGQLQETRQQMTETSERLDRSLRQ 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1210.........1220.........1230.........1240.........1250.........1260 
Sequence : DPGSSSVTRVPEKPFKGQELAGRITPPPADFQRPVFKTLLDQQADAARKALSDEADLLNQ 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1270.........1280.........1290.........1300.........1310.........1320 
Sequence : KVQTQLRQRDEQLSTAQNLWTDLVTRHKMSGGLDVTTPDAKALMEKPLETLRELLGKATQ 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1330.........1340.........1350.........1360.........1370.........1380 
Sequence : QLPYLSAERTVRWMLAFLEEALAQITADPTHPHHGSRTHYRNLQQQAVESAVTLAHQIEQ 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1390.........1400.........1410.........1420.........1430.........1440 
Sequence : NAACENFIAQHQEATANGASTPRVDMVQAVEAVWQRLEPGRVAGGAARHQKVQELLQRLG 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1450.........1460.........1470.........1480.........1490.........1500 
Sequence : QTLGDLELQETLATEYFALLHGIQTFSYGLDFRSQLEKIRDLRTRFAELAKRCGTRLSNE 
Prediction: HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 
Ruler : .........1510.........1520.........1530.........1540.........1550.........1560 
Sequence : GALPNPRKPQATTSLGAFTRGLNALERHVQLGHQYLLNKLNGSSLVYRLEDIPSVLPPTH 
Prediction: ---------HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH-----EEE------------ 
Ruler : .........1570.........1580.........1590.........1600.........1610.........1620 
Sequence : ETDPALIMRDRLRRLCFARHHDTFLEVVDVFGMRQIVTQAGEPIYLVTDYGNVAFKYLAL 
Prediction: ----HHHHHHHHHHHHH------EEEE----------------EEEEE----EEEEEEE- 
Ruler : .........1630.........1640.........1650.........1660.........1670.........1680 
Sequence : RDDGRPLAWRRRCSGGGLKNVVTTRYKAITVAVAVCQTLRTFWPQISQYDLRPYLTQHQS 
Prediction: --------------------EEEEEEEEEEEEHHHHHHHHHHHHHHHH---HHHHH---- 
Ruler : .........1690.........1700.........1710.........1720.........1730.........1740 
Sequence : HTHPAETHTLHNLKLFCYLVSTAWHQRIDTQQELTAADRVGSGEGGDVGEQRPGRGTVLR 
Prediction: ---------EEEEEEEEEEEHHHHHHHH-----------------------------EEE 
Ruler : .........1750.........1760.........1770.........1780.........1790.........1800 
Sequence : LSLQEFCVLIAALYPEYIYTVLKYPVQMSLPSLTAHLHQDVIHAVVNNTHKMPPDHLPEQ 
Prediction: E-HHHHHHHHHH--HHHHHHHH---HHHHHHHHHHHHH---HHHHHH----------HHH 
Ruler : .........1810.........1820.........1830.........1840.........1850.........1860 
Sequence : VKAFCITPTQWPAMQLNKLFWENKLVQQLCQVGPQKSTPSLGKLWLYAMATLVFPQDMLQ 
Prediction: HHHHH------------HHHH--HHHHHHHHH-----HHHHHHHHHHHHH-EEE-HHHHH 
Ruler : .........1870.........1880.........1890.........1900.........1910.........1920 
Sequence : CLWLELKPQYAETYASVSELVQTLFQIFTQQCEMVTEGYTQPQLPTGEPVLQMIRVRRQD 
Prediction: HHHHHH--------HHHHHHHHHHHHHH-----EEE------------EEEEEEE----- 
Ruler : .........1930.........1940.........1950.........1960.........1970.........1980 
Sequence : TTTTDTNTTTEPGLLDVFIQTETALDYALGSWLFGIPVCLGVHVADLLKGQRVLVARHLE 
Prediction: --------------HHHHH--HHHHHHHH--EEEEEEEEEEEEEE------EEEEEEHHH 
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Ruler : .........1990.........2000.........2010.........2020.........2030.........2040 
Sequence : YTSRDRDFLRIQRSRDLNLSQLLQDTWTETPLEHCWLQAQIRRLRDYLRFPTRLEFIPLV 
Prediction: -------HHHHHH-----------------HHHHHHHHHHHHHHHH-----------EEE 
Ruler : .........2050.........2060.........2070.........2080.........2090.........2100 
Sequence : IYNAQDHTVVRVLRPPSTFEQDHSRLVLDEAFPTFPLYDQDDNTSADNVAASGAAPTPPV 
Prediction: EEE----EEEEEEE----------EEEEE-------EEE--------------------- 
Ruler : .........2110.........2120.........2130.........2140.........2150.........2160 
Sequence : PFNRVPVNIQFLRENPPPIARVQQPPRRHRHRAAAAADDDGQIDHAQDDTSRTADSALVS 
Prediction: ---------------------------------------------------HHHH----H 
Ruler : .........2170.........2180.........2190.........2200.........2210.........2220 
Sequence : TAFGGSVFQENRLGETPLCRDELVAVAPGAASTSFASPPITVLTQNVLSALEILRLVRLD 
Prediction: HHH-------------------EEEEE--------------HHHHHHHHHHHHHHHHHHH 
Ruler : .........2230.........2240. 
Sequence : LRQLAQSVQDTIQHMRFLYLL 
Prediction: HHHHHHHHHHHHHHHHHHH-- 
 
Key: H=helix; E=strand; -=coil; highlighted in yellow=amino acid 1504, where the sequence was 
divided into two halves (1-1504 and 1505-2241). 
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Appendix B | Codon Optimised Sequences 
 
Codon optimisation of UL74, US14 and US17 was performed by Dr. James Davies and Dr. 
Sepehr Seirafian (School of Medicine, Cardiff University). Sequence alignments were 
generated using the EMBOSS Stretcher bioinformatics tool [325]. 
 
B.1 Sequence alignment for canonical and codon optimised UL74 
 
UL74_Canon         1 ATGGGGAAAAAAGAGATGATAATGGTGAAAGGCATTCCTAAAATTATGCT     50 
                     |||||.||.|||||.|||||.|||||.||.|||||.||.||.||.||||| 
UL74_OPTIM         1 ATGGGCAAGAAAGAAATGATCATGGTCAAGGGCATCCCCAAGATCATGCT     50 
 
UL74_Canon        51 CCTGATCTCTATAACGTTCTTGCTCCTTTCCCTCATAAATTGTAATGTAT    100 
                     .|||||....||.||.||..||||.||.|||||.||.||.||.||.||.. 
UL74_OPTIM        51 GCTGATTAGCATCACCTTTCTGCTGCTGTCCCTGATCAACTGCAACGTGC    100 
 
UL74_Canon       101 TGGTAAACTCCAGAGGAACAAGACGTTCCTGGCCGTATACCGTGCTATCT    150 
                     ||||.|||..|.|.||.||.|||.|.||||||||.||.||||||||.||. 
UL74_OPTIM       101 TGGTCAACAGCCGGGGCACCAGAAGATCCTGGCCCTACACCGTGCTGTCC    150 
 
UL74_Canon       151 TATCGAGGTAAAGAGATTCTGAAGAAACAGAAGGAAGATATCTTAAAACG    200 
                     ||.||.||.||||||||.||||||||.|||||.||.||.|||.|.||.|| 
UL74_OPTIM       151 TACCGGGGCAAAGAGATCCTGAAGAAGCAGAAAGAGGACATCCTGAAGCG    200 
 
UL74_Canon       201 ATTGATGTCTAC-ATCATCTGACGGATACCGGTTTTTAATGTACCCCAGT    249 
                     ..|||||...|| |.||.| |||||.||||||||..|.|||||||||||. 
UL74_OPTIM       201 GCTGATGAGCACCAGCAGC-GACGGCTACCGGTTCCTGATGTACCCCAGC    249 
 
UL74_Canon       250 CAGCAAAAATTTCATGCCATCGTTATTAGCATGGATAAATTTCCTCAAGA    299 
                     |||||.|||||.||.||||||||.||.||||||||.||.||.||.||.|| 
UL74_OPTIM       250 CAGCAGAAATTCCACGCCATCGTGATCAGCATGGACAAGTTCCCCCAGGA    299 
 
UL74_Canon       300 CTACATTTTAGCGGGTCCCATTAGAAATGATAGCATTACCCATATGTGGT    349 
                     ||||||..|.||.||.|||||..|.||.||.|||||.|||||.||||||| 
UL74_OPTIM       300 CTACATCCTGGCCGGACCCATCCGGAACGACAGCATCACCCACATGTGGT    349 
 
UL74_Canon       350 TTGACTTTTACAGTACTCAACTCCGAAAACCAGCCAAGTACGTATATTCC    399 
                     |.|||||.|||||.||.||.||.||.||.||.|||||.|||||.||...| 
UL74_OPTIM       350 TCGACTTCTACAGCACCCAGCTGCGGAAGCCCGCCAAATACGTGTACAGC    399 
 
UL74_Canon       400 GAATATAATCACACGGCCCACAAAATAACGTTACGACCCCCACCTTGCGG    449 
                     ||.||.||.|||||.||||||||.||.||..|..|.||.||.|||||.|| 
UL74_OPTIM       400 GAGTACAACCACACCGCCCACAAGATCACCCTGAGGCCTCCCCCTTGTGG    449 
 
UL74_Canon       450 CACAGTGCCTTCTATGAACTGCCTATCCGAAATGTTAAATGTTTCCAAAC    499 
                     |||.|||||....|||||||||||...|||.|||.|.||.||.|||||.| 
UL74_OPTIM       450 CACCGTGCCCAGCATGAACTGCCTGAGCGAGATGCTGAACGTGTCCAAGC    499 
 
UL74_Canon       500 GCAATGATACCGGCGAAAAAGGTTGCGGTAATTTCACCACGTTTAATCCT    549 
                     |.||.||.||||||||.||.||.|||||.||.||||||||.||.||.||. 
UL74_OPTIM       500 GGAACGACACCGGCGAGAAGGGCTGCGGCAACTTCACCACCTTCAACCCC    549 
 
UL74_Canon       550 ATGTTTTTCAACGTACCACGTTGGAACACAAAACTGTACATAGGTTCCAA    599 
                     |||||.||||||||.||.||.||||||||.||.||||||||.||...||| 
UL74_OPTIM       550 ATGTTCTTCAACGTGCCCCGGTGGAACACCAAGCTGTACATCGGCAGCAA    599 
 
UL74_Canon       600 CAAAGTCAACGTGGATAGTCAGACAATCTACTTTTTGGGCCTAACCGCCC    649 
                     ||||||.||||||||.||.|||||.|||||||||.|||||||.||||||| 
UL74_OPTIM       600 CAAAGTGAACGTGGACAGCCAGACCATCTACTTTCTGGGCCTGACCGCCC    649 
 
UL74_Canon       650 TACTTTTACGATACGCGCAACGTAACTGCACTCGCAGTTTCTACCTGGTT    699 
                     |.||..|..|||||||.||.||.||||||||.||....|||||||||||. 
UL74_OPTIM       650 TGCTGCTGAGATACGCCCAGCGGAACTGCACCCGGTCCTTCTACCTGGTC    699 
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UL74_Canon       700 AACGCCATGAGCCGAAATTTATTCCGCGTTCCCAAGTATATTAACGGCAC    749 
                     ||||||||||||||.||..|.|||||.||.||||||||.||.|||||||| 
UL74_OPTIM       700 AACGCCATGAGCCGGAACCTGTTCCGGGTGCCCAAGTACATCAACGGCAC    749 
 
UL74_Canon       750 CAAGTTGAAAAACACTATGCGAAAACTCAAACGTAAACAAGCGCTTGTCA    799 
                     ||||.||||.|||||.|||||.||.||.||.||.||.||.||.||.|||| 
UL74_OPTIM       750 CAAGCTGAAGAACACCATGCGGAAGCTGAAGCGGAAGCAGGCCCTGGTCA    799 
 
UL74_Canon       800 AAGAACAACCACAAAAAAAGAATAAGAAATCTCAAAGTACTACTACGCCA    849 
                     ||||.||.||.||.||.|||||.|||||.||.||.||.||.||.||.||. 
UL74_OPTIM       800 AAGAGCAGCCCCAGAAGAAGAACAAGAAGTCCCAGAGCACCACCACCCCC    849 
 
UL74_Canon       850 TATCTTTCCTATACAACGTCTACCGCTTTCAACGTCACCACTAACGTGAC    899 
                     ||.||...|||.||.||.||.|||||.||||||||.|||||.|||||||| 
UL74_OPTIM       850 TACCTGAGCTACACCACCTCCACCGCCTTCAACGTGACCACCAACGTGAC    899 
 
UL74_Canon       900 TTATAGTGCTACCGCTGCTGTAACGCGGGTTGCCACATCTACGACAGGTT    949 
                     .||.||.||.||.||.||.||.||..|.||.||||||...||.||.||.| 
UL74_OPTIM       900 CTACAGCGCCACAGCCGCCGTGACCAGAGTGGCCACAAGCACCACCGGCT    949 
 
UL74_Canon       950 ATCGTCCTGATAGTAACTTTATGAAATCCATTATGGCCACGCAGTTAAGA    999 
                     |.||.||.||.||.|||||||||||.|||||.||||||||.|||.|.||| 
UL74_OPTIM       950 ACCGGCCCGACAGCAACTTTATGAAGTCCATCATGGCCACCCAGCTGAGA    999 
 
UL74_Canon      1000 GATCTCGCAACATGGGTATATACTACTCTGCGGTATCGGAATGAACCCTT   1049 
                     |||||.||.||.|||||.||.||.||.||||||||..|.||.||.||||| 
UL74_OPTIM      1000 GATCTGGCCACCTGGGTGTACACCACCCTGCGGTACAGAAACGAGCCCTT   1049 
 
UL74_Canon      1050 TTGTAAACCAGACCGTAACCGTACCGCCGTGTCAGAATTTATGAAAAACA   1099 
                     .||.||.||.|||||.|||.|.|||||||||...||.||.|||||.||.| 
UL74_OPTIM      1050 CTGCAAGCCCGACCGGAACAGAACCGCCGTGAGCGAGTTCATGAAGAATA   1099 
 
UL74_Canon      1100 CGCACGTACTGATTCGTAACGAAACGCCGTACACTATTTATGGCACTCTT   1149 
                     |.|||||.|||||..|.|||||.||.||.|||||.||.||.|||||.||. 
UL74_OPTIM      1100 CCCACGTGCTGATCAGAAACGAGACACCCTACACCATCTACGGCACCCTG   1149 
 
UL74_Canon      1150 GACATGAGCTCCTTATATTACAACGAAACCATGTCCGTGGAAAACGAAAC   1199 
                     |||||||||..|.|.||.||||||||.||.|||..||||||.|||||.|| 
UL74_OPTIM      1150 GACATGAGCAGCCTGTACTACAACGAGACAATGAGCGTGGAGAACGAGAC   1199 
 
UL74_Canon      1200 GGCTTCCGATAATAACGAAACTACACCTACGTCACCATCGACGAGGTTTC   1249 
                     .||...|||.||.||||||||.||.||.||.||.||....||..||||.| 
UL74_OPTIM      1200 AGCCAGCGACAACAACGAAACCACCCCCACCTCCCCCAGCACCCGGTTCC   1249 
 
UL74_Canon      1250 AGAGAACGTTCATAGATCCCCTATGGGACTATCTAGACTCGCTGCTGTTT   1299 
                     ||.|.||.|||||.||.|||||.||||||||.||.|||...||||||||. 
UL74_OPTIM      1250 AGCGGACCTTCATCGACCCCCTGTGGGACTACCTGGACAGCCTGCTGTTC   1299 
 
UL74_Canon      1300 CTAGATAAAATCCGTAACTTTAGCCTCCAGTTACCCGCGTATGGAAATCT   1349 
                     ||.||.||.|||||.|||||.|||||.|||.|.|||||.||.||.||||| 
UL74_OPTIM      1300 CTGGACAAGATCCGGAACTTCAGCCTGCAGCTGCCCGCCTACGGCAATCT   1349 
 
UL74_Canon      1350 TACCCCGCCGGAACACCGCCGGGCTGCAAATCTATCCACCCTCAATAGCC   1399 
                     .|||||.||.||.|||.|..||||.||.||.||...||||||.||.|||| 
UL74_OPTIM      1350 GACCCCCCCTGAGCACAGAAGGGCCGCCAACCTGAGCACCCTGAACAGCC   1399 
 
UL74_Canon      1400 TTTGGTGGTGGTCGCAG   1416 
                     |.|||||||||...|||    
UL74_OPTIM      1400 TGTGGTGGTGGAGCCAG   1416 
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B.2 Sequence alignment for canonical and codon optimised US14 
 
 
US14_Canon         1 ATGGAGACAGTTTCCACGCAGCGGGAAACCGCGTCGTCGGAAACGGAGCG     50 
                     ||||||||.||...|||.|||.|.||||||||.||.||.||.||.||..| 
US14_OPTIM         1 ATGGAGACCGTCAGCACCCAGAGAGAAACCGCCTCATCCGAGACAGAAAG     50 
 
US14_Canon        51 TACCAGGGAAGCCGCGTCCGCGGAAACGACGGACGCTACTTTCCGATCCT    100 
                     .||.||.||||||||.||.||.||.||.||.|||||.||.||||||||.. 
US14_OPTIM        51 GACAAGAGAAGCCGCCTCAGCCGAGACTACCGACGCCACATTCCGATCAC    100 
 
US14_Canon       101 TGGAAGAGGGAAGCACGATCTCCTCCCGGTATTCGGAAACAGCGTCCACA    150 
                     ||||.||.||.|||||.|||..|||||||||.||.||.||.||....||. 
US14_OPTIM       101 TGGAGGAAGGCAGCACCATCAGCTCCCGGTACTCTGAGACTGCAAGTACC    150 
 
US14_Canon       151 GCTTCCGAAGATGCGGTGTGTTGGCTACGTCGGACCGCGATCGTCATGCG    200 
                     ||.||.||||||||.|||||.|||||.||..|.||.||.||||||||||| 
US14_OPTIM       151 GCCTCAGAAGATGCCGTGTGCTGGCTGCGGAGAACAGCAATCGTCATGCG    200 
 
US14_Canon       201 TGTCTACGGATTGCTGACGCTGGAAACCGCTTTCAGCGTACTCATTAGCG    250 
                     .||.||.||..|||||||.|||||.||.||.||||||||.||.||.|||| 
US14_OPTIM       201 GGTGTATGGGCTGCTGACACTGGAGACTGCCTTCAGCGTGCTGATCAGCG    250 
 
US14_Canon       251 CGCTGGTTTGGCTGGGTTACCCCTCACTGGGCTACGAGTGCCGCGACGAT    300 
                     |.|||||.||||||||.||||||...|||||.||.||.|||.|.|||||| 
US14_OPTIM       251 CCCTGGTGTGGCTGGGCTACCCCAGTCTGGGGTATGAATGCAGGGACGAT    300 
 
US14_Canon       301 CCCTCGCCGCTATTGCTTAGCTGCACACCGGTGTTGGTTCTGGGCGCGCT    350 
                     |||||.||.||..||||....||.||.||.|||.||||.|||||.||.|| 
US14_OPTIM       301 CCCTCCCCTCTGCTGCTGTCTTGTACTCCAGTGCTGGTCCTGGGGGCCCT    350 
 
US14_Canon       351 GGAGCTCACCGACCACAGACACCCCAGCAACGGCCTGGTGTTTGCACTGT    400 
                     ||||||.|||||||||.|.||.|||||||||||.|||||.||.||.|||| 
US14_OPTIM       351 GGAGCTGACCGACCACCGGCATCCCAGCAACGGACTGGTCTTCGCTCTGT    400 
 
US14_Canon       401 ATGTGGCGCTTCTCTCGTTCACCACCGCCGGGCTCAACCTGTGCGCCACA    450 
                     |.|||||.||.||.||.||.|||||.||.||.||.||.|||||||||||. 
US14_OPTIM       401 ACGTGGCACTGCTGTCCTTTACCACAGCTGGACTGAATCTGTGCGCCACC    450 
 
US14_Canon       451 GCGCCCATCGGCGTTTCCAGCCTCATCCTAACGTGGACGTTGTTCGTGGC    500 
                     ||.||.||||||||.||.||.||.||.||.||.|||||..|||||||.|| 
US14_OPTIM       451 GCTCCTATCGGCGTGTCTAGTCTGATTCTGACATGGACTCTGTTCGTCGC    500 
 
US14_Canon       501 CTGCAACGGCGTGGCTTGGGAACACCGCCTCAGCTCTGTGTGGCGTGACG    550 
                     |||.|||||.|||||||||||||||.|.||.......||||||||.|||| 
US14_OPTIM       501 CTGTAACGGAGTGGCTTGGGAACACAGGCTGTCAAGCGTGTGGCGCGACG    550 
 
US14_Canon       551 CGCTTTTCACCTCCACACTTTTGACGGTGATGGTCAGCGTCCTGGCTTCT    600 
                     |.||.||.|||..||||||..||||.|||||||||...||.|||||...| 
US14_OPTIM       551 CTCTGTTTACCAGCACACTGCTGACCGTGATGGTCTCTGTGCTGGCAAGT    600 
 
US14_Canon       601 ACTTACACCTGGTTGCATAAGACTCTGCTGTGTCTCTACACCGTGTTCGT    650 
                     ||||||||||||.||||||||||.||||||||.||.||.||.||.||||| 
US14_OPTIM       601 ACTTACACCTGGCTGCATAAGACCCTGCTGTGCCTGTATACAGTCTTCGT    650 
 
US14_Canon       651 GGGCTGCATCCTGGCCGTCCTTTTCCAAGACGTGCGCTACATCGCCACCA    700 
                     ||||||.||||||||||||||.||.||.||.|||.|.|||||.||.||.| 
US14_OPTIM       651 GGGCTGTATCCTGGCCGTCCTGTTTCAGGATGTGAGATACATTGCTACAA    700 
 
US14_Canon       701 AAATGCCCGTGAGCCACATCATCCGCAGCTCGCTGGTACTTTACGCCACC    750 
                     ||||||||||||||||||||||..|...|||.|||||.||.||||||||. 
US14_OPTIM       701 AAATGCCCGTGAGCCACATCATTAGGTCCTCTCTGGTGCTGTACGCCACA    750 
 
US14_Canon       751 GAGACACTCATCTATCACACCACACTCCTGATGCTCACGCCCGTGGTGTG    800 
                     |||||.||.|||||.||.||.||.||.||||||||.||.||.|||||.|| 
US14_OPTIM       751 GAGACTCTGATCTACCATACTACCCTGCTGATGCTGACACCAGTGGTCTG    800 
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US14_Canon       801 GTCGGCACGCTGGGACCAAATGTTCAGCTACCTGGCCAAGCTGGGCACCT    850 
                     |...||||||||||||||.||||||...||.||||||||||||||.||.| 
US14_OPTIM       801 GAGTGCACGCTGGGACCAGATGTTCTCATATCTGGCCAAGCTGGGGACTT    850 
 
US14_Canon       851 ATCATCATTACCGGGTTGACAACGGCACGCTCAGCGTCATCCTCAACAGC    900 
                     |.||.|||||.||.||.||.||||||||.||....|||||.||.|||..| 
US14_OPTIM       851 ACCACCATTATCGAGTGGATAACGGCACTCTGTCAGTCATTCTGAACTCC    900 
 
US14_Canon       901 ACCACCGCGACGTTCCAGAGCAGGGTTGCT    930 
                     ||.|||||.||.||||||....||||.||. 
US14_OPTIM       901 ACAACCGCCACTTTCCAGTCACGGGTCGCA    930 
 
 
B.3 Sequence alignment for canonical and codon optimised US17 
 
US17_Canon         1 ATGTCTCCGAACTCAGAGGCCACCGGGACGGCCTGGGCGCCCCCACCCCC     50 
                     |||...||.||.|||||.||.|||||.||.||||||||.||.||.||||| 
US17_OPTIM         1 ATGAGCCCCAATTCAGAAGCAACCGGCACCGCCTGGGCACCACCCCCCCC     50 
 
US17_Canon        51 GCGACCCTCGCGCGGAGTCATTATGATTTCCTCCGTCTCGACGAACGACG    100 
                     .|||||.....|.|||||.|||||||||..||||||.||.||.||||||| 
US17_OPTIM        51 CCGACCTAGCAGAGGAGTGATTATGATTAGCTCCGTGTCAACAAACGACG    100 
 
US17_Canon       101 TACGTCGCTTTTTACTTTGTATGCGGGTCTACAGCACCGTGGCCGTGCAG    150 
                     |.||.||.||..|.||.||.||||||||.||||||||.|||||.||.||| 
US17_OPTIM       101 TGCGGCGGTTCCTGCTGTGCATGCGGGTGTACAGCACTGTGGCAGTCCAG    150 
 
US17_Canon       151 GGCACCTGCACCTTCTTGCTCTGTCTGGGCCTGGTGCTGGCTTTTCCGCA    200 
                     ||.||||||||.|||.||||.||.|||||||||||||||||||||||.|| 
US17_OPTIM       151 GGAACCTGCACATTCCTGCTGTGCCTGGGCCTGGTGCTGGCTTTTCCCCA    200 
 
US17_Canon       201 TCTTAAAGGCACCGTCTTTCTCTGTTGCACCGGCTTTATGCCGCCCTTGA    250 
                     .||.||.|||||||||||.||.||.||.||.||.||||||||.||..||| 
US17_OPTIM       201 CCTGAAGGGCACCGTCTTCCTGTGCTGTACAGGGTTTATGCCCCCTCTGA    250 
 
US17_Canon       251 GTTTGATGGTGCCCACCATCTGTTTGGCCCTGCTGCACGGCAAACGCGAT    300 
                     |..||||||||||.|||||||||.|||||||||||||.||.|||||.||| 
US17_OPTIM       251 GCCTGATGGTGCCTACCATCTGTCTGGCCCTGCTGCATGGAAAACGGGAT    300 
 
US17_Canon       301 GAAGGATCGTTCACGTCGCCGCCGAGCCCGGGCCTGCTCACCATTTATAG    350 
                     ||.||.||.||.||....||.||....||.||.|||||.|||||.||||| 
US17_OPTIM       301 GAGGGCTCTTTTACTAGTCCACCCTCACCCGGGCTGCTGACCATCTATAG    350 
 
US17_Canon       351 CGTGCTCACGACGCTTTCGGTGATCGTGGCCAGCGCCTGCTCCTCCTCTA    400 
                     .|||||.||.||.||.||.|||||.||.||.||.||||||||....||.| 
US17_OPTIM       351 TGTGCTGACCACACTGTCTGTGATTGTCGCAAGTGCCTGCTCTAGTTCAA    400 
 
US17_Canon       401 CGCTGGTGACCTTCTCGGGCCTCTTGGCTTGCGTGCTTTTTAGCCTCTGC    450 
                     |.||||||||||||...||.||..||||.||||||||.||.|||||.||| 
US17_OPTIM       401 CTCTGGTGACCTTCAGCGGACTGCTGGCCTGCGTGCTGTTCAGCCTGTGC    450 
 
US17_Canon       451 AGCTGCGTCACGGGTCTAGCCGGCCATAATCACCGTCGATGGCAGGTCAT    500 
                     ..||||||.||.||.||.||.||.||.|||||..|.||.||||||||||| 
US17_OPTIM       451 TCCTGCGTGACCGGACTGGCTGGGCACAATCATAGGCGCTGGCAGGTCAT    500 
 
US17_Canon       501 CGTCACGCTGTTTGTGATCGGCGTTATCGCGTTCTTGATCGCACTTTACC    550 
                     ||||||.|||||.|||||||||||.||.||.||..||||.||.||.|||| 
US17_OPTIM       501 CGTCACACTGTTCGTGATCGGCGTCATTGCATTTCTGATTGCCCTGTACC    550 
 
US17_Canon       551 TGCAGCCCGTACCGTTGGGGCACAAACTTTTTTTGGGCTATTACGCCATG    600 
                     |||||||.||.||..||||||||||.||.||..||||.||.||.||.||| 
US17_OPTIM       551 TGCAGCCTGTGCCACTGGGGCACAAGCTGTTCCTGGGATACTATGCTATG    600 
 
US17_Canon       601 GCGCTCAGCTTCATGCTGGTCGTCACGGTCTTTGACACCACGCGCCTGTT    650 
                     ||.||...|||.||||||||.|||||.||.||.|||||.||.||.||||| 
US17_OPTIM       601 GCACTGTCCTTTATGCTGGTGGTCACCGTGTTCGACACTACCCGACTGTT    650 
236 
 
 
US17_Canon       651 TGAGATCGCGTGGTCCGAGGCCGACCTGCTCACCTTGTGTCTCTATGAGA    700 
                     |||||||||.|||||.||.|||||||||||.||..||||.||.||||||| 
US17_OPTIM       651 TGAGATCGCTTGGTCTGAAGCCGACCTGCTGACACTGTGCCTGTATGAGA    700 
 
US17_Canon       701 ACCTGGTGTACCTGTACCTGCTCATTCTCATCCTTTTCACCACCGAGGAC    750 
                     ||||||||||||||||.|||||.||.||.||.||.|||||.||.||.||| 
US17_OPTIM       701 ACCTGGTGTACCTGTATCTGCTGATCCTGATTCTGTTCACAACTGAAGAC    750 
 
US17_Canon       751 TCATTAGACAAACTCATCGCTTGGATGACCTGGTTATCGTCACGCGCCAC    800 
                     ||..|.||.|||||.||.||.||||||||||||.|....||..|.||||| 
US17_OPTIM       751 TCCCTGGATAAACTGATTGCCTGGATGACCTGGCTGAGCTCCAGAGCCAC    800 
 
US17_Canon       801 CGGGGCCACCAACGCGGCCTCCATTTCGGGCTGTGACCTTTTGCGGGAGG    850 
                     .|||||.||.||.||.||...|||.||.|||||.|||||..||||.||.| 
US17_OPTIM       801 AGGGGCTACTAATGCCGCTAGCATCTCCGGCTGCGACCTGCTGCGCGAAG    850 
 
US17_Canon       851 TACAGAGAAACCTCACGCGAACCATGGCG    879 
                     |.|||||.|||||.||.|||||.|||||. 
US17_OPTIM       851 TCCAGAGGAACCTGACACGAACTATGGCA    879 
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Appendix C | Correlation of peptide quantification 
between replicate samples and controls 
 
Data underlying the graphs in Figure 5.1.2, depicting the correlation of the number of total, 
unique and bait peptides from each protein identified in the technical replicates. Peptide 
numbers were obtained from the ‘Summary Plots’ function provided within “MassPike”, the 
Sequest-based software pipeline for quantitative proteomics (described in 2.11.1)  
 
C.1 Replicate samples for viral baits 
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(Continued) 
  
0
5000
10000
15000
20000
25000
R
L1
0
R
L1
0
TR
S1
TR
S1
U
L1
1
7
U
L1
17
U
L1
4
U
L1
4
U
L1
4
4
U
L1
4
4
U
L1
50
U
L1
5
0
U
L2
7
U
L2
7
U
L3
5
U
L3
5
U
L4
5
U
L4
5
U
L4
9
U
L4
9
U
L6
9
U
L6
9
U
L7
0
U
L7
0
U
L7
5
U
L7
5
U
L8
3
U
L8
3
U
L8
5
U
L8
5
U
L9
8
U
L9
8
U
L9
9
U
L9
9
U
S
2
4
U
S
2
4
U
S
2
6
U
S
2
6
U
S
3
1
U
S
3
1
0
2000
4000
6000
8000
10000
12000
14000
16000
R
L1
0
R
L1
0
TR
S1
TR
S1
U
L1
1
7
U
L1
1
7
U
L1
4
U
L1
4
U
L1
4
4
U
L1
4
4
U
L1
5
0
U
L1
5
0
U
L2
7
U
L2
7
U
L3
5
U
L3
5
U
L4
5
U
L4
5
U
L4
9
U
L4
9
U
L6
9
U
L6
9
U
L7
0
U
L7
0
U
L7
5
U
L7
5
U
L8
3
U
L8
3
U
L8
5
U
L8
5
U
L9
8
U
L9
8
U
L9
9
U
L9
9
U
S2
4
U
S2
4
U
S2
6
U
S2
6
U
S3
1
U
S3
1
0
100
200
300
400
500
600
700
800
900
R
L1
0
R
L1
0
TR
S1
TR
S1
U
L1
1
7
U
L1
1
7
U
L1
4
U
L1
4
U
L1
4
4
U
L1
4
4
U
L1
5
0
U
L1
5
0
U
L2
7
U
L2
7
U
L3
5
U
L3
5
U
L4
5
U
L4
5
U
L4
9
U
L4
9
U
L6
9
U
L6
9
U
L7
0
U
L7
0
U
L7
5
U
L7
5
U
L8
3
U
L8
3
U
L8
5
U
L8
5
U
L9
8
U
L9
8
U
L9
9
U
L9
9
U
S2
4
U
S2
4
U
S2
6
U
S2
6
U
S3
1
U
S3
1
B
ai
t 
p
e
p
ti
d
e
s
To
ta
l p
e
p
ti
d
e
s
U
n
iq
u
e
 p
e
p
ti
d
e
s
240 
 
 
(Continued) 
  
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
R
L1
1
R
L1
1
U
L1
11
A
U
L1
1
1
A
U
L1
1
6
U
L1
16
U
L1
47
U
L1
4
7
U
L3
4
U
L3
4
U
L3
8
U
L3
8
U
L4
3
U
L4
3
U
L5
3
U
L5
3
U
L7
U
L7
U
L7
1
U
L7
1
U
L7
3
U
L7
3
U
L7
6
U
L7
6
U
L7
9
U
L7
9
U
L8
7
U
L8
7
U
L8
9
U
L8
9
U
L9
3
U
L9
3
U
L9
7
U
L9
7
U
S2
3
U
S2
3
U
S3
2
U
S3
2
U
S3
4
U
S3
4
0
2000
4000
6000
8000
10000
12000
14000
R
L1
1
R
L1
1
U
L1
1
1
A
U
L1
1
1
A
U
L1
1
6
U
L1
1
6
U
L1
47
U
L1
47
U
L3
4
U
L3
4
U
L3
8
U
L3
8
U
L4
3
U
L4
3
U
L5
3
U
L5
3
U
L7
U
L7
U
L7
1
U
L7
1
U
L7
3
U
L7
3
U
L7
6
U
L7
6
U
L7
9
U
L7
9
U
L8
7
U
L8
7
U
L8
9
U
L8
9
U
L9
3
U
L9
3
U
L9
7
U
L9
7
U
S
2
3
U
S
2
3
U
S
3
2
U
S
3
2
U
S
3
4
U
S
3
4
0
200
400
600
800
1000
1200
R
L1
1
R
L1
1
U
L1
1
1
A
U
L1
1
1
A
U
L1
16
U
L1
1
6
U
L1
47
U
L1
4
7
U
L3
4
U
L3
4
U
L3
8
U
L3
8
U
L4
3
U
L4
3
U
L5
3
U
L5
3
U
L7
U
L7
U
L7
1
U
L7
1
U
L7
3
U
L7
3
U
L7
6
U
L7
6
U
L7
9
U
L7
9
U
L8
7
U
L8
7
U
L8
9
U
L8
9
U
L9
3
U
L9
3
U
L9
7
U
L9
7
U
S2
3
U
S2
3
U
S3
2
U
S3
2
U
S3
4
U
S3
4
B
ai
t 
p
e
p
ti
d
e
s
To
ta
l p
e
p
ti
d
e
s
U
n
iq
u
e
 p
e
p
ti
d
e
s
241 
 
 
(Continued) 
  
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
R
L1
R
L1
R
L1
3
R
L1
3
R
L5
A
R
L5
A
U
L1
03
U
L1
0
3
U
L1
3
8
U
L1
3
8
U
L1
41
U
L1
4
1
U
L1
5
A
U
L1
5
A
U
L1
8
U
L1
8
U
L2
3
U
L2
3
U
L2
9
U
L2
9
U
L4
2
U
L4
2
U
L5
U
L5
U
L5
2
U
L5
2
U
L7
2
U
L7
2
U
L7
4
U
L7
4
U
L7
4A
U
L7
4A
U
S
1
0
U
S
1
0
U
S
1
1
U
S
1
1
U
S2
U
S2
U
S
2
2
U
S
2
2
0
2000
4000
6000
8000
10000
12000
R
L1
R
L1
R
L1
3
R
L1
3
R
L5
A
R
L5
A
U
L1
0
3
U
L1
0
3
U
L1
3
8
U
L1
3
8
U
L1
4
1
U
L1
4
1
U
L1
5
A
U
L1
5
A
U
L1
8
U
L1
8
U
L2
3
U
L2
3
U
L2
9
U
L2
9
U
L4
2
U
L4
2
U
L5
U
L5
U
L5
2
U
L5
2
U
L7
2
U
L7
2
U
L7
4
U
L7
4
U
L7
4
A
U
L7
4A
U
S1
0
U
S1
0
U
S1
1
U
S1
1
U
S2
U
S2
U
S2
2
U
S2
2
0
200
400
600
800
1000
1200
1400
1600
R
L1
R
L1
R
L1
3
R
L1
3
R
L5
A
R
L5
A
U
L1
0
3
U
L1
0
3
U
L1
3
8
U
L1
3
8
U
L1
4
1
U
L1
4
1
U
L1
5
A
U
L1
5
A
U
L1
8
U
L1
8
U
L2
3
U
L2
3
U
L2
9
U
L2
9
U
L4
2
U
L4
2
U
L5
U
L5
U
L5
2
U
L5
2
U
L7
2
U
L7
2
U
L7
4
U
L7
4
U
L7
4
A
U
L7
4
A
U
S1
0
U
S1
0
U
S1
1
U
S1
1
U
S2
U
S2
U
S2
2
U
S2
2
B
ai
t 
p
e
p
ti
d
e
s
To
ta
l p
e
p
ti
d
e
s
U
n
iq
u
e
 p
e
p
ti
d
e
s
242 
 
 
(Continued) 
  
0
2000
4000
6000
8000
10000
12000
14000
16000
U
L1
0
U
L1
0
U
L1
1
5
U
L1
1
5
U
L1
1
9
U
L1
1
9
U
L1
2
0
U
L1
2
0
U
L1
2
4
U
L1
2
4
U
L1
3
9
U
L1
3
9
U
L1
4
2
U
L1
4
2
U
L1
47
A
U
L1
4
7
A
U
L1
4
8
U
L1
4
8
U
L1
48
A
U
L1
4
8
A
U
L1
4
8
B
U
L1
4
8
B
U
L1
6
U
L1
6
U
L2
5
U
L2
5
U
L3
0
A
U
L3
0A
U
L3
6
U
L3
6
U
L4
1
A
U
L4
1
A
U
L8
0
U
L8
0
U
L8
2
U
L8
2
U
L9
2
U
L9
2
U
L9
6
U
L9
6
0
2000
4000
6000
8000
10000
12000
U
L1
0
U
L1
0
U
L1
1
5
U
L1
15
U
L1
1
9
U
L1
19
U
L1
2
0
U
L1
20
U
L1
2
4
U
L1
24
U
L1
3
9
U
L1
3
9
U
L1
42
U
L1
4
2
U
L1
47
A
U
L1
4
7
A
U
L1
48
U
L1
4
8
U
L1
48
A
U
L1
4
8
A
U
L1
4
8
B
U
L1
48
B
U
L1
6
U
L1
6
U
L2
5
U
L2
5
U
L3
0
A
U
L3
0A
U
L3
6
U
L3
6
U
L4
1A
U
L4
1
A
U
L8
0
U
L8
0
U
L8
2
U
L8
2
U
L9
2
U
L9
2
U
L9
6
U
L9
6
0
200
400
600
800
1000
1200
U
L1
0
U
L1
0
U
L1
15
U
L1
15
U
L1
1
9
U
L1
1
9
U
L1
2
0
U
L1
20
U
L1
24
U
L1
2
4
U
L1
3
9
U
L1
3
9
U
L1
42
U
L1
42
U
L1
47
A
U
L1
4
7
A
U
L1
4
8
U
L1
48
U
L1
48
A
U
L1
48
A
U
L1
4
8
B
U
L1
4
8
B
U
L1
6
U
L1
6
U
L2
5
U
L2
5
U
L3
0
A
U
L3
0
A
U
L3
6
U
L3
6
U
L4
1
A
U
L4
1
A
U
L8
0
U
L8
0
U
L8
2
U
L8
2
U
L9
2
U
L9
2
U
L9
6
U
L9
6
B
ai
t 
p
e
p
ti
d
e
s
To
ta
l p
e
p
ti
d
e
s
U
n
iq
u
e
 p
e
p
ti
d
e
s
243 
 
 
(Continued) 
  
0
5000
10000
15000
20000
25000
0
2000
4000
6000
8000
10000
12000
14000
16000
0
20
40
60
80
100
120
140
160
180
B
ai
t 
p
e
p
ti
d
e
s
To
ta
l p
e
p
ti
d
e
s
U
n
iq
u
e
 p
e
p
ti
d
e
s
244 
 
 
(Continued) 
  
0
5000
10000
15000
20000
25000
O
R
FL
1
47
C
O
R
FL
1
47
C
R
L1
2
R
L1
2
R
L6
R
L6
R
L8
A
R
L8
A
U
L1
0
5
U
L1
05
U
L1
1
U
L1
1
U
L1
3
2
U
L1
32
U
L1
50
A
U
L1
5
0
A
U
L1
9
U
L1
9
U
L2
0
U
L2
0
U
L2
1
A
U
L2
1
A
U
L3
0
U
L3
0
U
L3
2
U
L3
2
U
L4
7
U
L4
7
U
L5
5
U
L5
5
U
L5
6
U
L5
6
U
L5
7
U
L5
7
U
L8
0.
5
U
L8
0.
5
U
L8
6
U
L8
6
U
L9
U
L9
U
S
3
3
A
U
S
3
3
A
U
S
9
U
S
9
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
O
R
FL
1
47
C
O
R
FL
1
47
C
R
L1
2
R
L1
2
R
L6
R
L6
R
L8
A
R
L8
A
U
L1
05
U
L1
05
U
L1
1
U
L1
1
U
L1
3
2
U
L1
32
U
L1
5
0
A
U
L1
5
0
A
U
L1
9
U
L1
9
U
L2
0
U
L2
0
U
L2
1
A
U
L2
1A
U
L3
0
U
L3
0
U
L3
2
U
L3
2
U
L4
7
U
L4
7
U
L5
5
U
L5
5
U
L5
6
U
L5
6
U
L5
7
U
L5
7
U
L8
0.
5
U
L8
0.
5
U
L8
6
U
L8
6
U
L9
U
L9
U
S3
3
A
U
S3
3
A
U
S9
U
S9
0
100
200
300
400
500
600
700
800
900
1000
O
R
FL
1
47
C
O
R
FL
1
4
7
C
R
L1
2
R
L1
2
R
L6
R
L6
R
L8
A
R
L8
A
U
L1
0
5
U
L1
05
U
L1
1
U
L1
1
U
L1
3
2
U
L1
32
U
L1
5
0
A
U
L1
50
A
U
L1
9
U
L1
9
U
L2
0
U
L2
0
U
L2
1A
U
L2
1
A
U
L3
0
U
L3
0
U
L3
2
U
L3
2
U
L4
7
U
L4
7
U
L5
5
U
L5
5
U
L5
6
U
L5
6
U
L5
7
U
L5
7
U
L8
0
.5
U
L8
0.
5
U
L8
6
U
L8
6
U
L9
U
L9
U
S3
3A
U
S3
3
A
U
S9
U
S9
B
ai
t 
p
e
p
ti
d
e
s
To
ta
l p
e
p
ti
d
e
s
U
n
iq
u
e
 p
e
p
ti
d
e
s
245 
 
 
(Continued) 
  
0
5000
10000
15000
20000
25000
U
L1
00
U
L1
00
U
L1
3
3
U
L1
3
3
U
L1
4
8
C
U
L1
4
8
C
U
L3
3
U
L3
3
U
L7
8
U
L7
8
U
L8
U
L8
U
S1
2
U
S1
2
U
S1
3
U
S1
3
U
S1
4
U
S1
4
U
S1
5
U
S1
5
U
S1
6
U
S1
6
U
S1
7
U
S1
7
U
S1
8
U
S1
8
U
S1
9
U
S1
9
U
S2
0
U
S2
0
U
S2
1
U
S2
1
U
S2
7
U
S2
7
U
S2
8
U
S2
8
U
S2
9
U
S2
9
0
2000
4000
6000
8000
10000
12000
14000
16000
U
L1
0
0
U
L1
0
0
U
L1
3
3
U
L1
3
3
U
L1
4
8
C
U
L1
4
8
C
U
L3
3
U
L3
3
U
L7
8
U
L7
8
U
L8
U
L8
U
S
1
2
U
S
1
2
U
S
1
3
U
S
1
3
U
S
1
4
U
S
1
4
U
S
1
5
U
S
1
5
U
S
1
6
U
S
1
6
U
S
1
7
U
S
1
7
U
S
1
8
U
S
1
8
U
S
1
9
U
S
1
9
U
S
2
0
U
S
2
0
U
S
2
1
U
S
2
1
U
S
2
7
U
S
2
7
U
S
2
8
U
S
2
8
U
S
2
9
U
S
2
9
0
10
20
30
40
50
60
U
L1
0
0
U
L1
0
0
U
L1
3
3
U
L1
3
3
U
L1
48
C
U
L1
48
C
U
L3
3
U
L3
3
U
L7
8
U
L7
8
U
L8
U
L8
U
S1
2
U
S1
2
U
S1
3
U
S1
3
U
S1
4
U
S1
4
U
S1
5
U
S1
5
U
S1
6
U
S1
6
U
S1
7
U
S1
7
U
S1
8
U
S1
8
U
S1
9
U
S1
9
U
S2
0
U
S2
0
U
S2
1
U
S2
1
U
S2
7
U
S2
7
U
S2
8
U
S2
8
U
S2
9
U
S2
9
B
ai
t 
p
e
p
ti
d
e
s
To
ta
l p
e
p
ti
d
e
s
U
n
iq
u
e
 p
e
p
ti
d
e
s
246 
 
 
(Continued) 
 
 
 
 
 
 
 
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
0
2000
4000
6000
8000
10000
12000
0
100
200
300
400
500
600
700
B
ai
t 
p
e
p
ti
d
e
s
To
ta
l p
e
p
ti
d
e
s
U
n
iq
u
e
 p
e
p
ti
d
e
s
247 
 
C.2 Control samples 
 
Correlation of the number of total and unique peptides from each protein identified in the 
uninfected UL123 control samples (A1-A23) used to assess instrument performance 
(detailed in Table 5.1), and the technical replicates (A and B) and biological duplicates (A1, 
A2) for ‘No bait’ and GFP controls. 
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Appendix D | Annotated interactions in curated databases 
 
Data underlying the analysis on the overlap between HCMV interactome HCIPs and annotated interactions on Uniprot, Virus Mentha, BioGRID, 
IntAct and MINT, depicted in Figure 5.3.20. 
 
Bait Prey Databases 
Detection 
Method PubMed ID 
Identified in cells 
infected with HCMV Cell type 
Validated by 
interactome 
UL115 UL74 UNIPROT IP 28403202 No HFF Yes 
UL74 UL115 UNIPROT IP 28403202 No HFF Yes 
UL73 UL100 UNIPROT IP 11090188 No 293T Yes 
UL48A UL86 UNIPROT IP 12552013 No SF9 Yes 
UL86 UL48A UNIPROT IP 12552013 No SF9 Yes 
UL70 UL102 UNIPROT, MINT, INTACT, VM IP 12076828 No BHK-21 Yes 
UL75 UL115 UNIPROT IP 17942555 Yes HDF Yes 
UL115 UL75 UNIPROT IP 17942555 Yes HDF Yes 
UL99 UL94 UNIPROT Y2H 19345970 No AH109 Yes 
UL94 UL99 UNIPROT Y2H 19345970 No AH109 Yes 
UL51 UL56 UNIPROT IP 23175377 Yes HFF Yes 
UL56 UL51 UNIPROT IP 23175377 Yes HFF Yes 
UL70 UL105 UNIPROT, MINT, INTACT, VM IP 12076828 No BHK-21 Yes 
UL47 UL48 UNIPROT IP 24829352 Yes HFF Yes 
UL50 UL53 UNIPROT IP 24155370 Yes HFF Yes 
UL29 UL38 UNIPROT IP 23236067 No U2OS Yes 
UL44 UL114 UNIPROT IP 16022730, 18599070  Yes Primary HFF, HE Yes 
UL75 UL55 UNIPROT IP 27082872 Yes HFF Yes 
UL35 UL82 UNIPROT IP 15308743 Yes HFF Yes 
UL82 UL35 UNIPROT IP 15308743 Yes HFF Yes 
UL84 UL122 UNIPROT IP 8289376, 7933141 Yes HEL Yes 
UL54 UL44 UNIPROT IP 14671097 No BL21 Yes 
UL44 UL54 UNIPROT, VM IP 14671097 No BL21 Yes 
UL74 UL75 UNIPROT IP 28403202 No HFF Yes 
UL75 UL74 UNIPROT IP 28403202 No HFF Yes 
UL51 UL89 UNIPROT IP 23175377 Yes HFF Yes 
UL35 OGT UNIPROT, BIOGRID, VM AP-MS 22072767 No 293A Yes 
UL27 PSME3 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs Yes 
UL29 MTA2 UNIPROT IP 20585571 Yes HFF Yes 
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UL87 POLR2M UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL87 POLR2G UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL141 PVR UNIPROT SPR 23555243 No - Yes 
UL38 TSC2 UNIPROT IP 18407068 Yes HFF Yes 
UL83 IFI16 UNIPROT, INTACT IP 24237704 No 293T Yes 
UL36 UBR5 UNIPROT, VM AP-MS  22810585 No 293 Yes 
UL35 VPRBP UNIPROT, BIOGRID, VM AP-MS  22072767 No 293A Yes 
UL87 POLR2D UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL87 POLR2H UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL36 DDX28 VM AP-MS  22810585 No 293 Yes 
UL16 MICB UNIPROT PPBA 11239445 No CV-1/EBNA Yes 
UL82 DAXX UNIPROT, BIOGRID, VM IP 11992005 No 293 Yes 
UL16 RAET1G VM PPBA 19658097 No CV1 Yes 
UL16 ULBP2 UNIPROT, VM PPBA 19424970 No Cos-7 Yes 
UL87 POLR2K UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL29 HDAC1 UNIPROT IP 20585571 Yes HFF Yes 
UL123 STAT2 UNIPROT, BIOGRID IF 26559840 No HFF Yes 
UL42 ITCH UNIPROT, BIOGRID, VM IP 26555021 No 293T Yes 
UL27 PSMB6 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs Yes 
UL36 GDI2 VM AP-MS  22810585 No 293 Yes 
UL87 POLR2A UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL87 POLR2B UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL87 POLR2C UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL87 POLR2E UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL87 POLR2I UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL87 POLR2L UNIPROT, BIOGRID AP-MS  25544563 No 293T Yes 
UL97 CDH1 UNIPROT, BIOGRID, VM PPBA 20686030 No - Yes 
UL135 ABI1 UNIPROT IP 25121749 Yes HFF Yes 
UL27 DDB1 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs Yes 
UL27 UBR5 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs Yes 
UL102 UL70 UNIPROT, MINT, INTACT IP 12076828 No BHK-21 No 
UL105 UL70 UNIPROT IP 12076828 No BHK-21 No 
UL53 UL50 UNIPROT IP 24155370 Yes HFF No 
UL97 UL83 UNIPROT IP 17634236 Yes HFF No 
UL80 UL86 UNIPROT Y2H 8985337 No PCY2 No 
UL86 UL80 UNIPROT Y2H 8985337 No PCY2 No 
UL105 UL102 UNIPROT IP 12076828 No BHK-21 No 
       (Continued) 
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UL102 UL105 UNIPROT, MINT, INTACT, VM IP 12076828 No BHK-21 No 
UL46 UL86 UNIPROT Y2H 8892863 No PCY2 No 
UL84 UL44 UNIPROT IP 17959680 Yes HFF No 
UL44 UL84 UNIPROT IP 17959680 Yes HFF No 
TRS1 UL44 UNIPROT IP 20444996 Yes HFF No 
IRS1 UL44 UNIPROT IP 20444996 Yes HFF No 
UL104 UL89 UNIPROT IP 16282466 No BL21 No 
UL44 UL112 UNIPROT IP 20538862 Yes HFF No 
UL112 UL44 UNIPROT IP 20538862 Yes HFF No 
UL89 UL56 UNIPROT IP 11744697 Yes - No 
UL56 UL89 UNIPROT IP 11744697 Yes - No 
UL122 RB1 UNIPROT, BIOGRID, VM Y2H 9671498 No Y190 No 
US32 DLG1 MINT PPPD 24550280 No - No 
UL27 RAB1A UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 RAN UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL122 RPS17 UNIPROT, BIOGRID, VM AP-MS  22810585 No 293 No 
UL76 PSMD4 UNIPROT, BIOGRID, VM IP 23966401 Yes Hel 299 No 
UL76 UBC UNIPROT, BIOGRID, VM FRET 23966401 No 293 No 
UL35 SART3 UNIPROT, BIOGRID, VM AP-MS  22072767 No 293A No 
UL122 MCM3 UNIPROT IP 20545442 No U373MG No 
UL36 RAB10 VM AP-MS  22810585 No 293 No 
UL27 CBR1 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL123 TRIM5 UNIPROT, BIOGRID, VM IP 25412268 No 293 No 
UL27 PDIA4 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL123 PML UNIPROT, BIOGRID, VM Y2H 9671498 No Y190 No 
UL27 PSMD3 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 PSMD2 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 STAT3 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 EP400 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 ACLY UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL135 ABI2 UNIPROT IP 25121749 Yes HFF No 
UL135 TLN1 UNIPROT IP 25121749 Yes HFF No 
UL55 EGFR UNIPROT IP 12879076 Yes HEL No 
UL35 DDB1 UNIPROT, BIOGRID, VM AP-MS  22072767 No 293A No 
UL36 MYO9A VM AP-MS  22810585 No 293 No 
UL114 SMARCB1 UNIPROT, BIOGRID, VM Y2H, IP 22479537 Yes HFF No 
UL122 CSNK2A1 UNIPROT, BIOGRID, VM AP-MS  22810585 No 293 No 
       (Continued) 
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UL122 DYNLL1 UNIPROT, BIOGRID, VM AP-MS  22810585 No 293 No 
UL122 DYNLL2 UNIPROT, BIOGRID, VM AP-MS  22810585 No 293 No 
UL122 HSPA5 UNIPROT, BIOGRID, VM AP-MS  22810585 No 293 No 
UL122 KPNA3 UNIPROT, BIOGRID, VM AP-MS  22810585 No 293 No 
UL27 ACTL6A UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 FKBP10 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 HNRNPH3 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 NUDT21 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 PSMA3 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 PSMB4 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 PSMC4 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 PSMC6 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 RUVBL1 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 RUVBL2 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL27 TMEM43 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs No 
UL36 ATAD3A VM AP-MS  22810585 No 293 No 
UL36 HNRNPH2 VM AP-MS  22810585 No 293 No 
UL36 HSPA5 VM AP-MS  22810585 No 293 No 
UL36 NEFH VM AP-MS  22810585 No 293 No 
UL36 RPS27 VM AP-MS  22810585 No 293 No 
UL36 TUBB VM AP-MS  22810585 No 293 No 
UL44 SMARCB1 UNIPROT, BIOGRID, VM IP 22479537 Yes HFF No 
UL100 UL73 UNIPROT IP 11090188 No 293T ND 
UL48 UL47 UNIPROT IP 24829352 Yes HFF ND 
UL55 UL75 UNIPROT IP 27082872 Yes HFF ND 
UL86 UL46 UNIPROT Y2H 8892863 No PCY2 ND 
UL89 UL51 UNIPROT IP 23175377 Yes HFF ND 
UL89 UL104 UNIPROT IP 16282466 No BL21 ND 
UL27 TRRAP UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs ND 
UL111A IL10RA VM, UNIPROT XRC 12093920, 15837194  No - ND 
UL122 CSNK2B UNIPROT, BIOGRID, VM AP-MS  22810585 No 293 ND 
UL122 ZMYND11 UNIPROT, BIOGRID, VM AP-MS  22810585 No 293 ND 
UL123 DAXX UNIPROT, BIOGRID, VM IP 20444888 Yes U373 ND 
UL123 HES1 UNIPROT, BIOGRID IP 28750047 Yes NPC ND 
UL123 SP100 UNIPROT, BIOGRID IP 28750047 No 293T ND 
UL123 UBE2D1 UNIPROT, BIOGRID IP 28750047 Yes NPC ND 
UL144 TRAF6 UNIPROT, BIOGRID, VM, MINT IP 19176615 No HFF ND 
       (Continued) 
 252 
 
UL144 TRIM23 UNIPROT, BIOGRID, VM IP 19176615 No HFF ND 
UL16 RAET1L VM PPBA 19658097 No CV1 ND 
UL21A ANAPC7 UNIPROT, BIOGRID, VM AP-MS  22792066 Yes MRC-5 ND 
UL21A CDC23 UNIPROT, BIOGRID, VM AP-MS, IP 22792066 Yes MRC-5 ND 
UL21A CDC27 UNIPROT, BIOGRID, VM AP-MS, IP 22792066 Yes MRC-5 ND 
UL27 KAT5 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs ND 
UL27 WDR26 UNIPROT, BIOGRID, VM AP-MS  21320693 Yes Primary HFFs ND 
UL35 DDA1 UNIPROT, BIOGRID, VM AP-MS  22072767 No 293A ND 
UL35 IPO4 UNIPROT, BIOGRID, VM AP-MS  22072767 No 293A ND 
UL35 USP7 UNIPROT, BIOGRID, VM AP-MS, IP 22072767 No 293A ND 
UL36 ACTA2 VM AP-MS  22810585 No 293 ND 
UL36 ACTG2 VM AP-MS  22810585 No 293 ND 
UL36 CASP8 UNIPROT, VM AP-MS  22810585 No 293 ND 
UL36 IRS4 VM AP-MS  22810585 No 293 ND 
UL36 RPS27L VM AP-MS  22810585 No 293 ND 
UL36 TUBA1A VM AP-MS  22810585 No 293 ND 
UL36 TUBA1C VM AP-MS  22810585 No 293 ND 
UL36 USP54 VM AP-MS  22810585 No 293 ND 
UL82 ATRX UNIPROT, BIOGRID, VM IP 23135716 No HepaRG ND 
UL83 MNDA INTACT IP 24237704 No 293T ND 
UL83 PYHIN1 INTACT IP 24237704 No 293T ND 
UL87 POLR2J UNIPROT, BIOGRID AP-MS  25544563 No 293T ND 
US11 DERL1 VM IP 15215856 No Astrocytoma ND 
US11 TRAM1 UNIPROT, BIOGRID, VM IP 19121997 No U373  ND 
US2 TRAM1 UNIPROT, BIOGRID, VM IP 19121997 No U373  ND 
US3 PDIA2 UNIPROT, BIOGRID, VM IP 17055437 No HeLa ND 
US3 TAPBP UNIPROT, BIOGRID, VM IP 17055437 No HeLa ND 
 
VM: VIRUSMENTHA; AP-MS: Affinity-purification mass spectrometry; IP: Immunoprecipitation; Y2H: Yeast two-hybrid; SPR: Surface plasmon resonance; FRET: 
Fluorescent Resonance Energy Transfer; IF: Immunofluorescence; XRC: X-ray crystallography; PPBA: Purified protein binding assay; PPPD: Proteomic peptide-phage 
display. 
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Appendix E | PFAM domain association 
 
Data underlying the protein domain-domain association predictions shown in Figure 5.6.2. 
 
Bait 
PFAM 
Domain 
Prey 
Uniprot-l 
Prey Gene 
Name 
Interacting PFAM domains 
UL25 Herpes pp85 O43639 NCK2 SH2, SH3 9 
UL25 Herpes pp85 P16333 NCK1 SH2, SH3 9 
UL35 Herpes pp85 F5HBC6 UL82 Herpes UL82 83 
US27 7tm 1 P30825 SLC7A1 AA permease 
US27 7tm 1 Q9UK23 NAGPA NAGPA 
US27 7tm 1 P20338 RAB4A Ras 
US27 7tm 1 Q86YS6 RAB43 Ras 
US27 7tm 1 Q9NRW1 RAB6B Ras 
US27 7tm 1 Q15771 RAB30 Ras 
US27 7tm 1 P20340-2 RAB6A Ras 
US27 7tm 1 Q6IQ22 RAB12 Ras 
US27 7tm 1 P20337 RAB3B Ras 
US27 7tm 1 Q9UL25 RAB21 Ras 
US27 7tm 1 O14966 RAB29 Ras 
US27 7tm 1 Q9UP95 SLC12A4 SLC12, AA permease 
US27 7tm 1 Q9UHW9 SLC12A6 SLC12, AA permease 
US27 7tm 1 Q9BXP2 SLC12A9 SLC12, AA permease 
US27 7tm 1 O43752 STX6 SNARE 
US27 7tm 1 O14662 STX16 SNARE 
US27 7tm 1 Q86Y82 STX12 SNARE 
US27 7tm 1 O15400 STX7 SNARE 
US27 7tm 1 Q9UNK0 STX8 SNARE 
US27 7tm 1 P51809-2 VAMP7 Synaptobrevin 
US27 7tm 1 P51809 VAMP7 Synaptobrevin 
US27 7tm 1 P63027 VAMP2 Synaptobrevin 
US27 7tm 1 Q9Y487 ATP6V0A2 V ATPase I 
US27 7tm 1 Q9UEU0 VTI1B V-SNARE, SNARE 
US27 7tm 1 Q96AJ9 VTI1A V-SNARE, SNARE 
US28 7tm 1 Q9UKX2 MYH2 Myosin head, Myosin tail 1, Myosin N 
US28 7tm 1 P13533 MYH6 Myosin head, Myosin tail 1, Myosin N 
US28 7tm 1 A7E2Y1 MYH7B Myosin head, Myosin tail 1, Myosin N 
US28 7tm 1 Q9Y623 MYH4 Myosin head, Myosin tail 1, Myosin N 
US28 7tm 1 P11055 MYH3 Myosin head, Myosin tail 1, Myosin N 
US28 7tm 1 P12882 MYH1 Myosin head, Myosin tail 1, Myosin N 
US28 7tm 1 P12883 MYH7 Myosin head, Myosin tail 1, Myosin N 
US28 7tm 1 Q9UK23 NAGPA NAGPA 
US28 7tm 1 P20340-2 RAB6A Ras 
US28 7tm 1 Q9Y487 ATP6V0A2 V ATPase I 
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RL6 RL11D Q86V21 AACS ACAS N 
RL6 RL11D Q96K17 BTF3L4 NAC 
RL6 RL11D E9PAV3 NACA NAC 
RL6 RL11D P62256 UBE2H UQ con 
RL6 RL11D Q16763 UBE2S UQ con 
RL6 RL11D P61088 UBE2N UQ con 
RL6 RL11D Q13404-1 UBE2V1 UQ con 
UL117 Herpes IE2 3 Q9H3K6 BOLA2 BolA 
UL122 Herpes IE2 3 Q9H3K6 BOLA2 BolA 
UL14 UL141 Q14697-2 GANAB Glyco hydro 31, Gal mutarotas 2 
UL14 UL141 Q14697 GANAB Glyco hydro 31, Gal mutarotas 2 
UL141 UL141 O00220 TNFRSF10A TNFR c6 
UL141 UL141 Q9UBN6 TNFRSF10D TNFR c6 
UL141 UL141 O14763 TNFRSF10B TNFR c6 
UL141 UL141 P19438 TNFRSF1A TNFR c6 
US3 
Cytomega 
US3 
Q06481 APLP2 
Kunitz BPTI, APP N, APP E2, APP Cu bd, APP 
amyloid 
US3 
Cytomega 
US3 
P05067 APP 
Kunitz BPTI, APP N, APP E2, APP Cu bd, APP 
amyloid 
US7 CMV US Q5VSL9 STRIP1 N1221, DUF3402 
US9 CMV US Q9ULQ0 STRIP2 N1221, DUF3402 
US9 CMV US Q5VSL9 STRIP1 N1221, DUF3402 
US9 CMV US Q9NVK5 FGFR1OP2 SIKE 
US9 CMV US Q9NVK5-2 FGFR1OP2 SIKE 
US9 CMV US Q9BRV8-2 SIKE1 SIKE 
US9 CMV US O43815 STRN Striatin 
US9 CMV US Q13033 STRN3 Striatin 
US12 Bax1-I Q29980 MICB C1-set 
US12 Bax1-I Q29983 MICA C1-set 
US12 Bax1-I P00533 EGFR Recep L domain, GF recep IV, Furin-like 
US12 Bax1-I P04626 ERBB2 Recep L domain, GF recep IV, Furin-like 
US15 Bax1-I Q68D85 NCR3LG1 C1-set 
US20 Bax1-I P01860 IGHG3 C1-set 
US20 Bax1-I P01834 IGKC C1-set 
US20 Bax1-I P01857 IGHG1 C1-set 
US20 Bax1-I P04626 ERBB2 Recep L domain, GF recep IV, Furin-like 
US21 Bax1-I Q14643 ITPR1 
Ion trans,MIR, RYDR ITPR, RIH assoc, Ins145 P3 
rec 
US21 Bax1-I Q14573 ITPR3 
Ion trans, MIR, RYDR ITPR, RIH assoc, Ins145 P3 
rec 
US21 Bax1-I Q14571 ITPR2 
Ion trans, MIR, RYDR ITPR, RIH assoc, Ins145 P3 
rec 
US21 Bax1-I P04626 ERBB2 Recep L domain, GF recep IV, Furin-like 
IRS1 US22 Q9P2N7-5 KLHL13 CH, BTB 
IRS1 US22 Q9P2J3 KLHL9 CH, BTB 
IRS1 US22 P46109 CRKL SH3 2 
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IRS1 US22 P46108-2 CRK SH3 2 
IRS1 US22 P46108 CRK SH3 2 
IRS1 US22 Q99962 SH3GL2 SH3 2 
IRS1 US22 Q96JP2 MYO15B SH3 2 
UL23 US22 Q8N3F8 MICALL1 CH 
UL23 US22 Q8IZ07 ANKRD13A CH 
UL23 US22 O76071 CIAO1 WD40 
UL26 US22 Q9UL63 MKLN1 CH 
UL26 US22 Q9H871 RMND5A CLTH 
UL26 US22 Q7L5Y9 MAEA CLTH 
UL26 US22 Q6VN20 RANBP10 CLTH, LisH 
UL26 US22 Q96S59 RANBP9 CLTH, LisH 
UL26 US22 Q9NWU2 GID8 CLTH, LisH 
UL26 US22 Q8IUH3-3 RBM45 RRM 1 
UL26 US22 Q8IUH3 RBM45 RRM 1 
UL26 US22 Q9NNW5 WDR6 WD40 
UL26 US22 Q9H7D7 WDR26 WD40 
UL26 US22 Q9C0J8 WDR33 WD40 
UL26 US22 Q8NFH4 NUP37 WD40  
UL26 US22 O95486 SEC24A 
zf-Sec23 Sec24, Sec23 trunk, Sec23 helical, 
Sec23 BS, Gelsolin 
UL26 US22 Q15437 SEC23B 
zf-Sec23 Sec24, Sec23 trunk, Sec23 helical, 
Sec23 BS, Gelsolin 
UL26 US22 Q15436 SEC23A 
zf-Sec23 Sec24, Sec23 trunk, Sec23 helical, 
Sec23 BS, Gelsolin 
UL29 US22 Q9UPU5 USP24 CH 
UL29 US22 Q14839-2 CHD4 
Chromo, DUF1087, DUF1086, CHDNT, CHDCT2, 
SNF2 N, Helicase C, CH 
UL29 US22 Q8TDI0 CHD5 
Chromo, DUF1087, DUF1086, CHDNT, CHDCT2, 
SNF2 N, Helicase C, CH 
UL29 US22 Q9NWU2 GID8 CLTH, LisH 
UL29 US22 Q8WXI9 GATAD2B GATA 
UL29 US22 O94776 MTA2 GATA, MTA R1, ELM2, BAH 
UL29 US22 O60907 TBL1X LisH, WD40 
UL29 US22 Q9BZK7 TBL1XR1 LisH, WD40 
UL29 US22 Q9UBB5 MBD2 MBD C, MBDa, MBD 
UL29 US22 O95983 MBD3 MBD C, MBDa, MBD 
UL29 US22 O75376 NCOR1 Myb DNA-binding 
UL29 US22 Q9Y618 NCOR2 Myb DNA-binding 
UL29 US22 Q9BTC8 MTA3 Myb DNA-binding, GATA, MTA R1, ELM2, BAH 
UL29 US22 Q13330 MTA1 Myb DNA-binding, GATA, MTA R1, ELM2, BAH 
UL29 US22 Q9NNW5 WDR6 WD40 
UL36 US22 Q9UK99 FBXO3 F-box-like 
UL36 US22 Q9NUL7 DDX28 Helicase C 
UL38 US22 Q9UPU5 USP24 CH 
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UL38 US22 Q14839-2 CHD4 
Chromo, DUF1087, DUF1086, CHDNT, CHDCT2, 
SNF2 N, Helicase C, CH 
UL38 US22 Q9UBB5 MBD2 MBD C, MBDa, MBD 
UL38 US22 O95983 MBD3 MBD C, MBDa, MBD 
UL38 US22 Q9BTC8 MTA3 Myb DNA-binding, GATA, MTA R1, ELM2, BAH 
UL38 US22 Q13330 MTA1 Myb DNA-binding, GATA, MTA R1, ELM2, BAH 
UL38 US22 Q03468 ERCC6 SNF2 N, Helicase C 
UL38 US22 Q16576 RBBP7 WD40 
UL43 US22 P62258 YWHAE 14-3-3 
UL43 US22 Q04917 YWHAH 14-3-3 
UL43 US22 P61981 YWHAG 14-3-3 
UL43 US22 P63104 YWHAZ 14-3-3 
UL43 US22 P31946 YWHAB 14-3-3 
UL43 US22 P27348 YWHAQ 14-3-3 
US22 US22 Q5BKZ1 ZNF326 AKAP95 
US22 US22 Q9ULX6 AKAP8L AKAP95 
US22 US22 O43823 AKAP8 AKAP95 
US22 US22 Q9UKB1 FBXW11 Beta-TrCP D, F-box-like, WD40 
US22 US22 Q7RTP6 MICAL3 CH 
US22 US22 P78332 RBM6 CH 
US22 US22 O14647 CHD2 Chromo, SNF2 N, Helicase C, CH 
US22 US22 Q969H0 FBXW7 F-box-like, WD40 
US22 US22 Q96E39 RBMXL1 RBM1CTR, RRM 1 
US22 US22 O75526 RBMXL2 RBM1CTR, RRM 1 
US22 US22 P38159 RBMX RBM1CTR, RRM 1 
US22 US22 Q8IXT5 RBM12B RRM 1 
US22 US22 Q9Y580 RBM7 RRM 1 
US22 US22 Q96PK6 RBM14 RRM 1 
US22 US22 Q1KMD3 HNRNPUL2 SAP 
US22 US22 Q00839 HNRNPU SAP 
US22 US22 Q9NWH9 SLTM SAP, RRM 1 
US22 US22 Q14151 SAFB2 SAP, RRM 1 
US22 US22 Q8NDT2 RBM15B SPOC, RRM 1 
US22 US22 Q96T37 RBM15 SPOC, RRM 1 
US22 US22 Q9H5H4 ZNF768 zf-C2H2 
US22 US22 Q02447 SP3 zf-C2H2 
US22 US22 Q6DD87 ZNF787 zf-C2H2 
US22 US22 O43474 KLF4 zf-C2H2 
US22 US22 P08047 SP1 zf-C2H2 
US22 US22 Q9HBE1 PATZ1 zf-C2H2, BTB 
US23 US22 Q9Y297 BTRC Beta-TrCP D, F-box-like, WD40 
US23 US22 Q15052 ARHGEF6 RhoGEF, CH,betaPIX CC 
US24 US22 Q9UKB1-3 FBXW11 Beta-TrCP D, F-box-like, WD40 
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US24 US22 Q9Y297 BTRC Beta-TrCP D, F-box-like, WD40 
US24 US22 Q9UKB1 FBXW11 Beta-TrCP D, F-box-like, WD40 
US24 US22 Q15052 ARHGEF6 RhoGEF, CH, betaPIX CC 
US24 US22 Q14155 ARHGEF7 RhoGEF, CH, SH3 2 
US26 US22 Q5JSZ5-4 PRRC2B BAT2 N 
US26 US22 Q9Y520-7 PRRC2C BAT2 N 
US26 US22 Q5JSZ5 PRRC2B BAT2 N 
US26 US22 P48634 PRRC2A BAT2 N 
US26 US22 Q8IY92 SLX4 BTB 
US26 US22 Q7RTP6 MICAL3 CH 
US26 US22 Q8WWI1 LMO7 CH 
US26 US22 P78332 RBM6 CH 
US26 US22 Q9P2N5 RBM27 CH 
US26 US22 Q92620 DHX38 Helicase C 
US26 US22 P42285 SKIV2L2 Helicase C, CH 
US26 US22 O60907 TBL1X LisH, WD40 
US26 US22 O75376 NCOR1 Myb DNA-binding 
US26 US22 Q9Y618 NCOR2 Myb DNA-binding 
US26 US22 Q12774 ARHGEF5 RhoGEF 
US26 US22 Q96PE2 ARHGEF17 RhoGEF 
US26 US22 Q92888-3 ARHGEF1 RhoGEF 
US26 US22 Q9Y580 RBM7 RRM 1 
US26 US22 Q9NWH9 SLTM SAP, RRM 1 
US26 US22 P51532 SMARCA4 SNF2 N, Helicase C 
US26 US22 Q92576 PHF3 SPOC 
US26 US22 Q9H2Y7 ZNF106 WD40 
US26 US22 Q9C0J8 WDR33 WD40 
US26 US22 Q9Y4X4 KLF12 zf-C2H2 
US26 US22 P57682 KLF3 zf-C2H2 
US26 US22 Q8N554 ZNF276 zf-C2H2 
US26 US22 O43474 KLF4 zf-C2H2 
US26 US22 O95365 ZBTB7A zf-C2H2, BTB 
US26 US22 Q5VYS8 ZCCHC6 zf-CCHC, CH 
US26 US22 Q6NZY4 ZCCHC8 zf-CCHC, CH 
US26 US22 Q15637-5 SF1 zf-CCHC, CH 
 
 
 
 
 
